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The Molecular And Regulatory Mechanism Of Multi-Subunit N-Terminal
Acetyltransferases
Abstract
N-terminal acetylation (NTA) is one of the most widespread protein modifications, which occurs on most
eukaryotic proteins, but is significantly less common on bacterial and archaea proteins. This modification
is carried out by a family of enzymes called N-terminal acetyltransferases (NATs). To date, 12 NATs have
been identified, harboring different composition, substrate specificity, and in some cases, modes of
regulation. In the first chapter, we review the molecular features of NATs.NatA/E, NatB and NatC, are
multi-subunit enzymes, responsible for the majority of eukaryotic protein NTA. Their mechanisms of
action and regulation remain poorly understood before this dissertation. In the second chapter, we
determined the X-ray crystal structure of yeast NatA/Naa50 as a scaffold to understand coregulation of
NatA/Naa50 activity in both yeast and human. We found that Naa50 makes evolutionarily conserved
contacts to both the Naa10 and Naa15 subunits of NatA. These interactions promote catalytic crosstalk
within the human complex, but do so to a lesser extent in the yeast complex, where Naa50 activity is
compromised. Thirdly, we reported the Cryo-EM structures of human NatE and NatE/HYPK complexes
and associated biochemistry. We revealed that NAA50 and HYPK exhibit negative impacts on their
binding to NAA15 in vitro and in human cells by inducing NAA15 shifts in opposing directions. NAA50 and
HYPK each contribute to NAA10 activity inhibition through structural alteration of the NAA10 substrate
binding site. Fourthly, we reported the Cryo-EM structure of hNatB bound to a CoA-αSyn conjugate,
together with structure-guided analysis of mutational effects on catalysis. This analysis revealed
functionally important differences with human NatA and Candida albicans NatB, resolved key hNatB
protein determinants for αSyn N-terminal acetylation, and identified important residues for substratespecific recognition and acetylation by NatB enzymes. Lastly, we report the Cryo-EM structure of S.
pombe NatC with a NatE/C-type bi-substrate analogue and inositol hexaphosphate (IP6), and associated
biochemistry. We find that all three subunits are prerequisite for normal NatC acetylation activity, IP6
binds tightly to NatC to stabilize the complex, and we determine the molecular basis for IP6-mediated
stability of the complex and the overlapping yet distinct substrate profiles of NatC and NatE.
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ABSTRACT

THE MOLECULAR AND REGULATORY MECHANISM OF MULTI-SUBUNIT N-TERMINAL
ACETYLTRANSFERASES
Sunbin Deng
Ronen Marmorstein

N-terminal acetylation (NTA) is one of the most widespread protein modifications,
which occurs on most eukaryotic proteins, but is significantly less common on bacterial
and archaea proteins. This modification is carried out by a family of enzymes called Nterminal acetyltransferases (NATs). To date, 12 NATs have been identified, harboring
different composition, substrate specificity, and in some cases, modes of regulation. In
the first chapter, we review the molecular features of NATs.
NatA/E, NatB and NatC, are multi-subunit enzymes, responsible for the majority
of eukaryotic protein NTA. Their mechanisms of action and regulation remain poorly
understood before this dissertation. In the second chapter, we determined the X-ray
crystal structure of yeast NatA/Naa50 as a scaffold to understand coregulation of
NatA/Naa50 activity in both yeast and human. We found that Naa50 makes
evolutionarily conserved contacts to both the Naa10 and Naa15 subunits of NatA. These
interactions promote catalytic crosstalk within the human complex, but do so to a lesser
extent in the yeast complex, where Naa50 activity is compromised.
Thirdly, we reported the Cryo-EM structures of human NatE and NatE/HYPK
complexes and associated biochemistry. We revealed that NAA50 and HYPK exhibit
negative impacts on their binding to NAA15 in vitro and in human cells by inducing

v

NAA15 shifts in opposing directions. NAA50 and HYPK each contribute to NAA10
activity inhibition through structural alteration of the NAA10 substrate binding site.
Fourthly, we reported the Cryo-EM structure of hNatB bound to a CoA-αSyn
conjugate, together with structure-guided analysis of mutational effects on catalysis. This
analysis revealed functionally important differences with human NatA and Candida
albicans NatB, resolved key hNatB protein determinants for αSyn N-terminal acetylation,
and identified important residues for substrate-specific recognition and acetylation by
NatB enzymes.
Lastly, we report the Cryo-EM structure of S. pombe NatC with a NatE/C-type bisubstrate analogue and inositol hexaphosphate (IP6), and associated biochemistry. We
find that all three subunits are prerequisite for normal NatC acetylation activity, IP6 binds
tightly to NatC to stabilize the complex, and we determine the molecular basis for IP6mediated stability of the complex and the overlapping yet distinct substrate profiles of
NatC and NatE.
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CHAPTER 1: Protein N-Terminal Acetylation: Structural Basis, Mechanism,
Versatility, and Regulation

This chapter is adapted from Trends Biochem Sci (Deng and Marmorstein 2021) © Cell Press
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1.1 Evolutionarily conserved NTA has diverse biological functions
The majority of eukaryotic proteins are subject to several N-terminal
modifications at the early stage of their biogenesis by the ribosome, including Ntmethionine excision (NME), Nt-acetylation (NTA), Nt-myristoylation (MYR), Ntmethylation and Nt-arginylation (Eldeeb and Ragheb 2018; Varland, Osberg, and
Arnesen 2015; Giglione, Fieulaine, and Meinnel 2015). The evolutionarily conserved and
irreversible NME and NTA modifications affect the functions of many proteins and
increase the diversity of the proteome (Varland, Osberg, and Arnesen 2015; Giglione,
Fieulaine, and Meinnel 2015). NTA occurs when the iMet is removed or retained, cotranslationally or post-translationally (Aksnes, Ree, and Arnesen 2019; Aksnes et al.
2016; Linster and Wirtz 2018) and on 50-90% of eukaryotic proteins but only 10-29% of
bacterial and archaea proteins (Arnesen et al. 2009; Bienvenut et al. 2012; Kelkar et al.
2011; Bienvenut, Giglione, and Meinnel 2015; Schmidt et al. 2016; Kirkland et al. 2008;
Aivaliotis et al. 2007), correlating the abundance of NTA with organism complexity.
NTA changes the chemical properties of the protein N-termini: neutralizing the
charge, creating a new h-bond acceptor, changing the α-amino nitrogen nucleophilicity
and basicity, and increasing its hydrophobicity and size. These changed chemical
properties have diverse biological consequences on protein function including protein
half-life, folding, complex formation, and localization (Aksnes et al. 2016; Oh, Hyun, and
Varshavsky 2017). Correlating with these diverse functions, knockout of individual
eukaryotic

N-terminal

acetyltransferases

(NATs)

display

different

phenotypes,

presumably associated with the differential misregulation of their respective client
proteins (Aksnes et al. 2016). Alteration in NTA activity is also linked to disease such as
various developmental and neurodegenerative disorders and cancers (Myklebust, Stove,
2

and Arnesen 2015; Kalvik and Arnesen 2013; Dorfel and Lyon 2015) in humans and
stress response in plants (Linster and Wirtz 2018; Huber et al. 2020). While several
other reviews cover the biology of NATs (Aksnes, Ree, and Arnesen 2019; Ree,
Varland, and Arnesen 2018; Aksnes et al. 2016; Dorfel and Lyon 2015) , this chapter will
focus on their structure, mechanism and regulation over evolution.

1.2 General molecular features of NATs
The GCN5 related N-acetyltransferases (GNAT) superfamily of proteins is one
of the largest protein families, with over 10,000 protein members present in all domains
of life. These proteins catalyze a bi-reactant process: transferring an acetyl group from
the donor acetyl-CoA cofactor to the primary amine group of a variety of biomolecules
including small molecules and protein or peptides lysine sidechains and N-termini.
GNATs share a common structurally conserved α/β fold, despite their low degree of
sequence identity; and mode of acetyl-CoA binding (Salah Ud-Din, Tikhomirova, and
Roujeinikova 2016). GNATs typically contain distinct flanking N and C terminal regions
that directly contributing to their distinct functions.
NTA is carried out by the NAT subfamily of GNATs, which typically contain four
α-helices and seven β-strands, although addition secondary structural elements are
often present at their N or C termini (Figure 1.1A). β1-β4 and β5-β6 are arranged
antiparallelly, while the parallel β4 and β5 strands split to create a splay in between for
binding peptide and acetyl-CoA (Figure 1.1A). The peptide binding site of NATs is
typically flanked by the β6-β7 and α1-α2 loops, which directly participate in N-terminal
substrate binding and take on a relatively closed configuration relative to GNATs that
3

acetylate internal lysine substrates, thereby disfavoring lysine sidechain binding (Magin,
March, and Marmorstein 2016; Evjenth et al. 2009; Abboud et al. 2020). NATs typically
make extensive h-bond interactions with the backbone atoms of the first 2-3 N-terminal
residues further contributing to specificity for protein N-termini. These two distinct
features distinguish NATs from KATs (lysine acetyltransferases) and other members
of GNATs. NTA by NATs follows an ordered Bi-Bi reaction mechanism, where acetylCoA cofactor binding promotes subsequent N-termini binding prior to direct acetyl-group
transfer from the cofactor to protein (Evjenth et al. 2012). One or two residues function
as a general base (s) (often through an intervening water molecule) to deprotonate the
terminal amino group to facilitate its nucleophilic attack of the acetyl group of acetyl-CoA
(Figure 1.1B). This reaction proceeds through a tetrahedral intermediate, thus making
CoA-peptide conjugate bi-substrate analogues in which N-terminal peptides are linked to
CoA through an acetaldehyde group potent NAT inhibitors (Figure 1.1C) (Foyn et al.
2013).
A wealth of mechanistic information about the substrate specific activities of
NATs has been derived from their structures and associated biochemical studies. The
NATs that have been structurally characterized to date are listed in Table 1.1. As
described below, each NAT employs a unique strategy to achieve substrate-specific
acetylation and regulation.
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Table 1.1 N-terminal acetyltransferases are characterized in all domains of life

Bacteri
a

Archae
a

Substrates
specificity

NATs

Subunits

RimI

monomer

RimL

homodimer

RimJ

monomer

ssNAT

monomer

relaxed

NAA10

monomer

Acidic substrates

NatA

NAA10, NAA15

NatA/HYPK

NAA10,
NAA15, HYPK

Ribosomal protein
S18, relaxed
Ribosomal protein
L7/L12
Ribosomal protein
S5, relaxed

A-, S-, T-, V-, G-

NatB
NatC
Eukary
-otes

NatD

NAA20, NAA25

M-D/E/N/Q-

NAA30,
NAA35, NAA38
NAA40,
monomer

M-L/I/F/Y/KHistones H2A/H4
(S-G-R-G-)
MS/T/A/V/L/I/F/Y/K-

NAA50

monomer

NatE

NAA50,
NAA10, NAA15

NatE/HYPK

NAA50,
NAA10,
NAA15, HYPK

NatF

Homodimer/mo
nomer

M-L/I/F/Y/K-

NatG

NAA70

M-, A-, S-, T-

NatA- and NAA50type

5

PDB
S.
typhimurium
S.
typhimurium

Mycobacteri
um
S.
solfataricus
S. pombe

2CNM
1S7N
6C32
4LX9
4KVX

S. pombe
Human

4KVM
6C9M

C.
thermophilu
m

5NNR
6C95

Human
C. albicans
Human
S. pombe
S. pombe
Human

5K18
6VP9
6YGD
7L1K
4UA3
4U9W

Human

3TFYc,e

S.
cerevisiae
Human

6O07c
6PPL

Human

6PW9

Human
A. thaliana

5ICW,5I
CV
6TGX

S. cerevisiae

-

NatH
NatH/profilin
/actin

NAA80,
monomer
NAA80, profilin,
actin

Actins (D/E-D/ED/E-)

Drosophila

5WJE

Human

6NBE

Figure 1.1 NAT catalytic domains share common topology and related catalytic
mechanism
(A) The general topology of NAT catalytic subunits is depicted as in 2D cartoon on the
left and 3D on the right panel with secondary structures shown. NATs usually contain
seven β strands and four helices, but additional secondary structural elements within this
topology and at their N-, C- termini are sometimes present. The α1- α2 and β6-β7
substrate binding loops are highlighted in yellow. The length of α helices and β strands
6

does not accurately reflect actual scale in the 2D representation. The transparent
magenta dots and spheres in the 3D representation represent the peptide and acetylCoA substrates, respectively. The 3D representation was generated using human
NAA50 PDB: 3TFY. (B) General catalytic mechanism of NATs, which transfer an acetyl
group from acetyl-CoA to protein Nt-amino group is depicted. The acetyl and Nt-amino
groups are colored as blue and red, respectively. A general base (or two, sometimes
through a coordinated water molecule) is utilized to deprotonate the protein Nt-amino
group, which subsequently attacks the acetyl group to form a tetrahedral intermediate.
The deprotonated CoA is then deprotonated by a general acid (not shown) and released
as the tetrahedral intermediate collapses. (C) The chemical structure of a CoA-peptide
conjugate Bi-substrate analogue is shown. A linker (acetaldehyde group) is used to
covalently link the CoA and peptide substrate. Abbreviations: NAT, N terminal
acetyltransferase; CoA, Coenzyme A; PDB, Protein Data Bank.

1.3 Bacterial NATs
The three E. coli homologs, RimI, RimJ and RimL were among the first
characterized NATs, showing post-translational NTA activity towards the ribosomal
proteins S18, S5, and L7/L12, respectively (Favrot, Blanchard, and Vergnolle 2016).
Some recombinant proteins overexpressed in E coli were later found to undergo NTA
(Bernal-Perez et al. 2012), and more recent proteome-wide analysis found that ~30-100
E. coli N-termini are at least partially acetylated, predominantly at N-terminal serine,
alanine, methionine and threonine residues (Bienvenut, Giglione, and Meinnel 2015;
Schmidt et al. 2016). The abundance of NTA in Pseudomonas aeruginosa PA14 and
Mycobacterium tuberculosis appears to be in the range of 10% ~ 29% (Kelkar et al.
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2011; Ouidir et al. 2015), although their biological importance have not been rigorously
evaluated.
Bacterial orthologs of each of the Rim proteins have been structurally
characterized. The Salmonella typhimurium RimI (StRimI) structure was determined in
complex with CoA, acetyl-CoA or a CoA-peptide conjugate showing a typical GNAT fold
(Figure 1.2A) (Vetting et al. 2008). Several StRimI residues change conformation when
in complex with the peptide portion of the conjugate with several residues making
backbone h-bonds to carbonyl and nitrogen atoms of the first three residues of the
peptide portion, while several RimI residues make van der Waals and h-bonds to side
chains 2-4 (Figure 1.3). RimI Glu103 is proposed to function as a general base through
an intervening water molecule, while Tyr115 is proposed to act as the general acid
(Figure 1.3). A more recent biochemical characterization of Mycobacterium tuberculosis
RimI demonstrated a conventional eukaryotic NatA/NatC/NatE substrate preference,
consistent with a relaxed substrate specificity for RimI (Pathak et al. 2016).
Crystal structures of StRimL in apo form and in complex with CoA reveals a
similar overall fold to bacterial StRimI, however StRimL forms a homodimer through
antiparallel b-strands (b6) from opposing subunits to form a contiguous b-sheet that
spans the entire dimer (Figure 1.2B) (Vetting et al. 2005). This 2-fold symmetry appears
to be precisely configured to acetylate its cognate dimeric L7 N-termini (Wahl et al. 2000;
Bocharov et al. 2004). Compared to the apo StRimL structure, the bound of CoA
appears to stabilize the α1-α2 loop, which could also facilitate the cooperative binding of
the dimeric L7/L12. Like StRimI, StRimL is proposed to use a ternary complex
mechanism involving a glutamate general base residue (Glu160), while a tyrosine
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(Tyr98) is proposed to stabilize the tetrahedral intermediate, with a serine residue
(Ser141) functioning as a general acid.
Mycobacterium smegmatis RimJ structures alone and in complex with cofactor or
cofactor analogs has recently been deposited to the PDB (PDB: 6C32, 6C30, 6C37.
Taken together, the bacterial NAT proteins reveal a general GNAT fold in either
monomeric or homodimeric form with substrate protein recognition occurring through
backbone and sidechain interaction to the first few N-terminal residues, with acid-base
catalysis proceeding through dedicated residues.

Figure 2.2 Some NATs function independently, either in monomeric or homodimer
form
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(A) Structures of monomeric StRimI (PDB: 2CNM), SsNAT (PDB: 4LX9), uncomplexed
SpNAA10 (PDB: 4KVX), hNAA50 (PDB: 3TFY), hNAA40 (PDB: 4U9W), and DmNAA80
(PDB: 5WJE) are shown in cartoon and color in cyan. The α1- α2 and β6-β7 substrate
binding loops are highlighted in yellow. Substrates in the structures are shown in stick
and colored in magenta. The hNAA40-specific N terminal domain is highlighted in grey.
(B) Dimeric RimL (PDB:1S7N) and hNAA60 (PDB: 5ICW) are shown. The α1-α2 and β6β7 substrate binding loops are highlighted in yellow. Substrates in the structures are
shown in stick and colored in magenta. To form a dimer, StRimL utilizes the two β6
strands from each subunit, while hNAA60 uses the extended β6-β7 loops. The NAA60specific N terminal domain is highlighted in grey. NAT catalytic subunits that have not
been shown to function independently are not shown.
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Figure 3.3 NATs use related but distinct mechanism to recognize their peptide
substrate N-termini
Peptide binding sites of StRimI (PDB: 2CNM), complexed SpNAA10 (PDB: 4KVM, with
SpNAA15 hidden), CaNAA20 (PDB: 5K04, with CaNAA25 hidden), hNAA40 (PDB:
4U9W), hNAA60 (PDB: 5ICV), and DmNAA80 (PDB: 5WJE) are shown in cartoon.
Peptide substrates are shown in magenta sticks. The residues labeled with a * symbol
are proposed catalytic residues. Broken lines indicate h-bonds formed between atoms.
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The α1- α2 and β6-β7 substrate binding loops are highlighted in yellow. Water-mediate
interactions in the PDB structures are not shown.

1.4 Archaea NATs
Like in bacteria, while earlier studies indicated that NTA occurs on only ribosomal
proteins in archaea, more recent N-terminomics studies reveal that NTA occurs on 14–
29% of archaeal proteins (Falb et al. 2006; Aivaliotis et al. 2007; Kirkland et al. 2008).
Archaea contains only one conserved NAT, which exhibits a very relaxed substrate
spectrum including substrates by eukaryotic NatA/B/C/E (Mackay et al. 2007; Liszczak
and Marmorstein 2013). The Sulfolobus solfataricus NAT (SsNAT) shows the greatest
sequence conservation with the NAA10 catalytic subunit of the eukaryotic NatA complex,
with 33% sequence identity (Liszczak and Marmorstein 2013), as confirmed by its
structure bound to acetyl-CoA (PDB: 4LX9) (Figure 1.2A) (Liszczak and Marmorstein
2013). Interestingly, the monomeric SsNAT is more structurally similar to the active form
of Naa10 within the binary NatA complex, rather than NAA10 alone, which is not active
towards NatA substrates. A notable place where SsNAT and NAA10 diverge is in the Cterminal end of the a1 helix that is part of the a1-a2 loop substrate binding region of
NATs. This region of SsNAT is more similar to the eukaryotic NAA50, which is also
active towards NatE substrates as a monomer. This suggests that SsNAT is a hybrid of
the NAA10 and NAA50 eukaryotic NATs. This is consistent with biochemical studies on
SsNAT demonstrating that different catalytic residues are used to acetylate NatA (Glu84)
and NAA50/NatE (Tyr73/His112) -like substrates, analogous to corresponding residues
in these eukaryotic NATs (Liszczak and Marmorstein 2013). It is possible that the
archaea NAT serves as one of the ancestors of eukaryotic NATs, which subsequently
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evolved to be substrate-specific. An unusually long β3-β4 loop in SsNAT, was also
shown to play a more selective role in acetylating NAA50-type substrates, although the
mechanism for this is still unclear. A more recent SsNAT structure (called Ard1) (Chang
and Hsu 2015) and Thermoplasma volcanium Ard1 (Ma et al. 2014), were consistent
with the earlier study, reinforcing the substrate flexibility of the archaeal NATs.
Interestingly, it was demonstrated that mutations of the catalytic Glu residue of ssNAT
could shift its substrate preference (Chang and Hsu 2015).

1.5 Eukaryotic NATs
NatA: NatA acetylates ~ 40% of human proteins, the most of any NAT (Arnesen
et al. 2009). NatA is a heterodimer of catalytic NAA10 (also named ARD1) and auxiliary
NAA15 subunits (Mullen et al. 1989; Park and Szostak 1992). Notably, NAA10 can also
exist independently (Arnesen et al. 2005; Van Damme, Evjenth, et al. 2011a). When the
second residue of a protein is relatively small and uncharged (Table 1.1), it will be
acetylated by NatA after the initiator methionine is cleaved (Polevoda et al. 1999;
Arnesen et al. 2009). In contrast, the NAA10 monomer is not able to acetylate canonical
NatA substrate, but instead exhibits specificity for acidic N-terminal sequences in vitro
(Van Damme, Evjenth, et al. 2011a; Drazic et al. 2018; Goris et al. 2018).
The structure of Schizosaccharomyces pombe NatA (SpNatA) bound to a CoApeptide conjugate reveals that the SpNAA15 auxiliary subunit adopt a ring-like structure
of tetratricopeptide repeat (TPR) motifs, which completely wraps around the SpNAA10
catalytic subunit, with the two proteins making extensive hydrogen bonding and van der
Waals interactions (Figure 1.4A) (Liszczak et al. 2013). The Chaetomium thermophilum
13

(Weyer et al. 2017) and Saccharomyces cerevisiae (Deng et al. 2019) NatA display
similar overall folds. A structural comparison of the SpNatA complex with SpNAA10
alone, reveals that SpNAA15 binding to SpNAA10 induces a conformational change of
the a1-a2 loop region of SpNat10 to position key catalytic residues for substrate-specific
recognition and catalysis (Liszczak et al. 2013). The SpNAA10 active site reveals that hbonds to the backbone carbonyl groups of the first two residues and van der Waals
contacts to Ser1 anchor the peptide portion of the CoA-peptide conjugate (Figure 1.3).
Glu24 was also proposed to play role as a general base for catalysis. Each of the
residues revealed to play important roles in substrate binding and catalysis are highly
conserved within NatA orthologs and shown to result in decreased NatA activity when
mutated (Liszczak et al. 2013). Importantly, modeling of amino acid side chains in the
Ser1 position, reveals that only small uncharged amino acids could be accommodated,
consistent with the known substrate specificity of NatA (Liszczak et al. 2013).
Interestingly, this same study showed that a non-cognate EEE peptide could be
acetylated by the SpNAA10-E24A mutant but not by WT SpNatA, suggesting that free
NAA10 uses a different catalytic strategy to acetylate NatH-type substrates.
The structure of the human NatA (hNatA) shows a high degree structural
conservation with SpNatA (Gottlieb and Marmorstein 2018), except for the presence of
an extended metazoan-specific Sel1-like repeat region at the C-terminal end of the
hNAA15 auxiliary subunit, which was shown to play a role in overall hNatA stability
(Gottlieb and Marmorstein 2018). In addition, the hNatA structure reveals the presence
of an endogenously bound inositol hexaphosphate (IP6) molecule at an interface region
between hNAA10 and hNAA15 via electrostatic interactions (Gottlieb and Marmorstein
2018; Deng, McTiernan, et al. 2020). A recently identified hNatA mutant K450E displays
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defects in IP6 binding and leads to NatA activity loss which can be rescued by the
addition of IP6 (Cheng et al. 2019), consistent with a role of IP6 in hNatA stability and
activity.
NatB: NatB, conserved from yeast to man, acetylates ~21% of human proteins,
such as actin, tropomyosin, CDK2, and α-synuclein. NatB is a binary complex containing
catalytic NAA20 and auxiliary NAA25 subunits and has specificity for N termini
containing MD-, ME-, MN- and MQ- sequences (Van Damme et al. 2012). The structure
of Candida albicans NatB (CaNatB) was determined alone and in complex with a CoApeptide conjugate (Hong et al. 2017). The catalytic CaNaa20 subunit shows a typical
GNAT fold, and the CaNAA25 auxiliary subunit also displays high structural similarity to
SpNAA15, particularly in the way it wraps around the catalytic subunit (Figure 1.4A).
Unlike NAA10, NAA20 is unstable in the absence of NAA25. Extensive interactions are
observed between CaNAA25 and CaNAA20, with the major contact interface mediated
by the α1- α2 loop of CaNAA20 (Hong et al. 2017), similar to the NatA complex. The
interaction between NAA20 and the peptide substrate mainly involves h-bond
interactions to the backbone amides of the first three residues of the peptide portion of
the CoA-peptide conjugate, with side chain contacts to residues Met1 and Asp2 through
van der Walls and h-bond interactions (Figure 1.3).

Mutation of contact residues

generally reduce NatB acetylation activity, consistent with the structural observations
(Hong et al. 2017). A more recent Cryo-EM structure of human NatB bound to a CoA-asynulein peptide conjugate shows a high degree of structural similarity to CaNatB,
although provides structural and biochemical data consistent with a role for Tyr124
(hNAA20-Tyr123) acting as a general base for catalysis (Deng, Pan, et al. 2020).
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NatC: NatC is a heterotrimer of a catalytic subunit NAA30 and two auxiliary
subunits NAA35 and NAA38 (Polevoda and Sherman 2001). NatC acts co-translationally
on the peptide substrate staring with ML-, MF, MI, MW-, playing roles in viral particle
assembly, maintaining mitochondrial integrity and apoptosis (Van Damme et al. 2016a;
Starheim et al. 2009). Recent x-ray crystal structures of S. cerevisiae NatC with cofactor
and ligand bound revealed that it has distinct divergent architecture compared to other
NATs (Grunwald et al. 2020). Overall, the larger auxiliary subunit NAA35 serves as the
central assembly hub to form extensive interaction with the smaller auxiliary subunit
NAA38 and NAA30. NAA38 displays an Sm fold, consisting of an α-helix followed by a
five-strand β-sheet, and interacts with the N-terminal region of NAA35. The absence of
NAA38 compromises NatC activity in vitro, indicating its indispensable role in the whole
complex. NAA30 adopts a typical GNAT fold, however, unlike NatA or NatB, its α1–α2
and β6–β7 loops are both buried inside the interface between NAA30 and NAA35.
Biochemical analysis suggested that NatC preferably recognizes its substrates not just
by the identity of the second residue, but also residues beyond position 2 (Grunwald et
al. 2020). It was proposed that ScNaa30-Glu118 functions as the general base residue
to deprotonate the substrate and ScNaa30-Tyr130 serves as the general acid to reprotonate the initially formed thiolate anion of CoA (Grunwald et al. 2020). Our recent
structural and biochemical studies on SpNatC showed some distinct features but agreed
mostly with the results on ScNatC describe above (See chapter 5).
NatD: NatD (NAA40), which functions as a monomer, is conserved from yeast to
human, and is the most selective NAT, carrying out NTA of only histones H4 and H2A
(Song et al. 2003; Hole et al. 2011), which most commonly contain the sequence
SGRGK. The structure of hNatD bound to acetyl-CoA and CoA and an N-terminal
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histone H4/H2A peptide, reveals that while NatD adopts a GNAT fold, it also contains a
unique N terminal helix-loop-strand segment, which wraps around the GNAT domain
and plays an important role in hNatD stability, partially mimicking similar roles of the
auxiliary subunits of NatA and NatB (Magin, Liszczak, and Marmorstein 2015) (Figure
1.2A). Another unique feature of NatD is found in its substrate binding loops, where the
α1- α2 loop is extended and flipped towards the peptide substrate, such that the
opposing β6-β7 loop is flipped away (Magin, Liszczak, and Marmorstein 2015). This
alters the peptide binding site to make it uniquely suited for its cognate N-termini.
Indeed, the structure of hNatD bound to CoA and peptide reveals that nearly every
hydrogen bond donor and acceptor atom within the first four residues are engaged in
hydrogen bounding interactions, with Arg3 playing a particularly important role, and the
small sizes of Gly2 and Gly4 also being critical (Figure 1.3). Activity assays also
revealed that Glu139 is essential for catalyst, possibly acting as a general base (Figure
1.3).
NatE: NatE refers to the complex between the NAA50 catalytic subunit and the
NatA complex (also containing the NAA10 catalytic subunit). Monomeric NAA50 is also
stable. However, yeast NAA50 is inactive, while in higher eukaryotes, such as human
and Drosophila, NAA50 is active in the absence or presence of NatA (Evjenth et al.
2009; Liszczak, Arnesen, and Marmorstein 2011; Van Damme et al. 2015; Rong et al.
2016; Deng et al. 2019). NAA50 has specificity for N-terminal Met residues followed by a
less restricted set of amino acids at the second position (Table 1.1) (Evjenth et al. 2009)
. The structure of hNAA50 bound to CoA and an N-terminal peptide reveals that the
peptide is recognized almost exclusively through interactions to residues one and two
(Liszczak, Arnesen, and Marmorstein 2011) (Figures 1.2A and 1.3). While the carbonyl
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and amino groups of residues Met1 and Leu2 engage in h-bond interactions, the side
chains make extensive van der Walls interactions. Consistent with the known specificity
of NAA50, the active site appears exquisitely suited for Met1, while the Val2 binding site
appears to have greater flexibility to accommodate several amino acid substitutions
(Figure 1.3). A combination of mutagenesis, kinetics and structural observations
suggest that hNAA50 Tyr73 and His112 are essential for catalysis via an ordered water
molecule, likely serving as general acid or base residues (Liszczak, Arnesen, and
Marmorstein 2011) (Figure 1.3). Interestingly, these two catalytic residues of hNAA50
are absent in the corresponding positions of yeast homologous, which likely explains the
inactivity of the yeast NAA50 proteins. A recent structure of ScNatE and related
biochemical studies also shows that ScNAA50 has relatively poor acetyl-CoA binding
capacity, consistent with its catalytic inactivity (Deng et al. 2019).
The binding affinity between NAA50 and NatA is in the nanomolar range (Deng
et al. 2019), consistent with the fact that a significant portion of NAA50 in the cell is
bound to NatA (Hou et al. 2007). The molecular basis for association between NAA50
and NatA from yeast and human were recently revealed (Deng et al. 2019; Deng,
McTiernan, et al. 2020) , demonstrating that NAA50 docks onto a unique surface of the
NAA15 auxiliary subunit primarily through hydrophobic interactions, while making
significantly more modest electrostatic interactions with NAA10 (Figure 1.4).
Nonetheless biochemical experiments reveal that NAA10 and NAA50 can influence each
other’s activity within the NatE complex (Deng et al. 2019; Deng, McTiernan, et al. 2020)
.
NatF: NatF (NAA60), found only in higher eukaryotes (Rathore et al. 2016; Van
Damme, Hole, et al. 2011), is located on the cytosolic side of Golgi membranes to
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acetylate transmembrane protein (Aksnes et al. 2015; Aksnes et al. 2017). It has an
unique membrane binding domain at its C-termini (Aksnes et al. 2015; Chen et al. 2016;
Stove et al. 2016; Aksnes et al. 2017), which mediates Golgi membrane binding (Aksnes
et al. 2017). Recently, Arabidopsis thaliana NatF was demonstrated to associate with the
plasma membrane also via its C-termini (Linster et al.). NatF has specificity for Nterminal Met residues followed by Leu, Ile, Phe, Tyr and Lys residues (Table 1.1). Unlike
other NATs, NatF is homodimeric in solution but shifts to a monomer state when peptide
substrate binds (Figure 1.2B) (Stove et al. 2016). The structure of hNatF in complex
with CoA or a CoA-peptide conjugate reveals that it has a unique extended β -β7 loop,
which mediates dimerization and sterically occludes peptide binding, but participates in
peptide recognition of the NatF monomer when cofactor and peptide are both bound
(Stove et al. 2016). hNatF peptide recognition in hNatF is mainly to the first two residues,
through backbone h-bonds and a hydrophobic pocket (similar to NAA50) that recognizes
Met1 with less specificity for residue Lys2 (Figure 1.3) (Stove et al. 2016). Tyr97 and
His138 are proposed to function as general base residues in hNatF, similar to roles
played by residues of Tyr73 and His112 from hNAA50 (Stove et al. 2016), which is
consistent with mutagenesis studies (Figure 1.3) (Chen et al. 2016).
NatG: NatG is localized within the chloroplast of plant, processing M-, A-, S-, Tstaring-termini as substrates (Dinh et al. 2015). As of the writing of this review, a detailed
structure/function analysis of NatG had not yet been reported.
NatH: NatH (NAA80) is widespread only in animals (Drazic et al. 2018), and
post-translationally active toward processed cytoplasmic β- and γ-actin in vivo with acidic
N termini DDDI and EEEI, respectively (Drazic et al. 2018; Arnesen, Marmorstein, and
Dominguez 2018; Wiame et al. 2018). The structure of Drosophila melanogaster Naa80
19

(DmNaa80) bound to a CoA-peptide conjugate reveals a more open and highly basic
substrate binding site than other NATs, which is specifically configured to bind its acidic
substrates (Goris et al. 2018) (Figure 1.2A). H-bonds extend through the first three
backbone and side-chain residues (Figure 1.3), explaining the specificity for highly
acidic substrates. An unusual intramolecular hydrogen bond is also observed between
the backbone amide nitrogen of I4 and the sidechain of D2 (Figure 1.3). Mutational and
activity assays is consistent with substrate preference deriving mostly from the acidic
residues at positions two and three (Goris et al. 2018), which is unusual for NAT proteins
that typically specify residues one and two.
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Figure 4.4 Some NATs function by forming complexes with auxiliary subunits or
regulatory proteins
(A) Structures of SpNatA (PDB:4KVM), CaNatB (PDB:5K04), ScNatE (PDB: 6O07), and
hNAA80-actin-profilin complexes (PDB:6NBE) are shown in cartoon. (B) In humans, the
dynamics and interplay between hNatA, hNAA50, and HYPK are shown. hNAA10 can
exist independently. Two subunits and Inositol hexaphosphate (IP6) form hNatA (PDB:
6C9M) complex. HYPK and hNAA50 each can associate with hNatA to form competing
complexes (hNatA/HYPK PDB: 6C95 and hNatE PDB:6PPL). Tetrameric complex
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hNatE/HYPK (PDB: 6PW9) can be formed when both HYPK and hNAA50 are bound to
hNatA. hNAA10, HYPK, hNAA50, and hNAA15 are shown in chartreuse, salmon, teal,
and grey, respectively. (C) Structure of ScNatE bound to ribosome (PDB: 6HD7) is
shown. Two rRNA expansion segments ES27a and ES7a are contacting NAA15 and
NAA50, respectively. Two electropositive regions ERP1 (N terminus of NAA15), and
EPR2 (internal basic helix) on NAA15, which directly contact ribosome, are shown in the
zoom-in view.

1.6 Regulation of NATs
1.6.1 Huntingtin-Interacting Protein K regulates both NatA and NatE activity
The Huntingtin-Interacting Protein K (HYPK) , was found to associate with the
human NatA complex (Arnesen et al. 2010). It is absent in most yeast , but found in
Chaetomium thermophilum (Weyer et al. 2017) and human (Deng, McTiernan, et al.
2020; Gottlieb and Marmorstein 2018) where it was structurally characterized bound to
NatA. In both cases, HYPK was shown to have intrinsic NatA inhibitory activity, and in
the study of the human complex proposed to contribute to cognate substrate specificity
as HYPK was shown to be partially uncompetitive and noncompetitive with respect to
acetyl-CoA and peptide substrate, respectively (Gottlieb and Marmorstein 2018). When
bound to NatA, HYPK forms a bipartite structure: a C-terminal ubiquitin-associated
domain (a3-a5) binds extensively to the NAA15 auxiliary subunit, a N-terminal loop-a1helix region binds across the catalytic NAA10 subunit to distort its active site, and a long
a2 helix connects these two ends of HYPK. Biochemical data is consistent with the
structural findings that the ubiquitin-associated domain forms the high affinity interaction,
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while the loop-a1-helix region harbors the catalytic inhibitory activity. More recently,
structural and biochemical studies reveal that HYPK can also form a stable complex with
the NatE complex (Figure 1.4B), although HYPK and NAA50 where shown to
allosterically reduce the binding affinity of each other (Deng, McTiernan, et al. 2020).

1.6.2 NAA80 activity is regulated by the actin chaperone profilin
Naa80 is preferentially active towards monomeric actin and the presence of
profilin has been shown to increase its catalytic efficiency (Rebowski et al. 2020). The
crystal structure of hNaa80 in complex with monomeric actin and profilin with cofactor
and cofactor analogs reveals the first structure of a NAT bound to its intact protein
substrate (Rebowski et al. 2020). The structure shows that a Naa80-specific extended
β6-β7 proline-rich loop and α2-helix of hNAA80 is utilized to meditate interaction with
both actin and profilin (Rebowski et al. 2020). Thus formation of hNAA80-actin-profilin
complex orients the N termini of actin perfectly into the substrate binding groove of
hNAA80 (Figure 1.4A) (Rebowski et al. 2020). It is proposed that, with the aid of profilin,
hNAA80 can act more efficiently to compensate for the low abundance of hNAA80
relative to actin in the cell.

1.6.3 Ribosome association by NATs
In eukaryotes, NatA/B/C/E associate with the ribosome for co-translational
activity, utilizing their auxiliary subunits as the predominant anchoring point (Polevoda et
al. 2008), while NatD could potentially use its extended N terminal region (Magin,
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Liszczak, and Marmorstein 2015; Hole et al. 2011). This proximity of the NATs to the
ribosome likely facilitates the relatively high stoichiometry of NTA that is observed in
vivo.
The current molecular understanding of the interactions between NATs and the
ribosome is limited to NatA or NatE. Early studies suggested that NatA contacts
ribosomal protein uL23 and uL29 around the peptide exit tunnel (Polevoda et al. 2008) to
interact with the nascent chain (Gautschi et al. 2003). The ratio of ribosome to NatA is
around 40:1 in yeast, leading to questions about the dynamics of NatA/ribosome
interactions (Raue, Oellerer, and Rospert 2007). Purified non-translating ribosome can
also interact with NatA in vitro via two conserved electropositive regions (EPR) on
NAA15 (Magin et al. 2017), which is confirmed through mutational studies (Magin et al.
2017) and in vivo (Varland and Arnesen 2018). A recent structure of a ScNatE/ribosome
complex reveals that ScNatE docks at the nascent peptide exit tunnel near uL31 and
uL22, with rRNA expansion segments making key contacts to ScNAA15 and ScNaa50
(Figure 1.4C) (Knorr et al. 2019).

1.7 Remaining Questions
NTA occurs on countless proteins in three domains of life both co-translationally
and post-translationally, impacting diverse cellular functions of their client protein.
Although sharing an evolutionarily conserved GNAT fold and related catalytic
mechanism, each NAT employs unique elements to mediate substrate-specific activity to
carry out their distinct cellular functions. NAT auxiliary and regulatory subunits also play
NAT-type specific roles. While some NATs have dedicated co-translational and post24

translational roles, the mechanisms that may toggle some NATs such as NAA10 and
NAA50 between the two roles requires further investigation. Still missing from the PDB
are the chloroplast localized NATs, which may have unique functions. Do other NAT
agonists or antagonists exist and how might they work? Finally, a greater molecular
understanding of how NATs carry out and navigate between each other co-translational
NTA on the ribosome warrants further study (See Chapter 6 for more details).
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CHAPTER 2: Structure and Mechanism of Acetylation by the N-Terminal Dual
Enzyme NatA/Naa50 Complex

This work is adapted from Structure (Deng et al. 2019) © Cell Press
26

2.1 Introduction
The majority of nascent peptides biosynthesized by the eukaryote cytosolic
ribosome undergo several N-terminal co-translational modifications before they become
fully functional and mature proteins. Along with initial methionine cleavage by methionine
aminopeptidase (iMAP) and N-terminal myristoylation, N-terminal acetylation (Ntacetylation), which transfers an acetyl moiety from acetyl-CoA to the N-terminal amino
group of proteins, is an irreversible, highly conserved and abundant modification
(Giglione, Fieulaine, and Meinnel 2015). About 50-70% of S. cerevisiae proteins, 70%75% of A. thaliana proteins, and 70-90% of H. sapiens proteins are subject to Ntacetylation by a family of N-terminal acetyl transferases (NATs) (Starheim, Gevaert, and
Arnesen 2012). Nt-acetylation is generally considered to be a co-translational process,
with most NATs making direct interactions with both nascent peptide and the ribosome
(Gautschi et al. 2003; Polevoda et al. 2008; Magin et al. 2017; Knorr et al. 2019).
Numerous studies have demonstrated that Nt-acetylation can affect diverse
protein and cellular activities including gene regulation, apoptosis, protein folding, protein
degradation, protein complex formation and subcellular localization (Aksnes et al. 2016;
Holmes et al. 2014; Shemorry, Hwang, and Varshavsky ; Behnia et al. 2004; Yang et al.
2013; Dikiy and Eliezer 2014; Hwang, Shemorry, and Varshavsky 2010; Schiza et al.
2013; Starheim et al. 2009; Arnesen, Gromyko, et al. 2006; Setty et al. 2004b; Pavlou
and Kirmizis 2016). Knockout of NATs frequently results in severe cellular defects
including slow growth and reduced mating efficiency in yeast. In higher eukaryotes,
misregulation of N-terminal acetylation can lead to numerous developmental disorders
and cancers (Kalvik and Arnesen 2013; Myklebust, Stove, and Arnesen 2015; Lee et al.
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2010; Yu et al. 2009; Arnesen, Gromyko, et al. 2006; Ametzazurra et al. 2008; Starheim
et al. 2008; Starheim et al. 2009; Fluge et al. 2002; Hua et al. 2011). For example, the
NatA catalytic subunit, Naa10, plays important roles in mammalian cells including
cellular hypoxia, bone formation and DNA damage (Dorfel and Lyon 2015; Jeong et al.
2002; Yoon et al. 2014; Yi et al. 2007). Mutation in human Naa10 causes the genetic
disorder Ogden syndrome (Rope et al. 2011).
Several NATs, including NatA, NatB, NatC, NatD, NatE, and NatF are conserved
across eukaryotes (Aksnes et al. 2016) (Aksnes et al. 2015; Aksnes et al. 2017; Stove et
al. 2016). NatG is resident in chloroplasts of plant cells (Dinh et al. 2015), and the
recently identified NatH/Naa80 exists only in animals to acetylate a subset of processed
actins (Drazic et al. 2018). The presence of NatF, NatG, and NatH indicates that this
modification can also occur post-translationally. NATs can acetylate the N-termini either
when the initiator methionine (iMet) is cleaved or retained, mostly depending on the
identity of the first two amino acids of the nascent peptide (Aksnes et al. 2016), which
further enriches the complexity of the eukaryote proteome. Both NatA and NatD
complete the process after iMet is cleaved. NatA shows specificity toward the N-termini
of exposed A-, S-, T-, V-, C-, and sometimes G-, while NatD can only acetylate the Nterminal serine of histones H2A and H4 (Magin, Liszczak, and Marmorstein 2015;
Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Arnesen et al. 2009; Song et al.
2003). Other NATs like NatB, NatC, NatE, and NatF modify peptides with the iMet
retained. NatB prefers the Met-Asx/Glx type N-termini (MD-, ME-, MN-, and MQ-starting)
, whereas NatC, NatE, and NatF have some substrate overlap, and they acetylate
peptides with “hydrophobic/amphipathic” residues like L, I, F, Y, K directly following iMet
(Liszczak, Arnesen, and Marmorstein 2011; Stove et al. 2016; Van Damme et al. 2016b;
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Tercero, Dinman, and Wickner 1993; Evjenth et al. 2009; Van Damme, Hole, et al.
2011). NatA, B and C are the three major contributors to the Nt-acetylome, as they cover
about 80% of all NAT substrates (Aksnes et al. 2016). Notably, NatA, B and C contain at
least one auxiliary subunit to couple with the catalytic subunit for enzymatic activity
towards cognate substrates and anchoring of the catalytic subunit to the ribosome, while
NatD, F, G, H are each composed of only one single catalytic subunit. NatE is composed
to two catalytic and one auxiliary subunit.
NatA is comprised of the catalytic subunit Naa10 and the auxiliary subunit Naa15
(Liszczak et al. 2013; Gottlieb and Marmorstein 2018). Naa10 can also exist
independently of Naa15, exhibiting altered substrate specificity and might also be
involved in transcriptional activity inside the nucleus (Arnesen et al. 2005; Van Damme,
Evjenth, et al. 2011b). Alternatively, NatA can also form a complex with another catalytic
subunit Naa50 to form a ternary NatA/Naa50 complex (also called NatE) (Gautschi et al.
2003), and NatA from some eukaryotic species including Chaetomium thermophilum and
human exhibit tight binding affinity with a regulatory protein called HYPK (Gottlieb and
Marmorstein 2018; Weyer et al. 2017; Arnesen et al. 2010). Deletion of Naa50 in yeast
shows no phenotype (Gautschi et al. 2003), while Naa50 knockout can affect sister
chromatid cohesion in higher organisms like Drosophila and human (Hou et al. 2007;
Chu et al. 2011; Ribeiro et al. 2016; Williams et al. 2003). Endogenous pulldown of
NatA/Naa50 complexes from human cells indicates that over 80% of Naa50 is not
associated with NatA in vivo (Hou et al. 2007), whereas the remaining ~20% forms a
stable and stoichiometric complex. Furthermore, another recent study demonstrates that
loss of Naa50 in Drosophila leads to a decrease of NatA in vivo acetylation activity
(Rathore et al. 2016). A recent Cryo-EM structure of a yeast NatA/Naa50-ribosome
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complex with an 8 Å NatA local resolution reveals that both Naa50 and the Naa15
regulatory subunit of NatA contribute to ribosome interaction, with the Naa10 active site
about 50 Å from the ribosome exit tunnel, and the Naa50 active site about 2-times that
distance (Knorr et al. 2019). The underlying molecular basis for the potential functional
coupling and interplay between the catalytic subunits of the NatA/Naa50 complex is still
poorly understood.
To understand the molecular basis for NatA/Naa50 co-regulation of N-terminal
protein acetylation across species, we determined the X-ray crystal structure of a yeast
NatA/Naa50 complex and used it as a scaffold to understand coregulation of
NatA/Naa50 activity in yeast and human. We find that NatA/Naa50 forms a stable
complex in yeast and human through conserved interactions: Naa50 makes contacts to
both the Naa10 and Naa15 subunits of NatA. We demonstrate that NatA-Naa50
interactions can significantly promote the catalytic activities of the two catalytic subunits
within the human complex relative to NatA or Naa50 alone. In contrast, in the yeast
complex, Naa50 modestly increases the activity of NatA, and Naa50 is defective in
catalytic activity, likely through compromised peptide binding. These studies have
implications for understanding the role of the NatA/Naa50 complex in modulating the
majority of the N-terminal acetylome in diverse species.
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2.2 Results
2.2.1 NatA and Naa50 form stable complexes in yeast and human
We used recombinant proteins to characterize the interaction between Naa50
and NatA from human (h) and S. pombe (Sp) in vitro. Recombinant SpNatA, SpNaa50,
and human Naa50 were overexpressed and purified from E. coli, while hNatA was
prepared from baculovirus-infected Sf9 insect cells. Consistent with previous data
reporting a direct interaction between NatA and Naa50 (Gautschi et al. 2003; Hou et al.
2007), we found that N-terminal GST-tagged Naa50 can pull-down NatA. We also found
that human and

S. pombe NatA

and Naa50 co-migrate by size-exclusion

chromatography to form stochiometric complexes under near native salt concentration
(200 mM NaCl) (Figure 2.1A). Interestingly, SpNaa50 maintained the ability to comigrate with SpNatA in sizing buffer with NaCl concentration as high as 1 M (Figure
2.1A), suggesting that this interaction in S. pombe is robust and not dominated by
electrostatic interactions, while hNatA and hNaa50 failed to form a stochiometric
complex in the high salt buffer (Figure 2.1A) suggesting some divergence of the NatANaa50 interaction between the yeast and human complexes. In addition, we observed
that SpNaa50 displays similar comigration with ScNatA under both native and high NaCl
concentrations (Figure 2.1A), strongly indicating that the NatA-Naa50 interaction within
yeast is highly conserved.
To more quantitatively assess the interaction between NatA and Naa50, we
carried out a Fluorescence Polarization (FP) assay, using Naa50 labeled with
Fluorescein-5-Maleimide via exposed surface cysteines. We observed that Naa50 tightly
binds to NatA in both the S. pombe and human systems with Kd values of 17 ± 3.4 nM
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and 29 ± 5.6 nM, respectively (Figure 2.1B). These data, together with the high degree
of sequence conservation of the interaction interfaces between Naa50 and NatA in the
two species, suggest that Naa50 and NatA from yeast and human are very likely to have
similar association mechanisms. However, we found that GST-hNaa50 failed to pull
down SpNatA, and that hNaa50 and SpNatA could not form a stoichiometric complex in
size-exclusion chromatography (data not shown), indicating that the details of the
hNatA/Naa50 interaction have diverged over evolutionary time. This was further
validated using differential scanning fluorimetry experiments, where we found that the
addition of SpNaa50 to SpNatA and hNaa50 to hNatA had thermal melting temperature
increases of 37.8 °C to 40.4 °C and 44 °C to 46.6 °C, respectively; while the addition of
hNaa50 to SpNatA had a thermal melting temperature of 37.5 °C, very close to SpNatA
alone (Figure 2.1C). Notably, SpNaa50 significantly extended the melting temperature
of ScNatA by 7.4°C, further confirming the existence of a conserved robust interaction
across these two yeast species (Figure 2.1C).
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Figure 5.1 NatA and Naa50 form stable complexes in yeast and human
(A) Gel filtration elution profiles of Naa50 with NatA in S. pombe (top), human (middle),
and cross-species between yeast S. pombe and S. cerevisiae (bottom), using a
SuperdexS200column, with either 200 mM or 1MNaCl in sizing buffer. Coomassiestained SDS-PAGE of peak fractions are shown to the right of the chromatograms. (B)
Fluorescence polarization assays with NatA titrated into fluorescein-5-maleimide-labeled
Naa50 in both S. pombe (left) and human (right) systems. The data are fit to calculate a
dissociation constant between NatA and Naa50. Errors bars are reported in SD with n =
3. (C) Differential scanning fluorimetry assays of NatA alone or with Naa50 in both yeast
and human systems. Recorded melting temperature transitions are indicated. Error bars
in the figure indicate the SD of each sample, n = 3.

2.2.2 Crystal structure of the ternary NatA/Naa50 complex shows that Naa50 contacts
both subunits of NatA
To reveal the molecular basis for the association and regulation mechanism of
the NatA/Naa50 complex, we determined its crystal structure. We were unable to obtain
crystals of the human complex, and crystals of the S. pombe complex diffracted X-rays
poorly. However, we found that full-length ScNaa15 (residues 1–854) from S. cerevisiae
(Sc) with a C-terminal truncation of ScNaa10 (1–226 out of 238 total residues) and fulllength ScNaa50 (residues 1–176) produced crystals with good diffraction quality, in the
presence of inositol hexaphosphate (IP6) and bi-substrate analogs for both Naa50 and
Naa10. The crystals formed in the P212121 space group with one ternary complex in the
asymmetric unit. The diffraction data set was collected to 2.7 Å resolution, and the
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structure was determined by molecular replacement with an unpublished ScNatE
complex (Protein Data Bank code: 4XNH) as an initial search model. The final structure
was refined to Rwork and Rfree values of 22.21% and 25.03%, respectively. Refinement
statistics can be found in Table 2.1.
Not surprisingly, the ScNaa15 auxiliary subunit of NatA displays a high degree of
structure conservation with SpNaa15 and hNaa15, with root-mean square deviation of
1.409 Å (over 577 common Cα atoms) and 1.537 Å (over 640 common Cα atoms),
respectively. Shaped like a horseshoe, ScNaa15 is comprised of 15 TPR motifs, which
often mediate protein-protein interactions. The electron density for the first two alpha
helices (N terminal 1-53 residues) is poorly resolved and not built in our model. This
auxiliary subunit, consisting of a total 42 α-helices, serves as the binding scaffold for
both catalytic subunits. ScNaa10 is completely wrapped by the Naa15 helices (from α11
to α30, encompassing residues Lys198- Gly595) with extensive interactions, with an
overall contact surface area of 3555.5 Å2 (Figure 2.2A). The longest alpha helix is α29,
expanding to be as long as 70 Å across almost the entire length of the protein. This
extremely long helix bridges the overall ring-like tertiary structure of Naa15 and locks
Naa10 into the well-formed cradle made by the surrounding helices. Naa50 sits adjacent
to Naa10 and interacts mostly with several Naa15 helices (α21, α22, α23, α24,
encompassing residues Pro380-Asp448), and more modestly with the

2- 3 loop of

Naa10, with an overall contact surface area of only 632.3 Å2 (Figure 2.2B).
The significantly less contact surface between Naa50 and Naa15, relative to
between Naa10 and Naa15, is probably one reason that Naa50 in this ternary complex
displays surprising flexibility, as indicated by its high average B factor (87.6 Å2)
compared to Naa10 (48.9 Å2) and Naa15 (56.2 Å2). Several Naa50 residues away from
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the Naa50-Naa15 interface have poor side chain density and are therefore modeled as
alanine residues and some parts of α helices and β strands are built as loops.
Interestingly, the NatA bisubstrate analog used in the cocrystallization could not be
resolved due to its poor electron density and was therefore omitted from the model,
while only the CoA portion of the Naa50 bisubstrate inhibitor was well resolved and are
therefore included in the model.
Previous studies have revealed that human NatA contains a bound IP6 molecule
that bridges interactions between helices α19, α24, α25 of hNaa15 and the β2-loop-β3 of
hNaa10 (Gottlieb and Marmorstein 2018). To identify whether a similar IP6 binding
pocket exists in ScNatA, IP6 was added to the crystallization of the ternary
ScNatA/Naa50 complex. Clear electron density for IP6 was visible between Naa10 and
Naa15, in almost the same position identified in the corresponding human NatA complex
(data not shown). Extensive electropositive and hydrogen-bond interactions contribute to
this interaction including K80, Y85, and K91 from Naa10, and K429, K457, R464, R426,
H430 and Y461 from Naa15 (Figure 2.2C). All these residues in Naa15 are conserved
from yeast to human, which suggests that this binding mode is structurally conserved.
We validated the conserved intimate binding of IP6 by also showing its robust binding to
SpNatA using isothermal titration calorimetry (ITC), measuring a dissociation constant of
~130 nM, with a 1:1 stoichiometry (Figure 2.2D).
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Figure 6.2 Crystal structure of the ternary NatA/Naa50 complex shows that Naa50
contacts both subunits of NatA
(A) ScNaa10 (yellow), ScNaa15 (cyan), and ScNaa50 (violet) are shown in cartoon. The
N-terminal two alpha helices (residues 1-53) of Naa15 are not resolved and not shown in
the structure. Several alpha helices of Naa15 that contribute to Naa10 and Naa50
binding are labeled. (B) Zoom-in view of the interface between Naa50, Naa10 and
Naa15. Residues that contribute to interactions between Naa10 and Naa50 are shown.
(C) Zoom-in view showing key residues involved in interactions with IP6. (D)
Representative isothermal titration calorimetry (ITC) of curve of IP6 titrated into SpNatA
with the calculated dissociation constant indicated.
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Table 2.1 Data statistics for ScNatA/Naa50 crystal structure (PDB: 6O07)
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2.2.3 Hydrophobic interactions dominate the ScNatAScNaa50 binding interface
The NatA/Naa50 structure reveals that Naa15 is the primary docking site for
Naa50. The contact interface is mediated primarily by the Naa50 β2-β3 and β4-α2 loops
with the Naa15 α22-α23 loop. These regions form a network of hydrophobic interactions
mediated by several non-polar residues, including Met18, Leu22, Tyr65, Pro70, and
Val71 from Naa50 and Leu447, Val418, Thr416, Leu417 from Naa15 (Figure 2.3A). A
few H-bonds are observed: the Naa15 Thr414 sidechain bridges and interaction with the
side chain of Naa50 Tyr102 and Naa15 His413, and the Naa15 Thr416 sidechain
interacts with the backbone carbonyl group of Naa50 Pro70 (Figure 2.3A). The largely
hydrophobic nature of the interface is consistent with our biochemical observation that
the SpNatA and Naa50 interaction can be maintained under high salt. Importantly, we
found that the TPTLXE (where X represents either V or I) motif in the Naa15 α20-α21
loop is highly conserved in both yeast and human, thus suggesting that yeast and
human share a similar NatA-Naa50 binding mode.
Unlike Naa10, which is surrounded on all sides by interactions with Naa15 helical
segments, thereby locking Naa10 in place, contacts between Naa50 and Naa10 are
more modest and mediated by the α3-β4 loop of Naa10. Specifically, contact between
Naa10 and Naa50 involves several basic residues within the α3-β4 loop of Naa10
(Arg122, Arg125 and Arg126) and Glu68 within the β2-β3 of Naa50, which make a
network of electrostatic interactions (Figure 2.3B). The distance of Glu68 to Arg122,
Arg125 and Arg126 is 2.3 Å,3.8 Å, and 6.2 Å, respectively. The relative paucity of
Naa50-NatA interactions likely allows Naa50 to be conformationally flexible to allow it to
impose regulatory effects on Naa10 activity. Supporting this notion is the fact that Naa10
Arg125 is the first conserved residue of the acetyl-CoA binding motif Q/RxxGxG/A.
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Figure 7.3 Hydrophobic interactions dominate the ScNatA-ScNaa50 binding
interface
(A) Zoom-in view of the major hydrophobic binding interface between Naa15 and Naa50
with residues that participate in interaction shown. (B) Zoom-in view of the contacts
between Naa10 and Naa50 with residues that participate in interaction shown.

2.2.4 The NatA/Naa50 complex promotes catalytic crosstalk
Since deletion of ScNaa50 shows no phenotype (Gautschi et al. 2003), while
Naa50 knockout in higher organisms has been shown to perturb sister chromatid
cohesion (Hou et al. 2007; Chu et al. 2011; Ribeiro et al. 2016) and NatA acetylation
activity in vivo (Rathore et al. 2016), we hypothesized that there might be fundamental
functional differences in the catalytic properties of Naa50 within the NatA/Naa50
complexes in yeast and human. To test this hypothesis, we took advantage of the fact
that NatA and Naa50 have distinct substrate preferences. Canonical NatA substrates
include peptides with the first four amino acids of SASE (Arnesen et al. 2009; Liszczak
et al. 2013) (hereinafter called “SASE peptide”) and Naa50 substrates include peptides
with the first four amino acids MLGP (Liszczak, Arnesen, and Marmorstein 2011; Evjenth
et al. 2009) (hereinafter called “MLGP peptide”). These peptides were used because of
their high specificity by their cognate NATs. For our kinetic analysis, we ignored any
background activity contribution of NatA toward MLGP peptide and Naa50 toward SASE
peptide, based on our data that NatA has negligible activity towards an MLGP peptide
(Figure 2.7) and previously published data showing that Naa50 has negligible activity
towards non-methionine containing N-termini (Evjenth et al. 2009).
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We found that hNaa50, either alone or in complex with hNatA, harbored robust in
vitro acetylation activity toward the Naa50 cognate peptide, MLGP (Figure 2.4A). Unlike
hNaa50, we found that both SpNaa50 alone or with SpNatA, and ScNaa50 alone or with
ScNatA, were enzymatically inactive toward the MLGP peptide (Figure 2.4A), consistent
with the reported lack of in vivo phenotype of ScNaa50 deletion (Gautschi et al. 2003).
Notably, we found that that hNaa50 activity was significantly promoted within the ternary
hNatA/Naa50 complex (Figure 2.4B). Indeed, kinetic analysis as a function of peptide
substrate demonstrated that hNaa50 harbored a 14-fold decrease in Km value and 11fold increase of catalytic efficiency when bound to hNatA (Figure 2.4B, Table 2.2). The
dramatic change in Km value suggested that either hNaa15 or hNaa10 can affect
hsNaa50 activity by increasing its substrate binding affinity.
We also investigated the effect of Naa50 binding on hNatA activity towards its
cognate SASE peptide in both the yeast and human systems. We observed that hNatA
showed about a 2.29-fold decrease of Km value and 1.75-fold decrease of Vmax when it
bound to hNaa50 (Figure 2.4C, Table 2.2). Similarly, we found that SpNatA showed
about a 2.45-fold decrease of Km value and 1.60-fold decrease of Vmax when bound to
SpNaa50 (Figure 2.4D, Table 2.2). Overall, SpNatA and hNatA showed comparably
significant but modest increases in catalytic efficiencies of 1.53-fold and 1.31-fold,
respectively. It is noteworthy that both the Naa10 catalytic subunit of the NatA complex
and hNaa50 display a lower Km for peptide when in the ternary complex, while SpNaa10
also displays a lower Km in the yeast complex. Taken together, we conclude that the
acetylation activities of both catalytic subunits- Naa10 and Naa50 are promoted in this
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ternary human NatA/Naa50 complex and Naa10 activity is more modestly promoted in
the S. pombe complex.

Figure 8.4 The NatA/Naa50 complex promotes catalytic crosstalk
(A)

Time

course

acetylation

activity

of

SpNaa50,

SpNatA/Naa50,

hNaa50,

hNatA/Naa50, ScNaa50 and ScNatA/Naa50 against the MLGP peptide substrate. (B)
Michaelis–Menten kinetic curve of hNaa50 and hNatA/Naa50 against the MLGP peptide
substrate. (C) Michaelis–Menten kinetic curve of hNatA and hNatA/Naa50 against the
SASE peptide substrate. (D) Michaelis–Menten kinetic curve of SpNatA and
SpNatA/Naa50 against the SASE peptide substrate.
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Table 3.2 Catalytic parameters for NatA, Naa50, and NatA/Naa50
against peptide substrate
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2.2.5 Narrow substrate binding sites likely contribute to the catalytic inactivity of yeast
Naa50s
Since we were unable to observe catalytic activity for SpNaa50 and ScNaa50,
we were surprised to observe electron density in the ScNaa50 active site that could be
used to model the acetyl-CoA portion of the acetyl-CoA-MLGP bisubstrate inhibitor that
was used in the cocrystallization. Moreover, sequence alignment of Naa50 in human and
yeast reveals that SpNaa50 and ScNaa50 do not contain an optimal Q/RxxGxG/A
consensus acetyl-CoA binding motif, where in both SpNaa50 and ScNaa50 the first
glycine residue is replaced with a serine residue. Using ITC, we were able to detect
acetyl-CoA binding to hNaa50 (Figure 2.5A) but not to SpNaa50 (Figure 2.5B). We also
observed that the SpNatA/Naa50 complex bound acetyl-CoA about 4.5-fold more
strongly than SpNatA alone (Figures 2.5C and 2.5D). Given that SpNaa50 alone
binding is not detected in ITC, we propose that the 4.5-fold increase in acetyl-CoA
binding affinity for SpNatA/Naa50 relative to SpNatA alone suggests that SpNaa50
binding to SpNatA facilitates acetyl-CoA binding activity to SpNatA. This is consistent
with our structural observation that ScNaa50 sits closely to the Q/RxxGxG/A acetyl-CoA
binding motif of ScNaa10, and thereby able to modulate the acetyl-CoA binding activity
of ScNatA. Surprisingly, binding signal was detected by ITC between GST-ScNaa50 and
acetyl-CoA (Figure 2.5E), but not the free GST or GST-SpNaa50 controls (Figure 2.5F
and 2.5G). This result suggests that the lack of acetyltransferase activity of ScNaa50 is
unlikely due to a defect in acetyl CoA binding.
Consistent with the catalytic inactivity of SpNaa50 and ScNaa50, we found that
the α1-α2 and β6-β7 loops of ScNaa50 that typically flank the peptide substrate, form a
much narrower groove compared to hNaa50 for peptide binding, with the most intimate
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distance between the loops of less than 2.8 Å (Figure 2.5H). In addition, both SpNaa50
and ScNaa50 lack the characteristic YY motif found in the β6- β7 loop which is important
for substrate binding in all NATs except for Naa40 and Naa80 (Liszczak et al. 2013;
Liszczak, Arnesen, and Marmorstein 2011; Magin, Liszczak, and Marmorstein 2015;
Goris et al. 2018; Hong et al. 2017; Aksnes et al. 2015). Taken together, it appears that
the acetyl-CoA and N-terminal peptide substrate binding sites of SpNaa50 are not
properly configured for catalytic activity, while ScNaa50 binds acetyl-CoA but likely does
not bind peptide substrate.
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Figure 9.5 Weak acetyl-CoA binding activity and a narrow substrate binding grove
contributes to the catalytic inactivity of yeast Naa50
(A) Representative ITC curve of acetyl-CoA titrated into hNaa50. (B) Representative
ITC curve of acetyl-CoA titrated into SpNaa50. (C) Representative ITC curve of acetylCoA titrated into SpNatA. The calculated dissociation constant is indicated. (D)
Representative ITC curve of acetyl-CoA titrated into SpNatA/Naa50. The calculated
dissociation constant is indicated. (E) Representative ITC curve of acetyl-CoA titrated
into GST-ScNaa50. (F) Representative ITC curve of acetyl-CoA titrated into GSTSpNaa50. (G) Representative ITC curve of acetyl-CoA titrated into free GST. (H)
Superimposition of ScNaa50 and hNaa50 (PDB: 3TFY) structures.

2.2.6 NatA-Naa50 from yeast and human make conserved interactions
To evaluate the degree of evolutionary conservation of the NatA-Naa50 interface,
we first used the ScNatA/Naa50 complex as a scaffold to carry out mutagenesis and
binding studies of the yeast NatA/Naa50 complex, using S. pombe for mutagenesis for
consistency with the earlier biochemical studies in S. pombe. Superimposition of the
ScNatA/Naa50 and SpNatA structures highlighted a few potential key S. pombe
candidate residues for interaction, including SpNaa10 R117, SpNaa15 T412, and
SpNaa50 Y49 and V53 (Figures 2.3). Using pull-down assays, we demonstrated that
SpNaa10-R117E had an insignificant effect on SpNatA binding, while SpNaa50-V53K
and -Y49A displayed some decrease in SpNatA binding (Figure 2.6A, left). As
expected, the double mutation, SpNaa50- Y49A/V53K was significantly defective in
SpNatA and ScNatA binding (Figure 2.6A). As these two residues are conserved from
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yeast to human, it was not surprising that the double mutation of hNaa50-Y50A/I54K
displayed similar defects in hNatA binding. The ScNatA/Naa50 crystal structure reveals
that ScNatA-T412 sits roughly in the middle position of the conserved Naa15 TPTLXE
motif and is located in the center of the binding interface within Naa15 and Naa50
(Figure 2.3A). Interestingly, we found that a single SpNaa15-T412 mutation to either
tyrosine or lysine completely disrupted complex formation with SpNaa50 (Figure 2.6A).
As expected, sequence alignment demonstrates that SpNaa15-T412 is well conserved
in both human and yeast. We further observed that both ScNaa15-T416Y and hNaa15T406Y (hereinafter referred to as TY mutants) lost their ability to association with Naa50
in pull down assays (Figure 2.6A). Consistent with the pull-down results (Figure 2.6A),
the Naa15 TY mutant from S. pombe, S. cerevisiae and human did not co-migrate with
Naa50 by size-exclusion chromatography (Figure 2.6B). For further studies, we focused
on SpNatA T412Y and the conserved hNatA T406Y and characterized their roles in
NatA-Naa50 association. While the addition of Naa50 to NatA showed robust binding
using a FP assay (Figure 2.1A) and increased thermal melting temperature of NatA by
about 2.5 °C using DSF assay (Figure 2.1B), addition of Naa50 to the NatA TY mutants
did not show detectable binding (Figure 2.7A) or increase in NatA TY mutant thermal
melting temperature (Figure 2.7B). We further tested the effect of the NatA TY mutants
on NatA acetylation activity and found that they maintained acetylation activity towards
cognate substrates although the hNatA TY mutant showed an apparent increase in
acetylation activity relative to WT (Figure 2.7C). The reason for this is unclear. Taken
together, the Naa15 TY mutants can disrupt the association between NatA and Naa50 in
yeast and human. These studies highlight the important roles of this conserve threonine
residue in the association between Naa50 and NatA.
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Figure 10.6 NatA TY mutants are unable to pull-down Naa50 and co-migrate with
Naa50
(A) GST pull-down assay with NatA/Naa50 mutants to interrogate the contribution of
residues in Naa50-NatA association. (B) Gel filtration elution profiles of Naa50 with
either wild-type (dotted red line taken from Figure 1A) or TY mutants (blue line) of NatA
using a Superdex S200 column. Coomassie-stained SDS–PAGE of peak fractions of
Naa50 with NatA TY mutants shown below the chromatograms.
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Figure 11.7 NatA TY mutants disrupt NatA/Naa50 complex interactions
(A) Fluorescence polarization assays of NatA TY mutants and Naa50 in S. pombe and
human. (B) Differential scanning fluorimetry assays of NatA TY mutants with and without
Naa50. Recorded melting temperature transitions are indicated. (C) Comparison of
acetylation activity of NatA wild-type and TY mutants. Activities are normalized to WT
protein activity level.
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2.3 Discussion
While the molecular basis for acetylation activity by either NatA or Naa50
independently has been previously described, the underlying molecular mechanism of
how these enzymes work in complex was poorly understood before this study. Although
similar to an unpublished structure of ScNatE that has been deposited in the PDB
(4XNH), our reported crystal structure of the ScNatA/Naa50 complex in combination with
related biochemical data provides a peer reviewed and comprehensive analysis of the
structure and mechanism of acetylation by the N-terminal dual enzyme NatA/Naa50
complex across evolution. Overall, the Naa50 electron density is poorly resolved relative
to NatA, which suggested that its association with NatA is likely dynamic. Indeed, the
major contact region between Naa50 and Naa15 is mediated by loop-loop interactions,
unlike the extensive interactions made between Naa10 and Naa15 within the NatA
complex. We also found that ScNaa50 makes direct electrostatic interactions with
Naa10, providing a path of contact for Naa10 and Naa50 to influence each other’s
catalytic functions.
Because of their conserved association motif, the hNaa50 docking site on
hNaa15 could be identified, and was further supported by mutational analysis. We
propose that the proper distance between Naa10 and Naa50 that is required for cognate
acetylation of N-terminal protein substrates by the respective NATs, coupled to the less
rigid positioning of Naa50, relative to Naa10, may allow Naa50 to adopt multiple
conformations within the NatE complex to facilitate both Naa50 and Naa10 cognate
substrate binding. Indeed, we found that hNaa50 and hNatA displayed significant
enhancement in substrate affinity and catalytic efficiency in the context of the complex,
although such enhancement was not observed in the yeast complex, where we found
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that Naa50 is catalytically defective. This is consistent with our structural data showing
that unlike Naa10, Naa50 harbors a narrow substrate binding site that is incompatible
with N-terminal protein substrate binding. However, we cannot exclude the possibility
that yeast Naa50 is enzymatically active against another substrate. Regardless, our
findings suggest some evolutionary divergence between yeast and human NatE
complexes. Nonetheless, we also found that SpNaa50 does not bind human NatA and
vice versa, yet from conservation analysis there is no obvious reason why this should be
the case. There may be subtle differences in the yeast and human systems that have co
evolved, perhaps to reflect the regulatory role of the HYPK protein in the human but not
S. pombe and S. cerevisiae yeast systems (Arnesen et al. 2009).
Based on our in vitro activity data, it is noteworthy that both human Naa10 and
Naa50 catalytic subunits display lower Km values for their respective peptide substrates
and increased catalytic efficiencies, when they are in the NatA/Naa50 relative to when
they are not in complex. Meanwhile, we observed that the other substrate, acetyl-CoA,
while not showing detectable binding to SpNaa50, binds to SpNatA/Naa50 about 4.5-fold
tighter than SpNatA alone. It is likely that SpNaa50 facilitates acetyl-CoA binding to
SpNatA and the structural observation that ScNaa50 sits closely to the Q/RxxGxG/A
acetyl-CoA binding motif of ScNaa10 provides a plausible explanation for how SpNaa50
may modulate the acetyl-CoA binding activity of SpNatA. Taken together, we conclude
that in human, NatA and Naa50 have cooperative effects on their acetylation activities
when associating together, while in yeast, the inactive Naa50 still contributes to NatA
activity, which is consistent with previous result that reduction of some NatA type Ntermini was detected in yeast Naa50 deletion mutants (Van Damme et al. 2015) We note
that the cooperative effects between NatA and Naa50 that we observed in vitro are
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based only on single cognate NatA and Naa50 peptide substrates. It is currently
unknown if the degree of cooperation varies with different peptide substrates.
One surprising aspect of the ScNatA/Naa50 structure is the identification of
Inositol hexaphosphate (IP6), which bridges interactions between the Naa10 and Naa15
subunits of NatA with a dissociation constant in the sub-mircomolar range. A similar role
for IP6 was identified in the recently reported hNatA/HYPK complex (Gottlieb and
Marmorstein 2018), suggesting an evolutionarily conserved role of IP6 in stabilizing the
NatA complex. Since IP6 has long been appreciated to have many signaling properties in
diverse organisms including yeast and mammals (Kalam Shamsuddin and Bose 2012), it
is also possible that IP6 may have a yet unidentified signaling role in NatA function.
HYPK is an important regulatory protein that binds to hNatA but is not conserved
in S. pombe or S. cerevisiae. Recent structural studies suggest that HYPK was a
nanomolar dissociation constant NatA binding partner and that HYPK binding likely
inhibits Naa50 binding (Weyer et al. 2017; Gottlieb and Marmorstein 2018). Here we
have demonstrated that hNaa50 can promote hNatA acetylation activity. We propose
that the slightly divergent association mechanism between NatA and Naa50 in yeast and
human may be related to the presence of HYPK in human and higher eukaryotes but not
in most yeast. It will be of interest to further investigate the interplay among these
binding partners within the tetrameric human NatA/Naa50/HYPK complex.
We find in our study that SpNaa50 is catalytically inactive, and this is likely due to
its reduced affinity for acetyl-CoA and the relative narrowness of the peptide substrate
binding site of ScNaa50 observed in the ScNatA/Naa50 structure. Surprisingly, we
observed binding between ScNaa50 and acetyl-CoA, although the optimal acetyl-CoA
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binding motif is missing in both ScNaa50 and SpNaa50. Nonetheless, both ScNaa50
and SpNaa50 are catalytically inactive in out acetyltransferase assays. We propose that
the yeast lineage lost catalytically active Naa50 at least due to the lack of peptide
substrate binding. Indeed, unlike metazoans, ScNaa50 knock out displays no phenotype
(Gautschi et al. 2003). In another study, no impact on Met-starting yeast N-termini was
observed where yeast Naa50 was deleted (Van Damme et al. 2015). Meanwhile, Naa50
has functional roles in sister chromatic cohesion in higher organism, independent of the
NatA complex, which is not observed in yeast (Rong et al. 2016; Ribeiro et al. 2016;
Williams et al. 2003). Thus, yeast Naa50 is very likely enzymatically inactive, only
providing extra stability and regulatory roles for NatA, including participation in ribosome
binding (see below). We propose that Naa50 substrates are processed by NatC, which
recognizes a similar cognate sequence.
A recent Cryo-EM structure of a native ScNatA/Naa50-ribosome structure, where
the ribosome is resolved to 3.4 Å and the NatA/Naa50 portion is resolved to about 8 Å
resolution, indicates that NatA/Naa50 associates with the ribosome through interaction
with the ribosomal RNA expansion segments involving predominantly Naa15, but also
Naa50 (Knorr et al. 2019). While Naa10 is positioned proximal to the ribosome peptide
exit tunnel, Naa50 is remote from the peptide exit tunnel. A docking of our 2.7 Å
resolution NatE structure onto the Cryo-EM structure (PDB: 6HD7) provides a pseudo3.4 Å resolution structure of the NatE-ribosome complex (Figure 2.8). This superposition
reveals that Naa50 is positioned ~80 Å away from the peptide exit tunnel of the
ribosome, consistent with the finding of Knorr et al. that approximates this distance to be
~ 85 Å (Knorr et al. 2019). As this observation suggests that peptides emerging from the
ribosome exit tunnel encounter the Naa10 active site prior to the Naa50 active site, we
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speculate that it is likely that Naa50 requires a longer nascent chain for acetylation.
However, we found that SpNaa50 binding slightly promotes SpNatA acetylation catalytic
efficiency. This effect could be more significant in the context of the ribosome, given that
Knorr et al. observe that Naa50 makes contact to the ribosome RNA expansion
segment, thus also playing a role in NatA recruitment to the ribosome. Such a
contribution to NatA-ribosome recruitment by Naa50 is consistent with a recent
observation that D. melanogaster Naa50 knockout impairs NatA acetylation activity in
vivo (Rathore et al. 2016). We placed the Naa10 acetyl CoA binding site by overlapping
our structure to the SpNatA structure in complex with bi-substrate analogue
(PDB:4KVM) and found that the acetyl-CoA binding sites for both Naa10 and Naa50 are
oriented in the same direction and facing the ribosome nascent peptide exit tunnel and
separated by a distance of only 26.6 Å (Figure 2.8). It is likely that the relative position of
these two catalytic subunits, Naa10 and Naa50, might change on the ribosome to
accommodate the cognate peptide substrate that emerges out of the ribosome exit
tunnel. We propose that the flexibility of the hNatA-Naa50 interface (as suggested by the
relatively high B-factor of Naa50 relative to NatA) may also facilitate movement of Naa50
closer to the ribosome exit tunnel once its cognate substrate is in proximity for Nterminal acetylation. This might be facilitated further if human Naa50 did not participate
in NatA anchoring to the ribosome as it does in the yeast system. Additional interactions
might be compensated through the binding of HYPK.
Taken together, our biochemical and structural characterization of ternary
NatA/Naa50 complexes in yeast and human in this study has provided new and
significant insights into the association and regulatory mechanism of this unusual dual
enzyme system. These studies set the stage for future studies to decipher the molecular
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mechanism of the human NatA/Naa50/HYPK complex. In addition, our identification of
mutants that prevent NatA/Naa50 association in yeast and humans will facilitate analysis
of the uncoupling of co- and post-translational protein acetylation by Naa50.

Figure 12.8 Docking of our ScNatA/Naa50 crystal structure onto the ribosomeNatA/Naa50 Cryo-EM structure
The ScNatA/Naa50 crystal structure is aligned to the NatA/Naa50-ribosome structure
(PDB: 6HD7). The magnified view shows that Naa10 is most proximal to the ribosome
peptide exit tunnel, while the acetyl-CoA binding sites of Naa10 and Naa50 are facing
the same side.
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2.4 Materials and methods
2.4.1 NatA and Naa50 expression and purification
Human NatA (hNatA), human Naa50 (hNaa50), and Schizosaccharomyces
pombe NatA (SpNatA) were expressed and purified as described previously (Liszczak et
al.

2013;

2018;

Liszczak,

Arnesen,

and

Marmorstein

2011).

Full-length

Schizosaccharomyces pombe Naa50 (spNaa50) was cloned into pRSF with a N-terminal
GST fusion, and expressed and purified with the same method as described for spNatA
(Liszczak et al. 2013). Full-length Saccharomyces cerevisiae Naa15 (ScNaa15) was
cloned into pRSF_Duet vector with a N terminal PolyHis tag and a Tobacco Etch Virus
(TEV) cleavage site. C-terminal truncated ScNaa10 (1-226) with no tag was cloned into
pET_Duet, and un-tagged full-length ScNaa50 was cloned into pCDF-Duet. To express
the ternary ScNaa10-ScNaa15-ScNaa50 complex (ScNatA/Naa50 complex), these three
plasmids were co-transformed into Rosetta (DE3)pLysS competent E. coli cells, which
were grown to an OD600 of 1 and induced with 0.5 mM of Isopropyl β-D-1thiogalactopyranoside (IPTG) at 16 °C for ~16 h. ScNatA/Naa50 complex purification
procedure was modified from SpNatA as described (Liszczak et al. 2013). Cells were
isolated by centrifugation for 20 mins at 4500 rpm and lysed by sonication in a buffer
containing 25 mM Tris, pH 8.0, 500 mM NaCl, 0.1 mg/mL PMSF. After centrifugation, the
supernatant was isolated and passed over Ni-resin (Thermo Scientific), which was
subsequently washed with 10 column volumes of lysis buffer supplemented with 25 mM
imidazole and 10 mM 2-mercaptoethanol. Protein was eluted with 300 mM imidazole
and dialyzed into buffer containing 25 mM sodium citrate monobasic, pH 5.5, 10 mM
NaCl and 10 mM 2-mercaptoethanol. Protein was purified with a 5-mL HiTrap SP ionexchange column and eluted in a salt gradient (10–700 mM NaCl). Peak fractions were
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concentrated to ~ 0.5 mL with a 100-kDa concentrator (Amicon Ultra, Millipore), and
loaded onto an S200 gel-filtration column (GE Healthcare) in a buffer containing 25 mM
HEPES, pH 7.0, 200 mM NaCl, 5% glycerol and 1 mM TCEP. Proteins were aliquoted,
snap-frozen in liquid nitrogen, and stored at −80 °C for further use. Full-length ScNaa50
was cloned into pRSF with a N-terminal GST tag and a TEV cleavage site, to express
and purify ScNaa50 alone. We observed that ScNaa50 was not stable in the absence of
the GST tag and absorbs minimally at 280 nm. We therefore only worked with GSTScNaa50 in biochemical experiments. GST-ScNaa50 was purified using the same
method as described above. Concentrations of hNatA, hNaa50, SpNatA, SpNaa50,
ScNatA/Naa50 and GST-ScNaa50 were determined by absorbance at 280 nm and using
their extinction coefficient of 132,480 cm-1M-1,13,410 cm-1M-1, 120,000 cm-1M-1, 14,440
cm-1M-1, 151,800 cm-1M-1, and 58,790 cm-1M-1, respectively. All protein mutants were
generated using the QuikChange protocol from Stratagene and obtained following the
expression and purification protocols described above.

2.4.2 Fluorescence polarization (FP) assays
There are five cysteine residues present in SpNaa50 (Cys22, Cys54, Cys60, and
Cys96) and four cysteine residues in hNaa50 (Cys60, Cys61, Cys79, and Cys100). We
found that we did not have to make mutations to obtain the fluorescein labeled Naa50,
which suggested that at least one cysteine in each is exposed to solvent. 25-fold excess
of Fluorescein-5-Maleimide (ThermoFisher) was added into about 100 μL of 1 mg/ml
purified hNaa50 or SpNaa50 in sizing buffer. The reaction was quenched with 2mercaptoethanol after overnight incubation at 4°C. Excess Fluorescein-5-Maleimide was
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removed by S75 gel-filtration chromatography. To run the assays,10 nM of labeled
Naa50 was used in all reactions, and NatA concentrations were varied to determine the
dissociation constant (Kd). 5 mg/mL BSA and 0.2% v/v Tween were added into the
reaction buffer (25 mM HEPES, pH 7.0, 200 mM NaCl and 10 mM DTT) to prevent nonspecific binding. FP readings were recorded with a Perkin Elmer EnVision and each
curve was repeated in triplicate. GraphPad Prism, version 5.01, was used for all data
fitting. Errors were reported in SD with n = 3.

2.4.3 Acetyltransferase activity assays
All the acetyltransferase assays were performed essentially as previously
described (Liszczak et al. 2013; Liszczak, Arnesen, and Marmorstein 2011) and carried
out at room temperature in the reaction buffer containing 75 mM HEPES, pH 7.0, 120
mM

NaCl,

1

mM

DTT.

The

SASE

substrate

peptide

(NH2-

SASEAGVRWGRPVGRRRRP-COOH; GenScript) and the MLGP substrate peptide
(NH2-MLGPEGGRWGRPVGRRRRP-COOH; GenScript) were used to determine the
enzymatic activity of NatA and Naa50, respectively. For Naa50 activity test in time
course manner, 500 nM of SpNaa50, SpNatA/SpNaa50, hNaa50, hNatA/hNaa50,
ScNaa50, and ScNatA/Naa50 were mixed with 300 μM of C14 labeled acetyl-CoA (4 mCi
mmol−1; PerkinElmer Life Sciences), 500 μM MLGP peptide in a 100 μL reaction. To
quench the reaction at specific time, 15 µL of the reaction mixture was added to P81
paper discs (Whatman), and the paper discs were immediately placed in wash buffer
with 10 mM HEPES, pH 7.5. Unreacted acetyl CoA should be removed by washing at
least three times. Paper discs was then dried with acetone and mixed with 4 scintillation
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fluid for signal measurement by a Packard Tri-Carb 1500 liquid scintillation analyzer.
Data was plotted with GraphPad Prism, version 5.01. To determine steady-state catalytic
parameters, enzymes were mixed with 500 µM C14 labeled acetyl-CoA and
corresponding peptide substrate concentration was varied. 20 µL reaction were
performed but only 15 µL reaction mixture was quenched onto the paper discs after
specific time. For hNaa50 and hNatA/hNaa50 against MLGP peptide, 300 nM enzyme
was used in 40-minute reaction. For hNatA and hNatA/hNaa50 against SASE peptide,
100 nM enzyme was used in 12-minute reaction. For SpNatA and SpNatA/SpNaa50
against SASE peptide, 50 nM enzyme was used in 10-minute reaction. Paper discs
washes and signal reading steps were performed in the same manner as mentioned
above. GraphPad Prism, version 5.01, was used for all kinetic data fitting to the
Michaelis–Menten equation. Each curve was repeated at least 3 times. In NatA TY
mutant activity tests, 100 nM of SpNatA, SpNatA-T412Y, hNatA, hNatA-T406Y were
mixed with 300 μM of C14 labeled acetyl-CoA and 500 μM peptide substrate for a 30minutes reaction. Signals were normalized to the WT activity, and errors were reported
in SEM with n = 3.
2.4.4 Size exclusion chromatography assays
A total of 500 μl of purified NatA (4.2 µM) and purified Naa50 (12.6 µM) was
injected onto a S200 gel-filtration column (GE Healthcare). UV absorbance values were
normalized to the maximum value at first elution peak, then plotted against the elution
volume in GraphPad Prism, version 5.01. Only elution volume around two peaks were
shown in the figure. Corresponding peak fractions were run on SDS-PAGE and stained
with colloidal Coomassie blue for imaging.
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2.4.5 GST pull-down assays
1 µM of GST tagged Naa50 and 5 µM of NatA was incubate with 50 µL of
glutathione agarose resin at 4 °C for 1 hour in reaction buffer containing 25 mM HEPES,
pH 7.0, 200 mM NaCl and 1 mM TCEP. Resin was then washed extensively with the
same buffer and eluted with glutathione. Samples were collected for analysis on SDSPAGE.

2.4.6 Differential scanning fluorimetry assays
Sypro Orange (5000X stock, ThermoFisher Scientific) was diluted 1:200 and 4 µL
was mixed with 16 µL solution with 5 µM NatA and 5 µM Naa50 in sizing buffer.
Fluorescent readings were recorded using a qPCR (ABI 7900 RealTime PCR) with a 2%
ramp rate, while heated from 20 °C to 95 °C. Melting curves were generated from these
readings and melting temperatures were determined by taking the first derivative of the
curves. DSF scans of all samples were performed in triplicates. Error bars in the figure
indicated the SD of each sample.

2.4.7 ITC measurements
Measurements were recorded on a MicroCal iTC200 at 20 °C. Samples were
dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, 1 mM DTT. Protein
samples (SpNaa50, SpNatA, SpNatA/Naa50, GST-SpNaa50, GST-ScNaa50, GST) with
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concentrations of 50 μM in the cell and 1mM of acetyl-CoA in the syringe were used in
the experiments. For hNaa50, 100 μM protein and 0.5 mM of acetyl-CoA were used.
The raw data was analyzed with MicroCal ITC analysis software.

2.4.8 ScNatA/Naa50 crystallization and data collection
Ternary ScNatA/Naa50 complex was mixed with 3 molar excess of NatA
bisubstrate inhibitor (CoA-SASEA), Naa50 bisubstrate inhibitor (CoA-MLGPE) and IP6.
Bisubstrate inhibitors were prepared as previously described (Liszczak et al. 2013).
Crystals were grown within ~3 days by hanging drop vapor diffusion at 20 °C at 7.5
mg/ml, using one to one drop ratios against reservoir solution containing 10% PEG
3350, 0.1 M Sodium Malonate (pH 5.0). Crystals were transferred into mother liquor
supplemented with 25% glycerol and flash-frozen in liquid nitrogen. Data were collected
at the Advanced Photon Source (beamline 24-ID-C) and processed using HKL2000
(Otwinowski and Minor 1997).

2.4.9 ScNatA/Naa50 structure determination and refinement
The collected diffraction data showed strong anisotropy and ellipsoidal truncation
and anisotropic scaling was performed (Strong et al. 2006). The resolution limit along a*,
b*, c* are 2.7 Å, 3.4 Å, 2.7 Å, respectively. The crystal structure of ScNatA/Naa50 was
determined by molecular replacement using a structure of unpublished ScNatE (PDB ID
Code: 4XNH) without ligand or solvent molecules as a search model. Molecular
replacement was done using Phaser in Phenix (Adams et al. 2010).
64

Initial Manual model building was done in Coot (Emsley and Cowtan 2004) and
all subsequent rounds of refinement were performed using Phenix refine and Coot
interchangeably. Refinement statistics can be found in Table 2.1. The final model and
structure factors were submitted to the Protein Data Bank with code 6O07 (Research
Collaboratory for Structural Bioinformatics).
Distance calculations, as well as three-dimensional alignment r.m.s. deviations
and graphics were generated in PyMOL (http:// www.pymol.org/)
Sequence alignments in the manuscript were performed using Clustal Omega
(https://www.ebi.ac.uk/Tools/msa/clustalo/) and visualized using ESPript 3.0 (Robert and
Gouet 2014a) (http://espript.ibcp.fr/ESPript/ESPript/)
All surface area calculations were performed using PDBePISA (Proteins,
Interfaces, Structures and Assemblies) (http://www.ebi.ac.uk/pdbe/pisa/)
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CHAPTER 3: Molecular Basis for N-terminal Acetylation by Human NatE and Its
Modulation by HYPK

This work is adapted from Nat Commun. (Deng, McTiernan, et al. 2020) © Nature
Research
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3.1 Introduction
About one-half of the human N-terminal acetylome is mediated by hNatA.
Mutations in either the NAA10 catalytic or NAA15 auxiliary subunits have been
correlated with a broad spectrum of pathologies including intellectual disabilities,
developmental delay, autism spectrum disorders, craniofacial dysmorphology, congenital
cardiac anomalies and Ogden syndrome (Dorfel and Lyon 2015; Lee et al. 2010; Yoon
et al. 2014; Saunier et al. 2016; Popp et al. 2015; Esmailpour et al. 2014; Casey et al.
2015; Cheng et al. 2019; Ree et al. 2019; Rope et al. 2011). Aberrant NatA activity has
also been correlated with neurodegenerative disorders and cancer although a causative
role of NatA is less clear (Kalvik and Arnesen 2013). NatA forms complexes with at least
two other proteins, NAA50 and the chaperone protein Huntingtin interacting protein K
(HYPK) (Arnesen et al. 2010; Gautschi et al. 2003; Arnesen, Anderson, et al. 2006;
Liszczak et al. 2013; Weyer et al. 2017). The trimeric hNAA10/hNAA15/hNAA50
complex

is

referred

to

as

hNatE,

and

we

refer

to

the

tetrameric

hNAA10/hNAA15/hNAA50/HYPK complex as hNatE/HYPK. Previous studies have
demonstrated that HYPK may be important for cellular NatA activity and that NAA50 and
NatA can affect each other’s function (Weyer et al. 2017; Arnesen et al. 2010; Gottlieb
and Marmorstein 2018; Rathore et al. 2016; Deng et al. 2019). Previous studies also
demonstrated that hNatA can physically associate with hNAA50 (Gautschi et al. 2003)
and HYPK (Arnesen et al. 2010), separately. Moreover, the crystal structures of hNatA
with HYPK and related pull-down experiments indicated that HYPK and hNAA50 binding
to hNatA might be mutually exclusive (Gottlieb and Marmorstein 2018). However,
another study suggested that HYPK and NatE form a tetrameric complex in Drosophila
cells (Rathore et al. 2016).
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To delineate the mechanistic basis for how the NAA10 and NAA50 catalytic
subunits of the NatE complex coordinate function and how this is regulated by HYPK, we
characterized the human NatE and NatE/HYPK complexes biochemically, structurally
and in cells. We show that NAA50 and HYPK exhibit negative cooperative binding to
NatA in vitro and in human cells, by inducing NAA15 shifts in opposing directions. We
show that NAA50 and HYPK both mediate NAA10 inhibition through structural alteration
of the NAA10 substrate binding site. We show that NatE is about 10-fold more active
than NAA50, likely due to a reduced entropic cost for substrate binding through NatA
tethering, but is inhibited by HYPK through structural alteration of the NatE substrate
binding site. Taken together, these studies reveal the molecular basis for coordinated Nterminal acetylation by the NAA10 and NAA50 catalytic subunits of NatE and its
modulation by HYPK.

3.2 Results
3.2.1 hNatE and HYPK form a tetrameric complex
To determine if human NAA50 and HYPK can simultaneously bind to NatA to
form a NatE/HYPK complex, we prepared the recombinant hNatA/HYPK complex from
insect cells and mixed it with recombinant hNAA50 for analysis on size exclusion
chromatography (Fig. 3.1a – left). Analysis of the peak fractions on SDS-PAGE
revealed that the four protein components (hNAA10, hNAA15, hNAA50 and HYPK) coeluted in a single major peak with excess hNAA50 eluting in later fractions (Fig. 3.1a).
This result demonstrates that HYPK and hNAA50 can bind to hNatA simultaneously to
form a tetrameric hNatE/HYPK complex.
68

Figure 13.1 HYPK and hNatE form a tetrameric complex
(a) Left - gel filtration elution profile of the hNatA/HYPK complex with excess hNAA50,
using a Superdex S200 column. Right - Coomassie-stained SDS-PAGE of peak
fractions. Red bars indicated the peak of complex. (b) Fluorescence polarization assays
with either hNatA or hNatA/MBP-HYPK titrated into fluorescein-5-maleimide labeled
69

hNAA50. The data is fit to calculate a dissociation constant (Kd). Replicates were shown
in the curve with n = 3 independent experiments. Source data are provided as a Source
Data file. (c) Representative ITC curve of MBP-HYPK titrated into hNatA. The calculated
dissociation constant is indicated. (d) Representative ITC curve of MBP-HYPK titrated
into hNatE. (e) The ITC fitting information and calculated dissociation constant (Kd) is
provided for (c) and (d) curves.

3.2.2 HYPK and hNAA50 display negative cooperative binding to hNatA

Previous studies demonstrated that both human HYPK and hNAA50 bind
tightly to hNatA, with dissociation constants in the nanomolar range (Gottlieb and
Marmorstein 2018; Deng et al. 2019). We set out to determine if the HYPK and
hNAA50 binding properties to hNatA are altered in the context of the tetrameric
complex. Using fluorescence polarization (FP) assays, we observed that hNAA50
bound to hNatA with a Kd of 46 ± 8.8 nM (Fig. 3.1b), consistent with previous
results. However, in the presence of MBP-HYPK, this binding Kd decreased
about ~3-fold to 127 ± 13 nM (Fig. 3.1b). This data demonstrates that HYPK can
negatively affect the stability of the hNatE complex by about 3-fold. Based on this
data, we hypothesized that in the presence of hNAA50, the binding affinity
between hNatA and HYPK would also decrease. Using isothermal titration
calorimetry (ITC), we determined that the Kd between hNatA and MBP-HYPK
was 29.9± 16.7 nM (Fig. 3.1c), which is consistent with the previously reported
Kd in the thermophilic fungus Chaetomium thermophilum (Weyer et al. 2017).
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The reason for the apparent two-binding transition when HYPK is titrated into
hNatA is unknown. We further determined the Kd between HYPK and hNatE and
observed that the affinity was 154 ± 55.3 nM, ~ 5-fold weaker than HYPK binding
to hNatA (Fig. 3.1d). A control ITC run of MBP titrated into hNatA failed to show
binding. Taken together, these data indicate that HYPK and NAA50 display
negative cooperative binding with respect to hNatA.

3.2.3 hNAA50 and HYPK inhibit hNatA activity, and HYPK is dominant
While our previous studies demonstrated that yeast and human NatA have
slightly elevated catalytic efficiencies in the presence of NAA50, we set out to make a
more direct comparison of NatA activity as a function of added NAA50 vs. HYPK. To do
this, we used an in vitro acetylation assay using a cognate SASE NatA substrate to
compare the hNatA catalytic activity as a function of added hNAA50 or MBP-HYPK. This
comparison revealed that while MBP-HYPK showed about 90% inhibition of hNatA
activity at an MBP-HYPK concentration beyond ~100 nM, hNAA50 only decreased
hNatA activity by about 50% at concentrations between ~ 100 nM - 1µM (Fig. 3.2a),
consistent with previous data (Gottlieb and Marmorstein 2018; Deng et al. 2019).
Titrating both MBP-HYPK and hNAA50 into hNatA showed a similar degree to hNatA
inhibition as did titrating in MBP-HYPK alone, illustrating that HYPK inhibition of hNatA
overrides the incomplete inhibitory effect of hNAA50 (Fig. 3.2a).
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Figure 14.2 HYPK binding negatively affects hNatE acetylation activity
(a) Either MBP-HYPK (green), hNAA50 (red), or both (blue) are titrated into hNatA
(100 nM) to evaluate their modulatory effect on hNatA activity against an SASE peptide
substrate. A best line is drawn through the data points for ease of visualization. Source
data are provided as a Source Data file. (b) Comparison of time course acetylation
activity of hNAA50 (black), preformed hNatE (red), and preformed hNatE/HYPK (blue; all
500 nM) against an MLGP peptide substrate. Source data are provided as a Source
Data file. (c) hNatA acetylation activity against an SASE peptide with addition of buffer,
wild type (WT), or hNAA50 mutants. Errors were reported in SEM with n = 3 independent
experiments. Source data are provided as a Source Data file. (d) Activity of hNAA50 WT
and mutants against MLGP peptide was tested, either alone (black), in the context of
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hNatE (+hNatA; red), or in the context of preformed hNatE/HYPK (+hNatA/HYPK; blue).
Data were normalized to WT hNatE activity as 100%, represented as mean ± SD, n = 3
independent experiments.

3.2.4 HYPK inhibits hNatE activity
Given that HYPK was shown to be a negative regulator for hNatA acetylation
activity (Weyer et al. 2017; Gottlieb and Marmorstein 2018), we asked if it also inhibited
the activity hNatE. To do this, we used the same in-vitro acetyltransferase activity assay
but employed a cognate MLGP hNatE substrate in the absence or presence of HYPK,
as well as a hNAA50 only control. This analysis revealed that while hNatE was more
active than hNAA50, this improvement was essentially nullified with the addition of
HYPK (Figs. 3.2b, 3.2c and 3.2d). A full kinetic analysis of hNAA50, hNatE, and
hNatE/HYPK revealed the kinetic parameters responsible for this modulation of hNAA50
function. Specifically, we found that hNatE displayed ~8.6-fold decrease of Km, and ~1.1fold decrease of kcat, with an overall ~7.7-fold increase of catalytic efficiency, compared
to hNAA50 (Table 3.1). These findings are in general agreement with previous studies
with the orthologous yeast proteins (Deng et al. 2019). A comparison of the activities of
hNatE and hNatE/HYPK revealed that in the presence HYPK, hNatE displayed an ~1.3fold decrease in Km, and an ~3.8-fold decrease of kcat, with an overall ~2.9-fold decrease
in catalytic efficiency (Table 3.1). This data suggests that HYPK can compromise hNatE
activity. Taken together, while hNatA significantly enhances the catalytic efficiency of
hNatE, HYPK binding to hNatE largely nullifies this effect, demonstrating that HYPK can
indirectly inhibit hNatE activity.
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Table 4.1 Catalytic parameters for hNAA50, hNatE, and hNatE/HYPK

3.2.5 hNatA forms competing complexes with hNAA50 and HYPK in cells
To further confirm the existence of the tetrameric hNatE/HYPK complex
observed in vitro in human cells, we immunoprecipitated hNAA15 (c-terminal V5 tagged)
from HeLa cells to evaluate the associated proteins. Mass spectrometry analysis of this
sample revealed that endogenous hNAA10, hNAA50 and HYPK were all coimmunoprecipitated with NAA15-WT-V5, in agreement with the tetrameric hNatE/HYPK
complex formation (Fig. 3.3a).
In prior studies, we reported that a hNAA15-T406Y mutant can disassociate
hNAA50 from hNatA in vitro (Deng et al. 2019), while a hNAA15-L814P mutant is
defective for HYPK inhibition and reduces hNatA thermostability (Cheng et al. 2019).
Based on these observations, we also carried out a mass spectrometry analysis of the
V5-immunoprecipitates of the hNAA15-T406Y-V5 and hNAA15-L814P-V5 mutants to
evaluate the effect of the mutation’s on formation of the hNatE/HYPK tetrameric
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complex. For relative quantification of the hNatA proteins, the IBAQ intensities of the
hNatA components in each sample were normalized to the IBAQ intensity of hNAA15 in
the respective sample and to the corresponding protein in the WT sample (Fig. 3.3a).
This analysis demonstrated that hNAA15-T406Y-V5 and hNAA15-L814P-V5 had
reduced binding of hNAA50 and HYPK respectively, indicating that the mutations
negatively affected the ability of hNAA15 to bind hNAA50 and HYPK, respectively.
Furthermore, it appeared that the reduced binding of HYPK or hNAA50 resulted in
greater binding of the other component: hNAA15-T406Y-V5 bound less hNAA50, but
more HYPK than hNAA15-WT, while hNAA15-L814P-V5 bound less HYPK and more
hNAA50 than hNAA15-WT (Fig. 3.3a). These observations are in agreement with the in
vitro FP and ITC assays, demonstrating that HYPK and hNAA50 display negative
cooperative binding with respect to hNatA. Taken together, these cellular studies agree
with the in vitro studies by confirming the existence of the tetrameric hNatE/HYPK
complex and indicating that HYPK and hNAA50 display negative cooperative binding
with respect to hNatA.
The intrinsic hNatA catalytic activities of the hNAA15-T406Y-V5 and hNAA15L814P-V5 variants were also tested in a Nt-acetylation assay and westernbloted (Fig.
3.3b). Importantly, equal levels of hNAA10 were pulled out with the lysates supporting
that none of the mutants affect hNAA10 binding. The hNAA15-T406Y-V5 hNatA complex
displayed a decreased catalytic activity towards the hNatA substrate SESS24 compared
to WT hNatA. This could be explained by an increased binding and inhibitory effect of
HYPK and/or due to the reduced binding of hNAA50. The hNAA15-L814P-V5 hNatA
complex showed an increased catalytic activity compared to WT hNatA, which is
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consistent with the in vitro findings of reduced binding of HYPK and consequently less
inhibition of the catalytic activity and/or an increased binding of hNAA50.

Figure 15.3 hNatA forms competing complexes with hNAA50 and HYPK
(a) Heat map showing the mean relative IBAQ intensity of NatA components from three
independent MS analyses of immunoprecipitated NAA15 variants, NAA15-WT-V5,
NAA15-T406Y-V5, and NAA15-L814P-V5. The IBAQ intensities of each component
were normalized to the IBAQ intensity of NAA15 in the respective sample and to the
corresponding NatA WT protein. Source data are provided as a Source Data file.
(b) Western blot analysis and NatA Nt-acetylation assay of V5-immunoprecipiated
NAA15 variants. The measured DPM signal for each reaction was normalized to the
corresponding V5-band in the IP. The immunoprecipitation and activity assay were
performed in n = 3 independent experiments, each with three technical replicates
(indicated by dot plots) per assay.
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3.2.6 hNatE structure reveals molecular basis for enzyme crosstalk
To determine the molecular basis for interaction and enzymatic crosstalk
between human NAA10 and NAA50 enzyme subunits within the NatE complex, we
determined the single particle Cryo-EM structure of the hNatE complex in the presence
of inositol hexaphosphate IP6 and bi-substrate analogues of both hNatA and hNAA50.
The model of the human complex was rigid-body fitted with the coordinates of the crystal
structure of hNatA (PDB: 6C9M) and hNAA50 (PDB: 3TFY), with all ligands removed.
After refinement of the model, we observed clear density of IP6 and acetyl-CoA cofactors
in each catalytic subunit, but the peptide portion of the bisubstrate inhibitors were not
resolved. The structure was refined to an overall resolution of 3.0 Å, with most residues
of hNAA10 and hNAA50 subunits resolved to 2.5 Å. The refinement statistics can be
found in Table. 3.2. The N-terminal 112 residues of hNAA15 subunit were not modeled
due to a lack of traceable Cryo-EM density for this region.
Consistent with previous studies with the orthologous yeast proteins (Deng et al.
2019), hNAA50 predominantly interacts with hNAA15 (α21, α22, α23 and α24), and
makes relatively few interactions with hNAA10 (Fig. 3.4a), burying a solvent excluded
surface of 34,316 Å2 with hNAA15, and 9,100 Å2 with hNAA10. Based on the structure of
the ScNatE complex, a hNAA15-T406Y mutant was shown to disrupt the hNatA-NAA50
interaction (Deng et al. 2019). Indeed, we find that hNAA15-Thr406 is located at the
center of the hNAA50-hNAA15 interface, making hydrogen bond interactions with the
backbone carbonyl group of hNAA50-Ala55 (Fig. 3.4b). Additional hydrogen bonds are
formed between the backbone carbonyl of hNAA50-His14 with the backbone amide of
hNAA15-Thr439, between hNAA50-Arg21 and the backbone carbonyl of hNAA15Pro405, and between hNAA50-Asn52 and hNAA15-Thr371 (Fig. 3.4b). hNAA50-Arg21
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also makes direct ionic interaction with hNAA15-Glu433, which is absent in yeast (Fig.
3.4b). It is possible that this ionic interaction underlies the increased salt sensitivity of the
human vs. yeast NatE complex (Deng et al. 2019). Interestingly, we do not observe
significant hydrophobic interactions at the hNAA15-hNAA50 contact interface.
hNAA50-hNAA10 interactions are less extensive than hNAA50-hNAA15, yet still
significant. Interactions are observed between hNAA50-Glu7 and hNAA10-Arg116, and
between hNAA50-Asp53 and hNAA10-Arg83 (Fig. 3.4c). This structural observation
highlights the recent identification of a missense mutation of hNAA10 R83H which
exhibits

decrease acetylation activity in boys

with intellectual disability

and

developmental delay (Ree et al. 2019). It is noteworthy that hNAA10-Arg83 also makes
interaction with the 3’ phosphate of the acetyl-CoA molecule bound to hNAA10 (Fig.
3.4c).
To assess the importance of the NatA-NAA50 interactions on the catalytic
crosstalk of the two enzymes, we prepared hNAA50-E7A, -D53A and -E7A/D53A
mutants and evaluated their effect on hNatA activity (Fig. 3.2c). We found that the
single and double mutants were able to restore between 12-17% of hNatA activity
relative to the activity of hNatA bound to WT-hNAA50 (Fig. 3.2c). These results
demonstrate that the observed hydrogen bond interactions between NatA and NAA50
make a small, albeit significant, contribution to the catalytic crosstalk between the two
enzymes.
An overlay of the Saccharomyces cerevisiae (PDB: 6O07) and human NatE
structures reveals a high degree of structural conservation with a root-mean square
deviation (RMSD) of 1.517 Å (over 622 common Cα atoms). However, it is noteworthy
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that when bound to NatA, we observe that NAA50 shifts significantly closer to NAA10 in
the human over the yeast complex, resulting in more significant and intimate NAA10NAA50 interactions in the human complex (Fig. 3.5a). α3 and β7 of hNAA50 shift toward
NAA10 about 10 Å and 11 Å, respectively (Fig. 3.5a). Such significant shift in NAA50
position relative to NatA is surprising and may reflect a functional importance when
these proteins are associated with the ribosome (see discussion).
To understand other structural contributions that hNAA50 might have on hNatA
activity, we superimposed the hNatE structure with the hNatA crystal structure
(PDB:6C9M). We found that hNAA15 and hNAA10 in the ternary hNatE complex
displayed an RMSD of 0.747 Å (over 624 common Cα atoms), and 0.897 Å (over 141
common Cα atoms), respectively (Fig. 3.5b). The NAA10 β6-β7 loop displayed about a
4 Å shift toward hNAA50 in the hNatE complex relative to the hNatA complex (Fig.
3.5b). Given that the β6-β7 loop of NAA10 plays an important role in peptide substrate
recognition, we propose that this shift in position also contributes to the inhibitory effect
that hNAA50 binding has on hNatA activity.
To understand the molecular basis for why hNatA binding increases the catalytic
efficiency of hNatE by nearly 8-fold (Fig. 3.2b and Table 3.1), we superimposed the
hNAA50 crystal structure (PDB: 3TFY) with the hNAA50 subunits of the NatE structure.
Remarkably, we did not observe any significant structural changes in hNAA50 with an
overall RMSD for all atoms of 0.437 Å (Fig. 3.5b). Notably, the β6-β7 and α1-α2 peptide
substrate binding loops of hNAA50 within the hNatE complex superimposed well with
hNAA50 bound to CoA and substrate peptide (Fig. 3.5b). Based on this observation, we
hypothesize that the increased activity of hNatE is due to a reduced entropic cost for
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substrate binding to the hNAA50 subunit due to hNatA tethering. This is consistent with
the observations of Wand and colleagues for other protein systems (Caro et al. 2017).
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Table 5.2 Cryo-EM data collection, refinement, and validation statistics
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Figure 16.4 Cryo-EM structure of the hNatE complex
(a) hNAA50 (magenta), hNAA15 (green), and hNAA10 (orange) within the hNatE
complex shown in cartoon. (b) Zoom-in view of the contacts between hNAA15 and
hNAA50 with residues that participate in interaction labeled. (c) Zoom-in view of the
contacts between hNAA10 and hNAA50 with residues that participate in interaction
shown. Acetyl-CoA bound to hNAA10 is shown in ball and stick.
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Figure 17.5 Subunit crosstalk within the hNatE complex
(a) hNAA50 (magenta), hNAA15 (green), and hNAA10 (orange) within the hNatE
complex overlay with ScNatE (grey, PDB: 6O07). The α3 helix and β7 strand of Naa50 is
shown to shift towards Naa10 in the human structure (b) hNatE aligned with hNatA (light
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blue, PDB:6C9M) and hNAA50 (wheat, PDB: 3TFY). The top zoom-in area shows the
alignment of free hNAA50 and hNatE. The below zoom-in area shows the hNAA10
conformational change induced by hNAA50 binding.

3.2.7 hNatE/HYPK structure reveals negative cooperative mechanism
To obtain a molecular understanding of how NAA50 and HYPK can both bind
NatA we determined the structure of the hNatE/HYPK complex by Cryo-EM, which we
were able to resolve to an overall resolution of 4.0 Å. The starting structure was modeled
using the Cryo-EM NatE structure and the HYPK portion from the hNatA/HYPK crystal
structure (PDB: 6C95), which was placed into the Cryo-EM map through rigid-body fitting
into the EM density map, followed by adjustment and refinement. The refinement
statistics can be found in Table. 3.2.
In the tetrameric structure, we observe that both hNAA50 and HYPK
simultaneously dock onto the same binding regions on hNatA as previously identified in
the absence of the other protein (Gottlieb and Marmorstein 2018). While both hNAA50
and HYPK contact both subunits of hNatA, no direct interactions are observed between
hNAA50 and HYPK (Fig. 3.6a). HYPK binds NatA mainly through interactions with the
hNAA15 subunit of hNatA: only the α1 helix of HYPK interacts with hNAA10, while the
α2 and C-terminal UBA domain (α3, α4, and α5 helices) of HYPK interact with hNAA15
(Fig. 3.6a). Previous studies demonstrated that the UBA domain and α2 helix play key
roles in hNatA binding, while α1 is essential for hNatA activity inhibition (Gottlieb and
Marmorstein 2018; Weyer et al. 2017).
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Over the HYPK and hNatA interaction interface within the tetrameric complex, we
observe polar interactions between HYPK-Glu74 and hNAA15-Tyr158, between the
backbone carbonyl of HYPK-Thr100 and hNAA15-Lys687, between the backbone
carbonyl of HYPK-Asn129 and hNAA15-Arg697, between HYPK-Asn129 and hNAA15Lys696, which were all overserved similarly in the hNatA/HYPK crystal structure
(Gottlieb and Marmorstein 2018) (Fig. 3.6b). However, HYPK-Glu103 , hNAA15-Lys685
and hNAA15-Glu655 which form a salt bridge in the hNatA/HYPK structure do not show
a similar contact in the tetrameric hNatE/HYPK complex (Gottlieb and Marmorstein
2018) (Fig. 3.6b). We speculate that the absence of this interaction might contribute to
the slightly weaker affinity of HYPK for hNatE over hNatA.
hNAA15 and hNAA50 also make similar interactions in the absence or presence
of HYPK. The backbone carbonyl of hNAA50-His14 hydrogen bonds with the backbone
amide of hNAA15-Thr439, and hNAA50-Asn52 hydrogen bonds with hNAA15-Thr371
(Fig. 3.6c). Interestingly however, a key residue that stabilizes the hNatA-hNAA50
interaction, hNAA15-Thr406, shifts from in interaction with the carbonyl of hNAA50-A55
to a hydrogen bond to the hNAA50-Gln18 side chain in the tetrameric complex (Fig.
3.6c). An additional H-bond is formed between hNAA50-Gln18 and the backbone
carbonyl of hNAA15-Thr406 (Fig. 3.6c). hNAA50-Arg21, a residue that makes extensive
contacts to NAA15 in the hNatA/NAA50 complex (Fig. 3.4b) is only contacting hNAA15Glu433 in the tetrameric complex (Fig. 3.6c). In addition, while hNAA50-Asp53 and
hNAA10-Arg83 maintain interaction as observed in the hNatA/hNAA50 complex,
hNAA50-Glu7 and hNAA10-Arg116 loose interaction in the tetrameric complex (Fig.
3.6d). These observations correlate with the observed weaker binding interaction
between hNAA50 and hNatA in the presence of HYPK.
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To understand the molecular basis for the biochemical findings that the binding of
hNAA50 and HYPK to hNatA exhibit negative cooperativity, we superimposed the
ternary hNatA/HYPK and hNatE complexes onto the hNatE/HYPK complex (Fig. 3.7).
To align the hNatE and hNatE/HYPK complexes we superimposed the hNAA50 position
to delineate how the HYPK binding regions are affected by hNAA50 binding (Fig. 3.7a).
The overall overlay suggests that both the hNAA10 and hNAA15 subunits of hNatA shift
in the direction that is away from the hNAA50 binding region to make closer and more
optimal contacts with HYPK (Fig. 3.7a). The hNAA15 α36-α40 helices, which bind to the
C-terminal UBA domain (α3-α5) of HYPK in the tetrameric hNatE/HYPK complex, clearly
shift away from the binding interface, when only hNAA50 is bound to hNatA (Fig. 3.7c).
Notably, α40, α38, α37, α36 display shift of ~4.5 Å, ~2.3 Å, ~1.6 Å, and ~1.8 Å,
respectively. The important residues of hNAA15 (Lys696, Arg697, Lys687, Lys685),
which mediate HYPK interactions in this region suggested that most of them in the
hNatE structure exhibit an ~ 2 Å shift away from HYPK (Fig. 3.7c). Meanwhile, hNAA15
N-terminal helices of α7, α8, α9, α10 which are in close contact with HYPK-α2 also show
~3.0 Å, ~4.1 Å, ~1.9 Å, ~3.5 Å shifts, respectively (Fig. 3.7d), while Tyr 158 is about ~2
Å further away. Lastly, we observe that α2 and β3- β4 of hNAA50-bound hNAA10 move
~2.5 Å closer to contact the HYPK N-terminal α1 helix (Fig. 3.7e). Thus, it appears that
hNAA50 binding to hNatA, destabilizes hNatA-HYPK interactions through moving hNatA
away from its optimal binding position to HYPK.
Similarly, a superposition of hNatE/HYPK with the crystal structure of
hNatA/HYPK by aligning to the HYPK position to delineate how the hNAA50 binding
regions are affected by HYPK binding reveals that hNAA15 is shifted away from HYPK
and closer to hNAA50 in the hNatE/HYPK complex (Fig. 3.7b). A further zoom-in view of
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the hNAA50 binding regions in hNAA15 demonstrates that residues Glu433, Thr406,
Thr371 and Thr439 of hNAA15 are shifted by ~ 2-3 Å away from hNAA50 when HYPK is
bound relative to their positions in the absence of hNAA50 (Fig. 3.7f). Regarding the
hNAA50-hNAA10 binding interface, a 4.3 Å shift of hNAA10-Arg116 was observed, with
a 1.7 Å for hNAA10-Arg83 (Fig. 3.7g). It is also noteworthy that significant
conformational shift of the C-terminal hNAA15 helices α41- α45 (~2.2 - 4.2 Å) was
induced in order to have hNAA50 bound in the tetrameric hNatE/HYPK complex (Fig.
3.7h). This suggests that HYPK bound hNatA is also not optimal for hNAA50 binding.
Taken together, these comparisons reveal that hNAA50 and HYPK destabilize
the binding of the other protein to hNatA, despite their independent binding surfaces to
hNatA, and explain the observed negative cooperative binding of hNAA50 and HYPK to
hNatA.
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Figure 18.6 Overall structure of the hNatE/HYPK complex
(a) hNAA50 (pink), hNAA15 (green), hNAA10 (orange), and HYPK (red) within the
hNatE complex is shown in cartoon. (b) Zoom-in view of the contacts between HYPK
and hNAA15 with residues that participate in interaction shown. (c) Zoom-in view of the
contacts between hNAA15 and hNAA50 with residues that participate in interaction
shown. (d) Zoom-in view of the contacts between hNAA10 and hNAA50 with residues
that participate in interaction shown.
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Figure 19.7 Molecular basis for NAA50 and HYPK binding to NatA
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(a) hNatE/HYPK overlayed onto hNatE (purple) with NAA50 aligned. (b) hNatE/HYPK
overlayed onto hNatA/HYPK (PDB: 6C95, blue) with HYPK aligned. (c) zoom-in view of
HYPK C-terminal binding region as indicated in (a). (d) zoom-in view of HYPK α2
binding region as indicated in (a). (e) zoom-in view of HYPK N terminal α1 domain
binding region as indicated in (a). (f) zoom-in view shows the NAA50 binding region on
NAA15 as indicated in (b). (g) zoom-in view shows the NAA50 binding region on NAA10
as indicated in (b). (h) zoom-in view shows the NAA15 C-terminal helices conformal
changes when HYPK bound as indicated in (b).

3.2.8 Molecular basis for decrease of hNatE activity by HYPK
Our kinetic data demonstrated that the catalytic efficiency of hNatE is greater
than hNAA50 but that this increase is partially nullified in the presence of HYPK (Table
3.1 and Fig. 3.2b). To understand the molecular basis for this, we overlay structures of
hNatE and hNatE/HYPK with the common hNatA subunits aligned. This superposition
reveals that the largest structural differences within the hNAA50 subunit map to the β6β7 and α1-α2 loops, which shift such that the hNAA50 peptide substrate binding groove
is ~2.4 Å wider in the hNatE/HYPK complex relative to the hNatE complex (Fig. 3.8). In
addition, the hNAA50 β3-β4 loop is shifted in the direction away from hNatA by about 3.5
Å in the presence of HYPK (Fig. 3.8). Previous studies demonstrated that Tyr73 and
Met75 from hNAA50-β4 and Tyr138, Tyr139 and Leu142 from the hNAA50 β6-β7 loop
are important for hNAA50 catalytic function and substrate binding (Liszczak, Arnesen,
and Marmorstein 2011). To directly test this, we prepared the following mutants:
hNAA50-Y73F, -M75A, -Y138A, -Y139A and -I142A, and tested their effects on hNatE
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activity when HYPK was bound (Fig. 3.2d). Consistent with previous studies, Y73F,
Y138A and Y139A decreased hNAA50 activity to undetectable levels (Liszczak,
Arnesen, and Marmorstein 2011). For hNAA50-M75A and -I142A, we observed
increased activity when bound to hNatA to form the hNatE complex, as we observed for
hNAA50-WT.

As expected, the hNatE/HYPK complex displayed reduced activity

compared to both hNAA50 alone and hNatE. However, we observed that hNatEM75A/HYPK and hNatE-I142A/HYPK exhibited similar activity, compared to their
corresponding hNAA50 mutants alone. This data is consistent with the conclusion that
perturbation of the hNAA50 β3-β4 and

β6-β7 loops within the hNatE/HYPK complex

underlies the observed reduced catalytic efficiency of hNatE in the presence of HYPK.

Figure 20.8 Molecular basis for the decrease of NAA50 activity by HYPK
hNatE/HYPK (green) overlayed onto hNatE (magenta) with hNatA aligned. Zoom-in view
shows the local conformational change of hNAA50.
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3.3 Discussion
While the interaction and catalytic crosstalk within NatE in the yeast system had
previously been reported, the corresponding human system and the influence of HYPK
binding on hNatE activity had not previously been characterized. Here, we biochemically
and structurally characterize the mechanistic interplay of the hNAA10 and hNAA50
catalytic subunits within the hNatE complex and the role of HYPK in regulating hNatE
activity. Similar to the crystal structure of ScNatE (PDB:6O07), we find that hNAA50
binds hNatA mainly through hNAA15, using highly conserved residues, including a key
threonine residue located at the center of the binding interface. Notably, the distance
between hNAA50 and hNAA10 in the human complex is significantly shorter than in the
yeast complex. We find that these two acidic hNAA50 residues, Glu7 and Asp53 contact
two hNAA10 arginine residues, inducing a conformational change in hNAA10, which
contributes to a decrease in hNatA enzymatic activity.
While both hNAA50 and hNatA are conserved from yeast to human, it had long
been considered that HYPK is not present in yeast until the recently identified HYPK in
thermophilic fungus Chaetomium thermophilum (Weyer et al. 2017). Nevertheless, it
appears that evolutionarily NAA50 appeared as a NatA binding partner earlier than
HYPK did. In both budding and fission yeast, NAA50 is inactive but regulates NatA
acetylation activity (Deng et al. 2019). While in higher eukaryotes, NAA50 is
enzymatically active, either with or without NatA (Liszczak, Arnesen, and Marmorstein

92

2011; Evjenth et al. 2009). Thus, within the tetrameric NatE/HYPK complex, it is likely
that the regulation of NatA activity by NAA50 was replaced by HYPK.
Here, we have reconstituted the tetrameric hNatE/HYPK complex to demonstrate
that HYPK and hNAA50 can bind to hNatA simultaneously. We also confirmed the
physiological

relevance

of

the

tetrameric

hNatE/HYPK

complex

through

immunoprecipitation of the complex from HeLa cells. We find that while HYPK inhibits
hNatA activity directly, it also indirectly, but less potently, inhibits hNatE. We also find
that hNAA50 and HYPK exhibit negative cooperativity with respect to hNatA binding in
vitro and in vivo. The structure of the hNatE/HYPK complex suggests that this is due to
the ability of the hNAA50 and HYPK protein to bind to the hNAA15 subunit of hNatA in a
way that indirectly destabilizes binding of the other protein. This observation, together
with our findings that HYPK has a dominant regulatory effect on hNatA activity relative to
hNAA50 may explain why excess free hNAA50 is observed over hNatA in higher
organism and HeLa cells (Hou et al. 2007).
The nano-molar dissociation constants of HYPK and hNAA50 for hNatA is
consistent with our immunoprecipitation of the tetrameric hNatE/HYPK complex from
cells. Previous studies in Drosophila also reported that a dNAA50 knockout decreases
in-vivo dNatA catalytic activity in the presence of HYPK (Rathore et al. 2016). In terms of
the biological function of this tetrameric complex, we propose two non-mutually exclusive
regulatory mechanism for how hNAA50 protein levels could affect hNatA activity. First,
since hNAA50 has a negative effect on binding between hNatA and HYPK, the absence
of hNAA50, would promote HYPK binding to hNatA to inhibit hNatA activity. Second,
since a recent yeast NatE-ribosome structure demonstrated that yeast NAA50
participates in ribosome association (Knorr et al. 2019), it is likely that hNAA50 in higher
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eukaryotes also contributes to the association between tetrameric hNatE/HYPK and
ribosome. The lower level of hNAA50 could therefore decrease the fraction of ribosome
associated hNatA to regulate its co-translational activity.
The overall structures of hNAA50 and ScNAA50 are well conserved with a mix of
-helices and

-strands. However, the overlay of hNatE and ScNatE suggested that

NAA50 shifts closer to NAA10 in the human over the yeast complex. It is possible that in
the human system NAA10 and NAA50 have more intimate contact and crosstalk in
enzymatic activity. However, previous data indicated that the degree of NAA50 and
NAA10 activity crosstalk is similar in yeast and human (Deng et al. 2019). In a recently
reported yeast ScNatE-ribosome structure, the ScNAA10 and ScNAA50 catalytic sites
are 50 Å and 85 Å away from the peptide exit site on the ribosome (Knorr et al. 2019).
While unlike ScNAA50, hNAA50 is co-translationally enzymatically active (Evjenth et al.
2009). Thus, we propose that this shift of NAA50 closer to NAA10 in the human over the
yeast complex may have an impact on the relative distance between the nascent chain
and active sites of hNAA10 and hNAA50.
With respect to hNatA binding to the ribosome, it is possible that HYPK may also
contribute to ribosome binding by hNatA. This could then indirectly affect hNAA50
recruitment to the ribosome, which would be promoted by hNatA but inhibited by HYPK.
HYPK contains a UBA domain, which is also present at the C-terminus of the alpha
subunit of the Nascent Polypeptide-Associated Complex (NAC). Further studies are
required to test these hypotheses for hNatA recruitment to the ribosome.
The hNatE/HYPK complex co-translationally acetylates nascent peptides with N
termini of either methionine maintained or cleaved, which accounts for the largest
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number of substrates among all NATs. Given that this complex acetylates about 40-60%
of the human proteome and has altered function in many human diseases, the studies
presented here provides an important molecular scaffold for potential therapeutic
development.

3.4 Materials and methods
3.4.1 Plasmid construction.
A mammalian expression vector pcDNA3.1/NAA15-V5 was modified by sitedirected mutagenesis (Q5® Site Directed Mutagenesis Kit, New England Biolabs) to
encode hNAA15 variants c.1216-1218ACA>TAC (p.T406Y) and c.2441T>C (p.L814P).
Primer sequences for p.T406Y are AAGTACACCTTACTTAATAGAACTCTTTCTCGTG
and

TCAATAGCAGTATTTATGTAC.

Primer

sequences

for

p.L814P

are

TGATGGTAGCCCAGGAGACTGTA and TACAAGGCTTCCAATACC. The mutated
plasmid sequences were verified by sequencing.

3.4.2 Proteomics sample preparation of NAA15-V5 immunoprecipitates.
For immunoprecipitation of NAA15-V5 variants, two 10 cm dishes of HeLa cells
(ATCC CCL-2) were transfected with 10 µg of either pcDNA3.1/NAA15-WT-V5,
pcDNA3.1/NAA15-T406Y-V5 or pcDNA3.1/NAA15-L814P-V5 using X-tremeGENE™ 9
DNA Transfection Reagent (Roche). The growth medium was replaced after 24 h. 48 h
post transfection, cells were harvested and lysed in 200 µl IPH lysis buffer (50 mM Tris95

HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1× complete EDTA-free protease
inhibitor cocktail (Roche)) per cell dish for 15 min at 4°C on a rotating wheel. Cell debris
was pelleted by centrifugation (17000 × g, 4°C, 5 min) and the supernatant was mixed
with 2 µg of V5-tag mouse monoclonal antibody (Invitrogen, R960-25) and incubated for
2 h at 4°C on a rotating wheel. Thereafter, 20 µl of Dynabeads™ Protein G (Invitrogen)
washed in IPH lysis buffer was added to the cell lysates and incubated overnight. The
next day, beads were washed three times in IPH lysis buffer before the retrieved
immunocomplexes were eluted in 60 µl FASP buffer (2% SDS, 100 mM Tris-HCl pH 7.6,
0.1 M DTT) and heated for 5 min at 95 °C. Filter-aided sample preparation (FASP)
method was performed to process the eluates for LC-MS/MS analysis (Wisniewski et al.
2009). The protein samples were mixed with 200 µl UA buffer (8 M urea, 100 Mm TrisHCl pH 8.0), transferred to Microcon 30kDa MWCO filters and centrifuged. All
centrifugation steps were carried out at 23 °C and 14 000 x g for 15 min. The filters were
washed three times with 200 µl UA by spinning. Proteins were then Cys-alkylated by
incubation with 100 µl 50 mM iodoacetamide (IAA) in UA for 20 min, before IAA was
removed by centrifugation. Filters were then washed three times with 100 µl UA. Finally,
the UA buffer was exchanged by three washes with 100 µl 50 mM ammonium
bicarbonate (ABC), before 500 ng trypsin (Sequencing Grade Modified Trypsin,
Promega) was added to the filters and incubated overnight at 37 °C. Digested proteins
were collected by centrifugation and the filter was washed once with 75 µl ABC.
Peptides were acidified with 5% formic acid (FA) and desalted using PierceTM C18-Tips
(Thermo Scientific) according to manufacturer´s protocol. The final eluates were dried by
speed vacuum and diluted to desired concentration with 5% FA.
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3.4.3 MS analysis of NAA15-V5 immunoprecipitates.
Mass spectrometric analysis was performed with an Ultimate 3000 RSLC system
(Thermo Scientific) coupled to a Q-Exactive HF mass spectrometer (Thermo Scientific)
equipped with EASY-spray nano-electrospray ion source (Thermo Scientific). About 1 µg
tryptic peptides were loaded and desalted on a pre-column (Acclaim PepMap 100, 2cm x
75µm ID nanoViper column, packed with 3 µm C18 beads) with 0.1% TFA (flow rate 5
µl/min, 5 min). Peptides were separated during a biphasic ACN gradient from two
nanoflow UPLC pumps (flow rate of 200 nl/min) on an analytical column (PepMap RSLC,
50cm x 75 µm i.d. EASY-spray column, packed with 2 µm C18 beads). Solvent A and B
were 0.1% FA (vol/vol) in water and 100% ACN respectively. The gradient composition
was 5% B for 5 min, 5-8% B for 0.5 min, 8–24% B for 109.5min, 24–35% B for 25min,
and 35–80% B for 15 min, 80% B over 15 min for isocratic elution and 5% B over 20 min
for conditioning. The eluting peptides were ionized in the electrospray and analyzed by
the Q-Exactive HF. The mass spectrometer was operated in data-dependent mode to
automatically switch between full scan MS and MS/MS acquisition. MS spectra (m/z
375-1500) were obtained with a resolution of 120 000 at m/z 200, automatic gain control
(AGC) target of 3 x 106 and maximum injection time (IT) of 100 ms. The twelve most
intense peptides above a threshold of 50 000 counts and charge states 2 to 5 were
isolated (window of 1.6 m/z, AGC target of 1 x 105 and maximum IT of 110 ms) for
fragmentation at a normalized collision energy of 28%. Fragments were detected in the
orbitrap at a resolution of 15 000 at m/z 200, with first mass fixed at m/z 100. Precursor
masses selected for MS/MS analysis were excluded by dynamic exclusion for 25 s with
“exclude isotopes” enabled. Lock-mass internal calibration (m/z 445.12003) was used.
The raw data acquired was processed with MaxQuant v. 1.6.2.6 and Andromeda search
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engine. The spectra were searched against a database of Swiss-Prot annotated human
protein sequences (20431 sequences, retrieved 25.06.2019) and a reverse decoy
database. Cystein carbamidomethylation was selected as a fixed modification and
variable modifications included methionine oxidation and protein N-terminal acetylation.
The false discovery rate (FDR) was set to 1% for peptide and protein identification,
minimum peptide length allowed was 7 and match between runs (0.7 min match time
window, 20 min alignment time window) was enabled. Label-free quantification (LFQ)
(Cox et al. 2014) and intensity-based absolute quantification (IBAQ) were selected. All
other parameters were set to default values. The resulting proteingroups.txt file was
analysed using Perseus software v. 1.6.5.0. Proteins only identified by site, common
contaminants and reverse hits were filtered away. The IBAQ intensities of hNAA10,
hNAA50 and HYPK were normalized to the IBAQ intensity of NAA15 in each IP sample.
Thereafter, the IBAQ intensity of hNAA15, hNAA10, hNAA50 and HYPK in each sample
was normalized to the IBAQ intensity of the corresponding protein in the hNAA15-WT-V5
IP sample.

3.4.4 [14C]-Ac-CoA-based acetylation and western blot analysis

In order to test the NatA Nt-acetylation activity of hNAA15-T406Y and
hNAA15-L815P variants, immunoprecipitation of hNAA15-V5 was performed as
described above with minor adjustments. Five 10 cm dishes of HeLa cells (ATCC
CCL-2)

were

transfected

with

8

µg

pcDNA3.1/NAA15-WT-V5,

8

µg

pcDNA3.1/NAA15-T406Y-V5 or 10 µg pcDNA3.1/NAA15-L814P-V5. NAA15-WTV5 and NAA15-T406Y-V5 were co-transfected with 2 µg of empty pcDNA3.1/V5
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vector to ensure equal conditions for the cells. As a negative control, five dishes
of

HeLa

cells

were

transfected

with

10

µg

of

pcDNA3.1/LacZ-V5.

Immunoprecipitation from harvested and lysed cells was performed using 3 µg of
V5-tag mouse monoclonal antibody (Invitrogen) and 30 µl of Dynabeads™
Protein G (Invitrogen, R960-25). The beads were washed three times in IPH lysis
buffer and resuspended in 95 µl acetylation buffer (50 mM Tris-HCl pH 8.5, 1 mM
EDTA, 10% Glycerol). [14C]-Ac-CoA–based Nt-acetylation assays were
performed as described (Drazic and Arnesen 2017). In brief, three reaction
mixture replicates were prepared containing 10 µl of immunoprecipitated
enzyme,

200

µM

synthetic

24-mer

oligopeptide

SESS24:

NH2-

SESSSKSRWGRPVGRRRRPVRVYP-COOH (BioGenes), 50 µM [14C]-Ac-CoA
(Perkin-Elmer) and acetylation buffer to a final volume of 25 µl. Reaction mixtures
without oligopeptide were used as negative controls. The reaction mixtures were
incubated at 37 °C at 1400 rpm shaking for 30 min. The reaction was stopped by
isolating beads on a magnet and transferring 23 µl of the supernatant onto P81
phosphocellulose filter discs (Millipore). The filter discs were washed three times
in 10 mM HEPES buffer (pH 7.4) and air dried, before they were added to 5 ml
Ultima Gold F scintillation mixture (Perkin-Elmer) and the incorporated [14C]-Ac
was measured by a Perkin-Elmer TriCarb 2900TR Liquid Scintillation Analyzer.
The immunoprecipitate input was determined by Western blot analysis. Proteins
were separated by SDS-PAGE, transferred onto a nitrocellulose membrane
(Amersham Protran 0.2 µM NC) and probed with V5-tag mouse monoclonal
antibody (1:5000, Invitrogen, R960-25) and NAA10 rabbit monoclonal antibody
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(1:1000, Cell Signaling #13357). Protein bands were imaged by ChemiDocTM
XRS+ system (Bio-Rad) and quantified using ImagelabTM Software (Bio-Rad).
The measured DPM signal for each reaction was normalized to the amount of
NAA15-V5 in the respective IP sample.

3.4.5 Protein expression and purification
N-his tagged hNatA, N-his tagged hNatA/HYPK, were expressed in sf9 cells
(ThermoFisher, cat# 12659017) and purified as described previously (Gottlieb and
Marmorstein 2018). hNAA50 (Liszczak, Arnesen, and Marmorstein 2011) and MBPHYPK (Gottlieb and Marmorstein 2018) were expressed in BL21 (DE3)E. Coli cells
(Thermo Scientific) and Rosetta (DE3)pLysS E. coli cells (Millipore Sigma), respectively,
and purified as described previously. For hNatA and hNatA/HYPK sf9 expression, High
density (2 x106 cells/ml) suspension cultures of Sf9 cells were infected at a multiplicity of
infection (MOI) of 1 for 48hrs in Fernbach Shake flasks at 27 °C. Cells pellets were
resuspended in lysis buffer of 25 mM Tris, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 10
mM β-ME, 10 mg/ml PMSF (phenylmethanesulfonylfluoride), DNase, and complete,
EDTA-free protease inhibitor tablet (Roche). After sonication, clarified lysate was passed
on nickel resin (Thermo Scientific), washed with 10 CV of lysis buffer, and eluted with 25
mM Tris, pH 8.0, 200 mM NaCl, 200 mM Imidazole, 10 mM β-ME. Elute was further
purified with HiTrap SP ion-exchange column with the salt gradient (200mM to 1M).
Peak fractions were pooled and run on a Superdex 200 Increase 10/300 GL gel filtration
column in sizing buffer containing 25 mM HEPES, pH 7.0, 200 mM NaCl, and 1 mM
TCEP. Peak fractions were pooled and flash-frozen for storage in -80 °C until use.
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For E. coli protein expression, transformed cells were cultured at 37 °C until the
absorbance A600 reached ~ 0.7, induced with 0.5 mM IPTG (isopropyl 1-thio-β-Dgalactopyranoside), and grown overnight at 16 °C. E. coli cells overexpressing MBPHYPK were lysed in 25 mM Tris, pH 8.0, 150 mM NaCl, 10 mM β-ME, 10 mg/ml PMSF.
Clarified lysate was passed on to amylose agarose resin (New England Biolabs),
washed with lysis buffer, and elute in lysis buffer supplementary with 20 mM maltose.
Eluted protein was purified with a 5 mL HiTrap Q ion-exchange column (GE Healthcare)
in the same buffer with a gradient (150 mM to 1M NaCl). Peak fractions were pooled and
loaded to a Superdex 75 Increase 10/300 GL gel filtration column (GE Healthcare) in
buffer of 25 mM HEPES, pH 7.0, 200 mM NaCl, and 1 mM TCEP. Peak fractions were
pooled and flash-frozen for storage in -80 °C until use. E. coli cells over-expressing GST
tagged NAA50 were lysed in 25mM HEPES pH 7.5, 100 mM NaCl, and 10 mM β-ME by
sonication. The supernatant was isolated and loaded to GST-binding resin (Clontech),
washed with 10 CV lysis buffer. TEV (tobacco etch virus protease) was added to the
resin for on-column cleavage overnight at room temperature. Untagged Naa50 was
washed off the column with lysis buffer and collected for overnight dialysis in buffer with
25mM HEPES (pH 7.5), 50 mM NaCl, and 10 mM β-ME. Ion exchange was done with a
5-ml HiTrap SP ion exchange column (GE Healthcare) in gradient of 50 – 750 mM NaCl.
Peak fractions were further purified with Superdex 75 gel filtration column (GE
Healthcare) to homogeneity in buffer containing 25 mM HEPES, pH 7.5, 100 mM NaCl,
and 10 mM DTT (dithiothreitol). Protein was flash-frozen for storage in -80 °C until use.
Protein harboring mutations was generated with QuickChange protocol (Stratagene)
(Braman, Papworth, and Greener 1996) and obtained following the same expression
and

purification

protocol

as

wild

type.

AAGGTAGCCGGATCGCGCTGGGAGATGTG
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Primers

for

making

hNAA50-E7A:
and

CACATCTCCCAGCGCGATCCGGCTACCTT.

For

CTTGCCTATTTCAATGCTATTGCTGTAGGTGC
GCACCTACAGCAATAGCATTGAAATAGGCAAG.

hNAA50-D53A:
and

For

hNAA50-M75A:

GACTTTACATCGCGACACTAGGATG and CATCCTAGTGTCGCGATGTAAAGTC. For
hNAA50-Y138A:

ACAAAGAAGAACGCCTATAAGAGGATAG

and

CTATCCTCTTATAGGCGTTCTTCTTTGT. hNAA50-Y73F, hNAA50-I142A, hNAA50Y139A were generated as previously described (Liszczak, Arnesen, and Marmorstein
2011).

3.4.6 Acetyltransferase activity assays
Acetyltransferase assays were modified from previous studies (Liszczak et al.
2013; Liszczak, Arnesen, and Marmorstein 2011) and carried out at room temperature in
a reaction buffer containing 75 mM HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT. The
SASE substrate peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; GenScript) and the
MLGP substrate peptide (NH2-MLGPEGGRWGRPVGRRRRP-COOH; GenScript) were
used to determine the enzymatic activity of hNatA and hNAA50, respectively. Each
curve was repeated at least 3 times. To test the effect of hNAA50 and HYPK on hNatA
activity, 100 nM of hNatA was mixed with 500 µM SASE peptide, 300 µM C14 labeled
acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences), and varied concentrations of
hNAA50 or HYPK modulator were added for 12-minute reactions. Signals were
normalized against enzyme without modulator. For time course activity assays, 500 nM
of hNAA50, hNatE, or hNatE/HYPK were mixed with 500 µM MLGP peptide, and 300
µM C14 labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences) in a 20 µL
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reaction volume. Only 15 µL of each reaction mixture was quenched at specific times.
For kinetic assays of hNAA50, hNatE and hNatE/HYPK against MLGP peptide, 300 nM
enzyme was mixed with 300 µM C14 labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life
Sciences) and the concentration of the peptide substrate was varied for a 40-minute
reaction. Data was fit to a Michaelis–Menten equation in GraphPad Prism for
determination of kinetic parameters.

3.4.7 FP binding assays
Fluorescence polarization (FP) binding assays were performed essentially as
described previously (Deng et al. 2019). 10 nM of fluorescein labeled hNAA50 (Deng et
al. 2019) was used in all reactions, and hNatA or hNatA/MBP-HYPK concentrations
were varied to determine the dissociation constant (Kd). 5 mg/mL BSA and 0.2% v/v
Tween were added into the reaction buffer (25 mM HEPES, pH 7.0, 200 mM NaCl and
10 mM DTT) to prevent non-specific binding. FP readings were taken with a Perkin
Elmer EnVision and each curve was repeated in triplicate. GraphPad Prism (version
5.01) was used for all data fitting to determine Kd. A single-site specific binding model
was used, with equation 1,

(1)

where Fi is the fluorescence reading at ligand (either hNatA or hNatA/HYPK)
concentration [L]i; Kd is the equilibrium dissociation binding constant; [M] is the
concentration of hNaa50; F0 is the fluorescence reading extrapolated to no ligand; F1 is
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the maximum fluorescence increase at saturating ligand concentration. Fit parameters
for hNatA/HYPK (MBP tagged) binding were F0 = 161.3 ± 3.3, F1 = 222.0 ± 5.2, Kd =127
± 13 nM, and R2 = 0.98. For hNatA, F0 = 205.8 ± 4.4, F1 = 137.2 ± 5.4, Kd = 46 ± 8.8 nM,
and R2 = 0.95.

3.4.8 ITC measurements
ITC measurements were carried out using a MicroCal iTC200 at 20 °C. Samples
were dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, 1 mM DTT.
Protein samples (hNatA, hNatE) with concentrations of 15 μM in the cell and 150 μMof
MBP-HYPK in the syringe were used in the experiments. The raw data was analyzed
with the MicroCal ITC analysis software.

3.4.9 Cryo-EM sample preparation and data collection
To prepare hNatE complex, purified hNatA and three molar excess of hNAA50
were mixed and loaded onto a Superdex 200 10/30 GL column (GE Healthcare). Peak
fractions with all subunits present, as confirmed with SDS-PAGE analysis, were
concentrated to 1 mg/ml. Fresh sample incubated with 3 molar excess of both hNatA
and hNAA50 bi-substrate analogues for ~30 min on ice was applied to Quantinfoil
R1.2/1.3 holey carbon support grids. To prepare hNatE/HYPK complex, purified
hNatA/HYPK and three molar excess of hNAA50 were mixed and loaded onto an S200
gel-filtration column (GE Healthcare). Peak fractions with all subunits present, as
confirmed with SDS-PAGE were concentrated to 1 mg/ml. Fresh sample with 3 molar
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excess of acetyl-CoA and hNAA50 bi-substrate analogues for ~30 min in ice was applied
to Quantinfoil R1.2/1.3 holey carbon support grids.
Both sample grids were blotted for 10-12 seconds (blot force = 2) under 100%
humidity at 16°C before the sample was plunged into liquid ethane, using a FEI Vitrobot
Mark IV. An FEI TF20 was used for screening the grids and data collection was
performed either with a Talos Arctica microscope or Titan Krios equipped with a K2
Summit direct detector (Gatan).

3.4.10 Cryo-EM data processing
Original image stacks were summed and corrected for drift and beam-induced
motion at the micrograph level using MotionCor2 (Zheng et al. 2017). Defocus
estimation and the resolution range of each micrograph were performed with Gctf
(Zhang 2016). For hNatA/hNAA50, ~3,000 particles were manually picked to generate
several rough 2D class averages. Representative 2D classes were used to autopick
~1,229,331 particles from 4,025 micrographs using Relion (Kimanius et al. 2016). All
particles were extracted and binned to accelerate the 2D and 3D classifications. After
bad particles were further removed by 2D and 3D classification, 353,541 particles were
used for auto refinement, particle polishing and per particle CTF refinement. The final
map of the hNatE complex was refined to an overall resolution of 3.02 Å, with local
resolution estimated by Resmap (Kucukelbir, Sigworth, and Tagare 2014). For the
hNatE/HYPK complex, image processing workflow was similar as described above.
477,608 particles were picked from 1,004 micrographs and 168,536 particles were used
for refinement. The final resolution of the hNatE/HYPK complex was 4.03 Å.
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3.4.11 Cryo-EM model building and refinement
For hNatE model building, the crystal structures of hNatA (PDB: 6C9M) and
hNAA50 (PDB: 3TFY) were fit into the 3.02 Å EM map as rigid bodies, followed by
manual adjustment in coot (Emsley and Cowtan 2004) and real-space refinement in
PHENIX (Adams et al. 2010). For the hNatE/HYPK model building, the crystal structure
of hNatA/HYPK (PDB: 6C95) and hNAA50 (PDB: 3TFY) were used. All representations
of Cryo-EM density and structural models were performed with Chimera (Pettersen et al.
2004) and PyMol (The PyMOL Molecular Graphics System, Version 1.2r3pre,
Schrödinger, LLC.).
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CHAPTER 4: Molecular Basis for N-Terminal Alpha-Synuclein Acetylation by
Human NatB

This work is adapted from Elife (Deng, Pan, et al. 2020) © eLife Sciences Publications,
Ltd
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4.1 Introduction
NatB is conserved from yeast to human in both complex composition and in its
substrate specificity profile (Starheim, Gevaert, and Arnesen 2012). In Saccharomyces
cerevisiae, the deletion of NatB subunits produces more severe phenotypes, compared
to the knockout of NatA or NatC subunits. Deletion of either NAA20 or NAA25 leads to
similar phenotypes including slower growth rate, diminished mating, defects in actin
cable formation, and aberrant mitochondrial and vacuolar inheritance (Polevoda et al.
2003). These observations suggest that the proper function of actin and tropomyosin
requires NTA by the intact NatB complex (Polevoda et al. 2003). In humans, disruption
of NatB (hNatB) by knockout leads to defects in proper actin cytoskeleton structure, cell
cycle progression and cell proliferation (Ametzazurra et al. 2008; Starheim et al. 2008;
Ametzazurra et al. 2009; Neri et al. 2017). In addition, hNatB is upregulated in human
hepatocellular carcinoma (Ametzazurra et al. 2008), where it has been suggested as a
potential therapeutic target as silencing of this complex can block cell proliferation and
tumor formation (Neri et al. 2017). hNatB-mediated NTA of α-synuclein (αSyn) has been
shown to increase αSyn stability and lipid binding, and to reduce aggregation capacity
(Watson and Lee 2019; Mason et al. 2016; Maltsev, Ying, and Bax 2012; Dikiy and
Eliezer 2014; Trexler and Rhoades 2012; Fernández and Lucas 2018; Fauvet et al.
2012; Kang et al. 2012; Iyer et al. 2016). Since αSyn is a key protein in Parkinson's
disease (PD) (Halliday et al. 2011; Spillantini et al. 1998), hNatB might play an indirect
role in PD pathogenesis in vivo as supported by a recent study (Vinueza-Gavilanes et al.
2020). It was also recently demonstrated that NTA of αSyn increases its propensity for
lipid membrane binding without altering its structural properties of the bound state
(Runfola et al. 2020).
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Compared to the comprehensive structural and biochemical characterization of
NatA (Liszczak et al. 2013; Weyer et al. 2017; Gottlieb and Marmorstein 2018; Deng et
al. 2019; Knorr et al. 2019; Magin et al. 2017), the study of NatB has been limited,
particularly in humans. Recently, the crystal structure of Candida albicans (Ca) NatB
bound to a bisubstrate CoA-peptide conjugate was determined, providing important
insights into substrate specificity and NTA by caNatB (Hong et al. 2017). However,
hNAA20 and hNAA25 share only ~40% and ~20% sequence identity with the Candida
albicans homologue (Hong et al. 2017), respectively. Moreover, nearly all biological
studies of NatB have been conducted in Saccharomyces cerevisiae (Lee et al. 2014;
Caesar, Warringer, and Blomberg 2006; Singer and Shaw 2003), Arabidopsis
(Ferrandez-Ayela et al. 2013; Huber et al. 2020), mouse (Ohyama et al. 2012) and
human (Neri et al. 2017; Starheim et al. 2008; Ametzazurra et al. 2008; Ametzazurra et
al. 2009) as model organisms. As a result, the mode of human NatB-mediated catalysis
and αSyn-specific NatB recognition remains unresolved. In this study, we report the 3.5
Å resolution cryo-electron microscopy (Cryo-EM) structure of the ~130 KDa hNatB
bound to a bisubstrate CoA-αSyn conjugate, together with a structure-guided analysis of
mutational effects on catalytic activity.

This analysis reveals functionally important

structural differences between hNaB and related NAT enzymes, as well as insights into
the molecular mechanisms that define αSyn and related substrates that are recognized
for hNatB-mediated N-terminal acetylation.
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4.2 Results
4.2.1 hNatB is potently inhibited by a CoA-aSyn conjugate
While attempts to express recombinant hNatB in E. coli were unsuccessful, we
found that overexpression of hNatB complex with full-length hNAA25 (residues 1-972)
and C-terminally truncated hNAA20 (residue 1-163 out of 178 total residues) in
baculovirus-infected Sf9 insect cells produced soluble protein that could be purified to
homogeneity (Fig. 4.1A). To evaluate the activity of the recombinant hNatB, we tested it
against different peptide substrates. αSyn with an N-terminal sequence of “MDVF” has
been widely considered as an in vivo hNatB substrate (Anderson et al. 2006; Ohrfelt et
al. 2011; Theillet et al. 2016; Van Damme et al. 2012). We therefore incorporated this
sequence into a peptide substrate named “MDVF” for an in vitro acetyltransferase assay
(“MDVF” peptide sequence: NH2-MDVFMKGRWGRPVGRRRRP-COOH). In agreement
with in vivo studies (Theillet et al. 2016; Anderson et al. 2006; Ohrfelt et al. 2011; Van
Damme et al. 2012), we observed that the purified recombinant hNatB was active
against this “MDVF” peptide, while no activity could be observed in the absence of either
the enzyme or peptide (Fig. 4.1B). hNatB also showed no observable activity if either
the first residue “M” or the first two residues “MD” in this αSyn peptide substrate was
removed

(“DVFM”

peptide

sequence:

NH2-DVFMKGLRWGRPVGRRRRP-COOH;

“VFMK” peptide sequence: NH2- VFMKGLSRWGRPVGRRRRP-COOH) (Fig. 4.1B),
suggesting that peptide substrate recognition by NatB is highly dependent on the first
two N-terminal residues. To further confirm the substrate specificity of hNatB, we tested
it against several previously identified peptide substrates for other NATs (“SASE”
peptide sequence (NatA-type): NH2-SASEAGVRWGRPVGRRRRP-COOH; “MLRF”
peptide sequence (NatC-type): NH2-MLRFVTKRWGRPVGRRRRP-COOH; “SGRG”/H4
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peptide sequence (NatD-type): NH2-SGRGKGGKGLGKGGAKRHR-COOH; “MLGP”
peptide sequence (NatE-type): NH2-MLGPEGGRWGRPVGRRRRP-COOH) (Fig. 4.1B).
Consistent with previous results (Van Damme et al. 2012), hNatB is only active toward
its unique canonical substrate type, displaying no overlapping activity towards other NAT
substrates.
In order to understand the mechanism of hNatB substrate recognition, we
synthesized a bi-substrate inhibitor in which the first 10 residues of αSyn are covalently
linked to CoA (Liszczak et al. 2013) for enzymatic and structural studies. Half-maximum
inhibitory concentration (IC50) determinations revealed that this CoA-αSyn conjugate had
an IC50 of about 1.63 ± 0.13 µM (Fig. 4.1C), significantly lower than the Km values we
had determined for hNatB toward a “MDVF” peptide (45.08 ± 3.15 µM) and acetyl-CoA
(47.28 ± 5.70 µM) (Table 4.1).
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Figure 21.1 hNatB is active toward an α-Synuclein peptide and can be inhibited by
a CoA-Syn conjugate
A. Gel filtration elution profile of hNatB, using a Superdex S200 column. Coomassiestained SDS-PAGE of peak fractions is reproduced to the right of the chromatograms. B.
Comparison of hNatB activity toward different peptide substrates. All the activities are
normalized to the activity of hNatB toward αSyn peptide (MDVF). C. Dose-response
curve corresponding to the titration of CoA-αSyn conjugate (CoA-MDVFMKGLSK) into
hNatB acetyltransferase reactions. The calculated IC50 value is indicated. Reactions
were performed in triplicate; replicates are shown in the graph as vertical dots.
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Table 6.1 Catalytic parameter of wild-type hNatB and mutants

4.2.2 hNatB reveals potentially biologically significant structural differences with hNatA
and caNatB
We performed single particle Cryo-EM of hNatB in the presence of the CoA-αSyn
conjugate. A 3.46 Å-resolution Cryo-EM three-dimensional (3D) map was determined
from 982,420 particles, selected from 5,281 raw electron micrographs (Table 4.2, Fig.
4.2). The central core region of the EM map contains excellent side chain density with a
local resolution of ~ 2.5 Å, particularly around the catalytic subunit, hNAA20.
Consistent with previous NAT structural studies, the atomic model of hNatB
features a catalytic subunit, hNAA20, that adopts a canonical Gcn5-related NAcetyltransferase (GNAT) fold (Neuwald and Landsman 1997). Additionally, the model
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reveals that the auxiliary subunit hNAA25 is composed of a total of 39 α-helices among
where the predicted first and second α-helices were built as poly-alanine due to a lack of
resolvable side-chain density (Fig. 4.2). The 39 α-helices can be roughly divided into
three groups: an N-terminal region: α1- α8; a core region: α9- α29; and a C-terminal
region: α30-α39 (Fig. 4.2A). The N terminal region (residue 1-164) displays relatively
weak EM density compared to other regions, suggesting that it is relatively flexible. The
eight helices of the N terminal region form four helical bundle tetratricopeptide repeat
(TPR) motifs, which often participate in protein-protein interactions. While there are no
visible contacts between the N-terminal TPR motifs and hNAA20, it is possible that this
region participates in ribosome association, similar to the N-terminal region of the
NAA15 auxiliary subunits of Schizosaccharomyces pombe (Magin et al. 2017) and
Saccharomyces cerevisiae (Knorr et al. 2019) NatA. The 21 helices of the core region
also form a number of TPR motifs, which come together to form a ring that completely
wraps around and extensively contacts hNAA20 within its hollow center (Fig. 4.2A).
Indeed. the interaction between hNAA20 and the TPR motifs of this core region buries a
total interface area is about 2300 Å2. In the core region, it is noteworthy that there is a
long α-helix (α28, ranging 30 residues) that traverses almost from one side of the
complex to the other. The α28 helix closes the core ring structure, locking hNAA20 in
position, and bridging the N- and C-terminal and regions. This is similar to the role
played by α29-α30 of the hNAA15 auxiliary subunit of hNatA (Fig. 4.2A and 4.2B). The
C terminal region features helices that bundle together to protrude out of the plane of the
core ring structure at an angle of ~ 45° (Fig. 4.2B).
The sequence identity of the catalytic and auxiliary subunits of hNatA and
hNatB are 20%, and 15 %, respectively. To understand how this translates to key
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structural differences, we superimposed the crystal structure of hNatA (PDB: 6C9M) with
our model. Between the catalytic subunits, there is a high degree of superposition (1.151
Å root-mean-square deviation [RMSD] over 105 common Cα atoms), except for an
additional helix, α5, on the C-terminus of hNatA-NAA10, which is absent in hNatBNAA20 (Fig. 4.2B). Between the auxiliary subunits, the core and N-terminal regions of
both hNatA-NAA15 and hNatB-NAA25 display similar topology, although a higher
degree of deviation than the catalytic subunits. The core regions both wrap around their
respective catalytic subunits (8.369 Å RMSD over 262 common Cα atoms), while the Nterminal regions jut off to the side (7.360 Å RMSD over 55 common Cα atoms). In
contrast, the C-terminal regions of hNatA-NAA15 and hNatB-NAA25 diverge significantly
from one another. For hNA25, the C-terminal region of hNAA25 is oriented towards its
N-terminal region, while the C-terminal region of hNAA15 is positioned ~ 50Å away from
the relative position of the superimposed C-terminal domain of hNAA25 (Fig. 4.2B). The
positioning of hNAA25 may serve to promote hNAA25 intra-termini communication,
which is similar to the interaction of hNatA and its regulatory protein HYPK (Gottlieb and
Marmorstein 2018). HYPK, which does not interact with hNatB, interacts with both the
N- and C-terminal domains of hNatA-NAA15, potentially serving as bridge to enable
closer communication between these two domains (Fig. 4.2).

Recent reports have

described the role of the small molecule IP6 (inositol hexaphosphate) in hNatA activity,
where it is found to act as “glue” between the C-terminal and core domains in hNAA15
and hNAA10 via a series of hydrogen bonds and electrostatic interactions (Gottlieb and
Marmorstein 2018; Cheng et al. 2019). While no corresponding small molecules have
been identified to play a similar role in hNatB, our model shows that this interaction is
replaced by an extended loop that connects the
NAA25.

31 helix with the

32 helix of hNatB-

This loop, which is not present in hNatA-NAA15, appears to mediate
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hydrophobic interactions between hNatB-NAA25 and -NAA20, likely to serve a similar
role as IP6.
We also compared the structures from human and the previously described C.
albicans NatB (CaNatB, PDB: 5K18).

Although the two superimposed structures

revealed a high degree of structural conservation (NAA20: 0.698 Å RMSD over 125
common Cα atoms; NAA25 Core region: 3.267 Å RMSD over 266 common Cα atoms),
the N-terminal region of hNatB-NAA25 appears to overlay more closely to hNatA-NAA15
than to CaNatB-NAA25 (Fig. 4.2B and C). Compared to CaNAA25, the N-terminal
regions of hNatB-NAA25 and hNatA-NAA15 are positioned more closely to the peptide
substrate binding sites of the respective catalytic subunits. Based on the role that the Nterminal yeast NatA-Naa15p regions play in ribosome docking (Magin et al. 2017; Knorr
et al. 2019), we propose that the relative shift in position of the N-terminal regions of the
human NAT auxiliary subunits, hNAA15 and hNAA25, may reflect a difference in
mechanism for ribosome association and co-translational NTA in C. albicans compared
with humans. In addition, the overlay of C terminal regions of hNAA25 and CaNAA25
displays a RMSD of 15.960 Å over 133 common Cα atoms. We observe that the main
difference that contributes to this deviation in this region is the length of helices.
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Figure 22.2 hNatB shows structural differences with hNatA and C. albicans NatB
hNaa20 (light orange) and hNaa25 (cyan) are shown in cartoon. The CoA- Syn
conjugate inhibitor is shown in sticks and colored as magenta. The N- and C- terminal
regions are indicated as “N” and “C”, respectively. Some helices are as labeled. B.
hNaa20 (light orange) and hNaa25 (cyan) are shown overlapped with hNatA (marine
blue, PDB: 6C9M). Small molecule IP6 bound to hNatA is shown as surface
representation (red). C. hNaa20 (light orange) and hNaa25 (cyan) are shown
superimposed on CaNatB (slate blue, PDB:5K04).
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Table 7.2 Cryo-EM data collection, refinement, and validation statistics

4.2.3 hNAA25 and hNAA20 make intimate interactions within hNatB
The hNatB/CoA-αSyn structure reveals an extensive interaction interface
between the core region of the auxiliary hNAA25 and catalytic hNAA20 subunits (Fig.
4.3A). The most intimate contact between the two proteins are made by the α28 - α29
segment of hNAA25 and almost the entire length of hNAA20 α2, creating a large
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hydrophobic interface (Fig. 4.3B). Residues that contribute to interaction include Thr26,
Gly28, Ile29, Pro30, Leu33, Gln34, Leu36, Ala37, His38, Glu41 of hNAA20 and Lys535,
His536, Ile537, Phe569, Asp576, Thr577, Tyr580, Ala584, Tyr 587, Lys592, Phe596,
Phe599, Leu603 of hNAA25 (Fig. 4.3B).

Another region of interaction, involving

predominantly van der Waals interaction occurs between the hNAA20 β4- α3 loop and
the hNAA25 α18- α19 loop. Here, residues Lys362, Pro363, Lys362-Thr367, Cys364,
and Pro363 from hNAA25 and residues Arg85, Phe83, Glu82 and Arg84 from hNAA20
contribute to this small batch of hydrophobic interface (Fig. 4.3C).
Additional intimate contacts between hNAA20 and hNAA25 are mediated
between hNAA20 α1 helix and α26-α27 loop, and the hNAA25 α24-α25 loop, consisting
of a mix of polar and non-polar interactions.

A few hydrogen bonds are formed,

centered around hNAA20-Asn16, between the sidechain nitrogen atoms of hNAA20Asn16 and sidechain oxygen of hNAA25-Thr541, between the sidechain oxygen atom of
hNAA20-Asn16 and sidechain nitrogen atom of hNAA25-Gln538, and between the
sidechain nitrogen of hNAA20-Asn16 and the sidechain of hNAA25-Asp657 (Fig. 4.3D).
A salt bridge is found between the sidechain of hNAA20-Asp10 and the sidechain of
hNAA25-Arg602. In addition, there are hydrophobic interactions between residues
Phe15, Leu12, Phe13, Leu19, Pro22 from hNAA20 and residues Ile537, Asp540,
His536, Ala506, Phe662, Ser504, Ile542, Leu603 from hNAA25 (Fig. 4.3D).
Different sides of hNAA20 feature several potentially hNAA25-stabilizing polar
interactions. Hydrogen bonds are formed between the Asp261 side chain of the hNAA25
α14-α15 loop and the hNAA20-Thr2 backbone nitrogen atom (Fig. 4.3E), between the
Glu227 backbone carbonyl group of hNAA25 α12-α13 loop and the hNAA20-Arg102
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sidechain (Fig. 4.3F), and between the Lys535 sidechain from NAA25 α26-α27 loop and
the hNAA20-Ser141 backbone carbonyl group (Fig. 4.3G).

Figure 23.3 hNAA20 and hNAA25 make intimate interactions within hNatB
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A. hNAA20 (light orange) and hNAA25 (cyan) are shown in cartoon with major
associated interface denoted. B-G. Zoom-in views of the hydrophobic interface regions
as indicated in A.

4.2.4 hNatB makes specific interactions with the first 4 N-terminal residues of aSyn
In the Cryo-EM map, density for the CoA-αSyn conjugate bisubstrate inhibitor is
well resolved, allowing us to confidently model the CoA portion and the first five Nterminal residues (of ten residues present) of the αSyn portion (Fig. 4.4A and 4.4B).
Similar to other NATs, CoA enters the catalytic active site through a groove formed by
α3 and α4 of the catalytic subunit, while the peptide substrate enters the active site on
the opposite side of the catalytic subunit flanked by the α1-2 and β6- β7 loops (Fig.
4.4A).
hNAA20 contains a conserved acetyl-CoA binding motif among NATs:
R84R85XG87XA89. Here, we observe that the positively charged hNAA20-Arg 85 interacts
with the negatively charged 3'-phosphorylated ADP portion of CoA to form a salt bridge
while Arg84 makes Van der Waals interactions (Fig. 4.4C and 4.4D). A hydrogen
bonding network is formed mainly between the 5’-diphosphate group and backbone
atoms of a few residues including Val79, Gly87, Ala89, and Ala90 (Fig. 4.4C and 4.4D),
and mediated by the side chains of Arg85 and Gln125. The CoA molecule anchors to the
binding pocket through a series of van der Waals contacts formed by residues Ser67,
Val79, Leu77, Leu88, Val118, Met 122, and Tyr123 (Fig. 4.4D).
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Four N-terminal residues of αSyn participate in hNAA20 interactions. Anchoring
of the αSyn peptide is mediated by protein hydrogen bonds with the backbone atoms of
Met1 and Asp2 of αSyn. Hydrogen bonds are formed between the backbone N-H group
of αSyn-Met1 and the backbone carbonyl group of hNAA20-Phe111, as well as the
backbone carbonyl group of αSyn-Met1 with the sidechain of hNAA20-Tyr138. The
backbone N-H and carbonyl of αSyn-Asp2 also form hydrogen bonds to the sidechain of
Tyr27, and between the backbone carbonyl group of Asp2 and sidechain of hNAA20Tyr27 (Fig. 4.4D). Remarkably, hNAA20 contacts each of the first four N-terminal
residue side chains of αSyn via van der Waals interactions. The only side chain that
forms a hydrogen bond with hNAA20 is αSyn-Asp2, which hydrogen bonds with a
hNAA20-His73 ring nitrogen and the hNAA20-Thr75 side chain (Fig. 4.4D). The more
extensive van der Waals interactions include the following: αSyn-Met1 interacts with
hNAA20 residues Glu25, Phe27, Tyr56 and Ala76; αSyn-Asp2 interacts with hNAA20
residues Try27, Thr75, His73, Phe111, and Tyr138; αSyn-Val3 interacts with hNAA20
residues Tyr137 and Tyr138; and αSyn-Phe4 interacts with hNAA20 residues Glu25 and
Als140. αSyn-Met5 does not appear to make specific interactions (Fig. 4.4D). Consistent
with the importance of the residues that mediate αSyn binding, most of the residues are
highly conserved from yeast to humans.
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Figure 24.4 hNAA20 makes key CoA- and substrate peptide-interactions
A. The structure of hNAA20 bound to the CoA- Syn conjugate bound is shown in
cartoon, with corresponding secondary structures labeled. B. The fit of the CoA- Syn
124

conjugate ligand in the EM density map. The contour level is 4.0 sigma. C. Interaction
between CoA- Syn conjugate and hNAA20 residues is generated with LIGPLOT
(Laskowski and Swindells 2011). Hydrogen bonds are indicated by dashed green lines,
and van der Waals interactions are indicated with red semicirlcles. D. Highlighted polar
and hydrophobic interactions between CoA- Syn conjugate and the hNAA20 are
depicted in 3D view.

4.2.5 Mutational analysis identifies key residues for hNatB catalysis and cognate
substrate binding
To determine the functional importance of hNAA20 residues that appear to make
important peptide or CoA substrate contacts in our model, we used an in vitro
acetyltransferase assay to kinetically characterize WT and mutant hNatB proteins. Each
mutant was purified to homogeneity and displayed identical gel filtration chromatography
elution profiles (data not shown), indicating that they were all properly folded. We
prepared alanine mutants of several residues involved in the CoA binding including
Arg84, Arg85, Gly87 and Tyr123. Among them, R84A, R85A and G87A did not show
significant defects in overall protein catalytic function (Table 4.1). However, a Y123A
mutant nearly abolished protein activity, with a 95% loss of protein activity, affecting both
kcat and Km (Table 4.1). To further interrogate the properties of this residue, we prepared
a Y123F mutant which features a similar aromatic bulky side chain but not the polar phydroxyl group. We observed that Y123F displayed a similar ~88% loss of kcat, but had a
negligible effect on the peptide Km (Table 4.1). These data suggested that the Tyr123
hydroxyl group is critical for catalysis but not required for substrate binding, while the
aromatic ring of Tyr123 plays a role in peptide substrate binding. Given that the hydroxyl
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group of Tyr123 is about 3.5 Å from the sulfur atom of the CoA- Syn conjugate and 6.3
Å away from the αSyn N-terminus, it is in a position to play a role as a general base or
acid for catalysis, potentially through an intervening water molecule (Fig. 4.5A). This is
analogous to the proposed general base role of Tyr31 as a general base for hNAA50
catalysis (Liszczak, Arnesen, and Marmorstein 2011) (See discussion).
We also prepared alanine substitutions for residues that appeared to play
important roles in αSyn binding: Glu25, Tyr27, His73, Tyr137, Tyr138. We were
surprised to find that mutations of hNatB residues that mediated backbone hydrogen
bond interactions, Y27A and Y138A, had relatively modest effects on αSyn peptide NTA
with Y27A showing ~2-fold higher Km and Y138A showing ~2-fold reduced Kcat, together
suggesting that side chain contacts might dominate the binding energy (Table 4.1).
Consistent with this, and our structural observations, we found that H73A produced a
~90% reduction in activity (Table 4.1). This correlates with the importance of the His73
hydrogen bond and van der Waals contacts with αSyn-Asp2. Of note, other cognate
hNatB side chain residues at position 2, Glu, Gln, and Asn would also be well positioned
to form hydrogen bonds with His73. Together, hNAA20-His73 appears to play a critical
role in cognate substrate recognition by hNatB.
hNatB-Asn116 is a highly conserved NatB residue that caps the hNAA20
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helix, which also harbors the putative catalytic residue, Tyr123, and is also in position to
make a water-mediated hydrogen bond with to CoA pantetheine nitrogen (Fig. 4.5A).
This observation suggests that Asn116 could play an important functional role. To test
this, we prepared and evaluated an N116A mutant and, consistent with our hypothesis,
Ans116, we found that this mutant leads to ~ 90% loss in activity (Table 4.1).
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Taken together, our structural and mutational analysis of hNatB highlight the
functional importance of hNatB-NAA20 residues His73, Asn116, and Tyr123 in hNatBmediated N-terminal acetylation. While Tyr123 appears to play a critical catalytic role,
potentially as a general base and/or acid for catalysis; His73 appears to play an
important role in the recognition of substrate residue 2 and Asn116 likely plays a
structural role (Fig. 4.5A). Each of these residues could employ a bridging water
molecule to mediate their functional roles, although these putative water molecules are
not visible at the current resolution of our structure.
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Figure 25.5 Structural comparison between hNAA20 and hNAA50
A. Bi-substrate inhibitor-bound hNAA20 (light orange) is shown superimposed with
hNAA50 (grey, PDB: 3TFY). H73, N116, and Y123 (sticks), mediate important functional
roles in hNatB catalysis. B. Residues forming the Met1 binding pocket of hNAA20 are
depicted. C. Residues forming the Met1 binding pocket of hNAA50 are depicted.
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4.3 Discussion
Since the identification of hNatB more than a decade ago, many studies have
shown that it N-terminally acetylates important proteins such as actin, tropomyosin,
CDK2, and α-Synuclein, and its function has connections to diseases such as
hepatocellular carcinoma and Parkinson disease (Spillantini et al. 1998; Polevoda et al.
2003; Ametzazurra et al. 2008; Starheim et al. 2008; Halliday et al. 2011; Neri et al.
2017). Despite its clear biological importance, hNatB-mediated NTA by hNatB remained
poorly understood. Here, we developed a CoA-αSyn conjugate hNatB inhibitor,
determined the Cryo-EM structure of CoA-αSyn inhibitor-bound hNatB, and carried out
associated structure-guided mutagenesis and activity assays. This has led to the
identification of functionally important differences with human NatA and C. albicans
NatB. These studies have also provided evidence for important hNatB-specific elements
responsible for αSyn recognition and N-terminal acetylation, providing direct implications
for NatB recognition of other canonical substrate proteins.
Consistent with previous studies, we have demonstrated that hNatB acetylates
a cognate “MD” N-terminus, and is unable to N-terminally acetylate non-cognate Ntermini that are substrates for other NATs such as NatA, NatC, NatE. We demonstrated
for the first time that hNatB can acetylate an α-Syn peptide in vitro, directly linking hNatB
to NTA of α-Syn. We have also demonstrated that αSyn peptides lacking the Met1 or
both the Met1 and Asp2, do not serve as hNatB substrates, confirming the strict
substrate specificity of hNatB. This is consistent with our structural model showing
significant interactions between hNatB-NAA20 and both the first and second N-terminal
residues of an αSyn peptide, with important but less extensive interactions with the third
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and fourth residues. This hierarchy of interactions likely explains how NatB enzymes
can accommodate cognate substrates that diverge at positions three and four.
Here, we have presented hNatB-αSyn interactions that can be used to
rationalize the substrate specificity of hNatB: N-terminal sequences containing “MD-”,
“ME-”, “MN-”, and “MQ-”. αSyn-Met1 sits in a hydrophobic pocket that comfortably
accommodates a methionine residue, whereas shorter side chains or longer polar or
charged side chains would fit poorly (Fig. 4.5B-C). The nature of this binding pocket is
similar to the described hNAA50 recognition of Met1 (Liszczak, Arnesen, and
Marmorstein 2011) (Fig. 4.5B-C). Although both of hNAA50 and hNAA20 can Nterminally acetylate peptides with Met at the first position, no overlapping activity has
been observed. This can be rationalized based on the chemical properties of the second
residue in the cognate peptide. We find that the αSyn-Asp2 sidechain forms hydrogen
bonds with the hNAA20 side chains His73 and Thr75. These polar residues in the
peptide binding site of hNAA20 would likely serve as poor acceptors of the largely
hydrophobic residues targeted by hNAA50. The hNatB substrate client profile featuring
D-, E-, N- or Q-residues in position two is consistent with the mechanisms of substrate
recognition observed in the binding pocket for αSyn-Asp2. The aliphatic regions of each
of these side chains (D, E, N, Q) would all benefit from the extensive hNatB van der
Waals interactions surrounding the aliphatic region for αSyn-Asp2 (Tyr27, His73, Thr75,
Phe111, and Tyr138). This second residue would also form a hydrogen bond interaction
with His73 and Thr75, which may accommodate the carboxyl side chains of both the
shorter D- and N- and longer E- and Q- side chains. Notably, His73 and Thr75 are
strictly conserved from yeast to man (Fig. 4.5). In contrast, shorter polar or nonpolar side
chains would less efficiently fill the pocket for residue two, while larger polar or charged
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side chains would likely result in steric clashes. In agreement with this, we have
demonstrated that H73A mutation has severe impact on hNatB catalysis (Table 4.1).
The hNatB/CoA-αSyn structure has implications for the mode of hNatB
catalysis. While previous studies have suggested that hNAA50-Tyr31 plays an important
role in catalysis, mutation of the corresponding hNaa20 residue, Tyr27, had minimal
effects on hNatB kinetic parameters. Strikingly, our mutational analysis has identified the
functional importance of hNatB-NAA20 residues His73, Asn116 and Tyr123, although
Tyr123 is the only residue that is in position to play a catalytic role (Fig. 4.5A).
Specifically, Tyr123 is in position to play a catalytic role, potentially as a general base
and/or acid, through a bridging water molecule (although a water molecule is not visible
at the current resolution). Interestingly, hNAA50 contains a tyrosine residue at the same
position (hNAA50-Tyr124), although the mechanistic significance of this tyrosine residue
has not yet been described (Liszczak, Arnesen, and Marmorstein 2011). It would be of
interest to determine if hNAA50-Tyr124 also plays an important catalytic role (possibly in
combination with hNAA50-Tyr31), similar to the corresponding hNAA20-Tyr123 of
hNatB.
The biological importance of hNatB and its connection to various disease
processes highlights it as an important target for probe and inhibitor development.
Indeed, a recent study highlights hNatB as a therapeutic target for aSyn toxicity
(Vinueza-Gavilanes et al. 2020). Our development of a CoA-αSyn conjugate bisubstrate
with an IC50 of ~ 1.6 µM represents a step in this direction, although the structural
information provided here could further aid to the rational development of more drug-like
hNatB inhibitors with possible therapeutic applications.
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4.4 Materials and methods
4.4.1 Protein expression and purification
hNAA20 with a C-terminal truncation (1-163 out of 178 residues) and full-length
hNAA25 were cloned into two separate insect cell expression vectors pFASTBac HTA.
hNAA20 was untagged, while hNAA25 contained a Tobacco-etch virus (TEV)-cleavable
N-terminal 6xHis-tag. Human NatB complex (hNAA201-163/hNAA25FL) was obtained by
co-expressing these two plasmids in Sf9 (S. frugiperda) cells (ThermoFisher, cat#
12659017), and purified as described previously (Gottlieb and Marmorstein 2018). Sf9
cells were grown to a density of 1x106 cells/ml and infected using the amplified
hNAA201-163/hNAA25FL baculovirus to an MOI (multiplicity of infection) of 1-2. The cells
were grown at 27 °C and harvested for 48 hours post-infection by centrifugation. Cell
pellets were resuspended in lysis buffer (25 mM Tris, pH 8.0, 300 mM NaCl, 10 mM
Imidazole, 10 mM β-ME, 0.1 mg/mL PMSF, DNase, and complete, EDTA-free protease
inhibitor tablet) and lysed by sonication. After centrifugation, the supernatant was
isolated and passed over Ni-NTA resin (Thermo Scientific), which was subsequently
washed with 10 column volumes of lysis buffer. Protein was eluted with a buffer with 25
mM Tris, pH 8.0, 300 mM imidazole, 200 mM NaCl, 10 mM β-ME, which was dialyzed
into buffer with 25 mM HEPES pH 7.5 50 mM NaCl 10 mM β-ME. Ion-exchange was
carried out with an SP ion-exchange column (GE Healthcare) in dialysis buffer with a salt
gradient (50-750 mM NaCl). Peak fractions were concentrated to ~ 0.5 mL with a 50-kDa
concentrator (Amicon Ultra, Millipore), and loaded onto an S200 gel-filtration column (GE
Healthcare) in a buffer with 25 mM HEPES, pH 7.5, 200 mM NaCl, and 1 mM TCEP.
Proteins were aliquoted, snap-frozen in liquid nitrogen, and stored at −80 °C for further
use. Protein harboring mutations were generated with the QuickChange protocol
132

(Stratagene) and obtained following the same expression and purification protocol as
described for the wild-type protein.

4.4.2 Acetyltransferase activity assays
All acetyltransferase assays were carried out at room temperature in a reaction
buffer containing 75 mM HEPES, pH 7.5, 120 mM NaCl, 1 mM DTT as described (Deng,
McTiernan, et al. 2020; Deng et al. 2019). The “MDVF” peptide substrate was based on
the

first

7

amino

acid

of

α-Synuclein

(“MDVF”

peptide:

NH2-

MDVFMKGRWGRPVGRRRRP-COOH;

“SASE”

peptide:

NH2-

SASEAGVRWGRPVGRRRRP-COOH;

“MLGP”

peptide:

NH2-

MLGPEGGRWGRPVGRRRRP-COOH;

“SGRG”/H4

LGKGGAKRHR-COOH; “MLRF” peptide: NH2-ML

peptide:

NH2-SGRGKGGKG

RFVTKRWGRPVGRRRRP-COOH;

“DVFM” peptide: NH2- DVFMKGLRWGRPVGRRRRP-COOH; “VFMK” peptide: NH2VFMKGLSRWGRPVGRRRRP -COOH; GenScript). Reactions were performed in
triplicate. To determine steady-state catalytic parameters of hNatB with respect to acetylCoA, 100 nM hNatB was mixed with a saturating concentration of “MDVF” peptide
substrate (500 μM) and varying concentrations (1.95 μM to 1 mM) of acetyl-CoA (14Clabeled, 4 mCi mmol−1; PerkinElmer Life Sciences) for 10-minute reactions. To
determine steady-state catalytic parameters of hNatB with respect to peptide substrate,
100 nM hNatB was mixed with saturating concentrations of acetyl- CoA (300 μM,

14

C-

labeled) and varying concentrations of “MVDF” peptide (1.95 μM to 1 mM) for 10
minutes. Reactions were quenched by adding the solution to P81 paper discs
(Whatman). Unreacted acetyl-CoA was removed by washing the paper discs in buffer
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with 10 mM HEPES, pH 7.5, at least three times, each 5 minutes. The paper discs were
then dried with acetone and transferred to 4 mL scintillation fluid for signal measurement
(Packard Tri-Carb 1500 liquid scintillation analyzer). Data was fitted to a Michaelis–
Menten equation in GraphPad Prism to calculate kinetic parameters. Kinetic parameters
on mutants with respect to peptide were carried out in the same condition as for wild
type, with 300 μM 14C labeled acetyl-CoA and varied peptide concentration (1.95 μM to 1
mM). All radioactive count values were converted to molar units with a standard curve
created with known concentrations of radioactive acetyl-CoA added to scintillation fluid.
GraphPad Prism (version 5.01) was used for all data fitting to the Michaelis–Menten
equation. For IC50 determination of the CoA-αSyn conjugate, 100 nM hNatB was mixed
with 500 μM “MVDF” peptide and 300 μM

14

C labeled acetyl-CoA, and inhibitor

concentrations were varied (0.23 μM to 13.44 μM). Data were fit to a sigmoidal doseresponse curve with GraphPad Prism (version 5.01). Errors represent s.d. (n = 3).
4.4.3 Cryo-EM data collection
For initial sample screening, 0.6 mg/ml fresh hNatB sample with three-molar
excess bisubstrate was used. hNatB particles on these grids exhibited a severe
preferred orientation, which generated an incorrect 3D initial model (data not shown). To
solve this issue, 1 μL of 0.05% NP-40 was mixed with 20 μL of hNatB (4 mg/mL). 3 μL of
this sample was applied to glow-discharged Quantinfoil R1.2/1.3 holey carbon support
grids, blotted and plunged into liquid ethane, using an FEI Vitrobot Mark IV. An FEI TF20
was used for screening the grids and data collection was performed with a Titan Krios
equipped with a K3 Summit direct detector (Gatan), at a magnification of 105,000 x, with
defocus values from -0.1 to -2.0 µm. Each stack was exposed in super-resolution mode
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with a total dose of 45 e-/Å2, resulting in 35 frames per stack. Image stacks were
automatically collected with Latitude software (Gatan, Inc).
4.4.4 Cryo-EM data processing
Original image stacks were summed and corrected for drift and beam-induced
motion at the micrograph level using MotionCor2 (Zheng et al. 2017), and binned
twofold, resulting in a pixel size of 0.83 Å/pixel. Defocus estimation and the resolution
range of each micrograph were performed with Gctf (Zhang 2016). About 3000 particles
were manually picked to generate several rough 2D classaverages. Representative 2D
classes were used to automatically pick ~1,927,673 particles from 5281 micrographs in
Relion 3.0 (Kimanius et al. 2016; Zivanov et al. 2018). All particles were extracted and
binned to accelerate the 2D and 3D classification. After bad particles were removed by
2D and 3D classification, 982, 420 particles were used for auto-refinement and per
particle CTF refinement. After refinement, a mask was created in Relion with an initial
binarization threshold of 0.005, covering the protein complex and extending the binary
map and soft-edge by 12 pixels. The map was sharpened with the created mask by
estimating B-factor automatically in Relion. The final map was refined to an overall
resolution of 3.46 Å, with local resolution estimated by Resmap (Kucukelbir, Sigworth,
and Tagare 2014). We attempted particle polishing on this data set, but this surprisingly
resulted in artifactual density in the resulting map. We believe that this was due to some
small defects in the K3 camera during data collection, which corrupted the particle
polishing process. We therefore did not perform particle polishing on this data set. Raw
micrographs were deposited in EMPIAR with access ID of EMPIAR-10477.
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4.4.5 Cryo-EM model building and refinement
The hNatB atomic model was manually built de novo using the program COOT
(Emsley and Cowtan 2004) according to the Cryo-EM map, with the guidance of
predicted secondary structure and bulky residues such as Phe, Tyr, Trp and Arg. The
first two alpha helices of hNAA25 were built as poly-alanine, due to the lack of tracible
density in the 3D map. The complete model was then refined by real-space refinement in
PHENIX (Adams et al. 2010). All representations of Cryo-EM density and structural
models

were

performed

with

Chimera

(Pettersen

et

al.

2004)

and

PyMol

(https://pymol.org/2/). The sequence alignments with secondary structure display were
created by ESPript 3.0 (Robert and Gouet 2014b). hNAA25 TPR predictions were
performed using the TPRpred server (Karpenahalli, Lupas, and Söding 2007;
Zimmermann et al. 2018) (https://toolkit.tuebingen.mpg.de/#/tools/tprpred). The surface
area calculation was performed using PDBePISA (Krissinel and Henrick 2007) (Proteins,
Interfaces, Structures and Assemblies) (http://www.ebi.ac.uk/pdbe/pisa/).
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CHAPTER 5: Molecular Mechanism of N-terminal Acetylation by the Ternary NatC
Complex

This work is adapted from bioRxiv preprint (Deng et al. 2021)
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5.1 Introduction
Substrate recognition by eukaryotic NATs is usually dictated by the first few
residues of the substrate via the active site structure (Liszczak et al. 2013; Hong et al.
2017; Magin, Liszczak, and Marmorstein 2015; Stove et al. 2016; Goris et al. 2018;
Deng et al. 2019; Deng and Marmorstein 2021; Deng, Pan, et al. 2020). The active site
of NatA contains a relatively small binding pocket to accommodate a small, uncharged
residue at position 1 such as alanine, valine or threonine residues that remains following
initiator methionine (iMet) - cleavage (Liszczak et al. 2013). NatB has a hydrophobic
pocket for a retained iMet and uses a histidine residue to recognize sequences with
D/E/N/Q at position 2 via hydrogen bonding (Arnesen et al. 2009; Deng and Marmorstein
2021). Interestingly, NatC and NatE share similar and relatively versatile substrate
profiles toward substrates containing a retained iMet followed by residues other than
D/E/N/Q (Van Damme et al. 2016a; Arnesen et al. 2009). NatD is a highly selective
enzyme with histones H4 and H2A as its only known substrates (Hole et al. 2011; Song
et al. 2003), arising from extensive and specific interactions with each of the first four
residues of its substrate (Magin, Liszczak, and Marmorstein 2015). Although NATs vary
in terms of their modes of substrate recognition, their mechanism of catalysis usually
involves the use of dedicated residues to serve as general base and acid residues
(Deng and Marmorstein 2021).
The activity of some NATs is further regulated by other protein modulators. For
example, within the human NatE complex, there is catalytic crosstalk between the two
NAA10 and NAA50 catalytic subunits (Deng et al. 2019). Moreover, the activities of both
NatA and NatE are inhibited to a different extent by a small protein binding partner called
Huntingtin-interacting protein K (HYPK) (Deng, McTiernan, et al. 2020; Gottlieb and
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Marmorstein 2018; Weyer et al. 2017; Arnesen et al. 2010). Inositol hexaphosphate (IP6,
also named inositol hexaphosphate or phytic acid), a small molecule, usually reserved
for cellular signaling, appears to act as a stabilizing ligand for both NatA and NatE, by
binding in a pocket between NAA15 and NAA10, and, thus, plays an indirect role in
promoting NatA and NatE acetylation activity (Gottlieb and Marmorstein 2018; Deng,
McTiernan, et al. 2020; Deng et al. 2019; Cheng et al. 2019).
NatC is distinct from other NATs since it contains two eukaryotic conserved
auxiliary subunits – Naa38 and Naa35 – that act together with the Naa30 catalytic
subunit (Polevoda and Sherman 2001; Ochaya et al. 2019; Starheim et al. 2009). Initial
studies reported that NatC activity requires the interaction of all three subunits, since
knock out of any single subunit produced a similar phenotype in yeast that was
accompanied by diminished N-terminal acetylation of a cognate N-terminal substrate,
MIRLK- (Polevoda and Sherman 2001). However, it was subsequently reported that the
Naa38 subunit is not required for in vivo acetylation of an Arl3p substrate with an Nterminal protein sequence of MPHLV- (Setty et al. 2004a). In plants, knockout of
AtNAA35 did not lead to similar phenotypic effects as the deletion of AtNAA30 (Pesaresi
et al. 2003), and the single subunit of the A. thaliana analogue AtNAA30 can rescue the
knockout of yeast NatC complex subunits (Pesaresi et al. 2003). Similarly, recombinant
human NAA30 (hMak3) was shown to have substrate-specific acetylation activity, even
in the absence of its auxiliary subunits (Starheim et al. 2009). Thus, the functional roles
of the NatC auxiliary subunits are not clear, particularly with respect to Naa38, which is
not well-conserved across species. Although the recently reported crystal structures and
associated biochemical studies of S. cerevisiae NatC (ScNatC) by Grunwald et al. have
provided some important insights into NatC substrate specificity and its catalytic
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mechanism (Grunwald et al. 2020), several questions remain unanswered. In particular,
those regarding the mechanisms dictating the overlapping yet distinct substrate profiles
of NatC and NatE and the influence of IP6 on NatC.
In this study, we report that yeast NatC complex formation of all three subunits is
a prerequisite for normal NatC acetylation activity and that, like NatA and NatE, IP6 binds
tightly to and stabilizes NatC. We also report the Cryo-EM structure of ~100 kDa S.
pombe NatC (SpNatC) bound to a NatE/C-type bisubstrate analogue and IP6, with
related biochemistry, to reveal the molecular basis for IP6-mediated stabilization of the
complex and the similar substrate profiles of NatE and NatC. Comparison of these
studies with the recently published structural and functional studies of the ScNatC
complex (Grunwald et al. 2020) reveal evolutionarily conserved and divergent features of
NatC.
5.2 Results
5.2.1 NAA38 is required for normal NatC acetylation activity in yeast
We found that overexpression of the SpNatC complex containing full-length
SpNaa30 (residues 1–150), N-terminally truncated SpNaa35 (residues 31–708, with
deletion of divergent residues, 1-30) and SpNaa38 (residues 48-116, with deletion of
divergent residues, 1-47) in E. coli produced soluble protein that could be purified to
homogeneity (Figure 5.1a). To evaluate the activity of the recombinant ternary SpNatC,
we used an in-vitro acetyltransferase activity assay with different peptide substrates.
Consistent with previous studies, the recombinant SpNatC is active toward both its own
canonical substrate - “MLRF peptide” and the canonical NatE substrate – “MLGP
peptide”, but with preference for the “MLRF peptide” (Grunwald et al. 2020) (Figure
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5.1b, see methods section for full peptide sequences). To investigate the catalytic roles
of Naa38, we could readily purify both binary (ScNaa301-161 and ScNaa3519-733) and
ternary ScNatC complexes (ScNaa301-161 and ScNaa3519-733, and ScNaa381-70) from
Saccharomyces cerevisiae to compare their activities. Consistent with the studies by
Grunwald et al (Grunwald et al. 2020), evaluation of the activities of the binary and
ternary ScNatC complexes toward the canonical NatC substrate (MLRF peptide)
revealed that the ternary complex showed robust activity, while the binary complex
showed compromised activity (Figure 5.1b). Thus, it appears that Naa38 is required for
optimal NatC activity in yeast.
5.2.2 Inositol hexaphosphate (IP6) binding contributes to yeast NatC complex stability
Earlier reports demonstrated that IP6 interacts with and stabilizes both the yeast
and human NatA and NatE complexes (Deng, McTiernan, et al. 2020; Deng et al. 2019;
Gottlieb and Marmorstein 2018; Cheng et al. 2019), but does not appear to interact with
human NatB (Deng, Pan, et al. 2020). To determine if IP6 could bind to the recombinant
NatC complex, we employed isothermal titration calorimetry (ITC). We found that IP6
binds to SpNatC with a Kd of ~225 nM (with a stoichiometry of ~1) (Figure 5.1c), similar
to its Kd value for yeast NatA (Deng et al. 2019). Differential scanning fluorimetry (DSF)
was used to evaluate a potential role of IP6 binding in NatC complex stability. We found
that addition of IP6 increased the thermal stability of ternary SpNatC, binary ScNatC, and
ternary ScNatC, by ~4.9°C, 2.7°C, and 2.1°C, respectively. Thus, IP6 can provide
additional thermal stability to the yeast NatC complexes (Figure 5.1d).

141

Figure 26.1 Binary NatC displays deficiency in acetylation activity and inositol
hexaphosphate (IP6) binding stabilizes NatC complex formation
(a) Gel filtration elution profile of the ternary SpNatC complex using a Superdex S200
column. Coomassie-stained SDS–PAGE of elution peak is shown in the box, with bands
for corresponding SpNatC subunits labeled. (b) Comparison of SpNatC activity toward
different peptide substrates. The activities shown in gray are normalized to the activity of
SpNatC toward MLRF peptide. The pink and blue columns show the activity of binary
and ternary ScNatC toward the MLRF peptide, respectively, and are normalized to the
pink column. Errors are shown in SEM with n = 3. (c) Representative isothermal titration
calorimetry (ITC) curve of IP6 titrated into SpNatC. The ITC fitting information is N =
0.830 ± 0.00943 sites, ΔH = -1.091x104 ± 177.0 cal mol-1, ΔS = -6.79 cal mol-1 deg-1. (d)
142

Differential scanning fluorimetry assays of NatC alone or with IP6. Average calculated
melting temperature transitions are indicated. Error bars in the figure indicate the SD of
each sample, n = 3.

5.2.3 NatC adopts a distinct NAT architecture
In order to understand the molecular details underlying the ternary NatC
complex, its overlapping yet distinct substrate specificity with NatE, and the mode of IP6
stabilization, we performed single particle Cryo-EM analysis using ternary SpNatC
prepared in the presence of the CoA-Ac-MLGP bisubstrate conjugate and IP6. The
MLGP sequence was selected for synthesis of the conjugate inhibitor as it is a predicted
substrate for both NatC and NatE. A 3.16 Å-resolution Cryo-EM three-dimensional (3D)
map was determined from 607,131 particles, which were selected from 5,397 raw
electron micrographs (Figure 5.2). Most areas of the EM map contained excellent
sidechain density, with a local resolution of ~3 Å, suggesting the relative rigidity of the
recombinant complex (Figure 5.2 and 5.3). The atomic model was built de novo based
on the EM map and details for the model refinement statistics can be found in Table 5.1
(Figure 5.3).
The ternary SpNatC complex contains three proteins, the catalytic Naa30
subunit, the large auxiliary Naa35 subunit, and the small auxiliary Naa38 subunit. Upon
superficial inspection of the complex, it appears as though it is only formed by two
proteins, as Naa38 is embedded within the Naa35 fold to form a “composite” auxiliary
subunit (Figure 5.4a and 5.4b). While Naa30 displays a canonical NAT fold with mixed
α/β secondary structure, the Naa35/38 complex forms a clamp that pinches Naa30 on
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opposite sides. This clamp-like structure is distinct from the architecture of the large
auxiliary subunits of NatA and NatB, which surround the base of their respective catalytic
subunits (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Hong et al. 2017; Deng,
Pan, et al. 2020). The Naa35 architecture is mostly helical, with 25 helices, three short βstrands in its N-terminal region and a single β-hairpin at its C-terminal region that are
unique to the NatC complex (Figure 5.4b). Naa38 adopts an Sm-like fold, with an Nterminal α-helix, followed by a sharply bent β-sheet consisting of 5 five antiparallel βstrands (Figure 5.4b). The Naa35/Naa38 clamp contains α4-α13 from Naa35 at its
base, and α14-α25 and the C-terminal β-hairpin of Naa35 flanking one side of Naa30.
The opposing side of Naa30 is flanked by a composite of the N-terminal end of Naa35
(a2, a3, b1-b3) and the entirety of Naa38 (Figure 5.4a and 5.4b). Consistent with the
composite nature of the Naa35-Naa38 interaction, the buried surface area between
Naa38 and Naa35 is ~1925 Å2, which is notably higher than the area buried between
Naa30 and Naa35 (~1735 Å2), and between Naa30 and Naa38 (~197 Å2).
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Table 8.1 Cryo-EM data collection, refinement and validation statistics
SpNatC with Bisubstrate and IP6
EMD-23110
PDB: 7L1K
Data collection and processing
Magnification
Voltage (keV)
Electron exposure (e/Å2)

105,000
300
42

Defocus range (μm)

-1.0 to -3.0

Pixel size (Å)

0.84

Symmetry imposed

C1

Initial particles (no.)

1,860,276

Final particles (no.)

607,131

Map resolution (Å)

3.16

FSC threshold
Map resolution range (Å)
Refinement
Initial model used (PDB code)
Model resolution (Å)
FSC threshold
Model resolution range (Å)
Map sharpening B factor (Å2)
Model composition

0.143
2.5-3.5
3.4
0.5
159.1

Non-hydrogen atoms

7216

Protein residues
Ligands
B factors (Å2)
Protein
Ligand
R.M.S. deviations
Bonds lengths (Å)

883
2
26.97/110.48/71.91
86.46/102.51/93.10
0.006

Bond angles (°)

1.036

Validation
MolProbity score
Clash score
Poor rotamers (%)
Ramachandran plot

1.76
4.10
0.38

Favored (%)

89.55

Allowed (%)
Disallowed (%)

10.22
0.23
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Figure 27.2 Cryo-EM workflow and resolution of SpNatC EM map
(a) 2D and 3D classification scheme and workflow for SpNatC EM map determination.
(b) Local resolution of the final SpNatC EM map. (c) Viewing direction distribution of
SpNatC final EM map 3D reconstruction generated by cryoSPARC v2. (d) Gold standard

146

Fourier Shell Correlation (FSC) curves of SpNatC EM map 3D reconstruction, generated
by cryoSPARC v2.

Figure 28.3 Correlation between Cryo-EM map of SpNatC EM and its atomic model
(a) Atomic model of SpNatC fitted into the Cryo-EM map. (b) FSC curves of the refined
model versus the overall map that it was refined against (black); of the model refined in
the first of the two independent maps used for the gold-standard FSC versus the same
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map (green); and of the model refined in the first of the two independent maps versus
the second independent map (orange). (c) The fit of several helical segments or βstrands from all three subunits of NatC in the EM density. The contour level is 5 sigma.
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Figure 29.4 Overall structure of SpNatC reveals intimate interactions among all
subunits
(a) NAA30 (bright orange), NAA38 (deep purple) and NAA35 (lime green) are shown in
transparent surface and cartoon, with the boxed area labeled. (b) The CoA-MLGP
bisubstrate conjugate and inositol hexaphosphate (IP6) is shown in sticks and colored in
blue. (c) Zoom-in view of the first sub-interface between NAA38 and NAA35. Hydrogen
bonds are indicated by dashed black lines. For simplicity, only some of the hydrophobic
interactions are shown. (d) Zoom-in view of the second sub-interface between NAA38
and NAA35. (e) Zoom-in view of the third sub-interface between NAA38 and NAA35,
which also involves some residues from NAA30 (light orange). (f) Zoom-in view of the
interface between NAA35 and NAA30 α1-α2 segment. (g) Zoom-in view of the interface
between NAA35 and NAA30 β6-β7 segment. (h) Zoom-in view depicting key residues
involved in interactions with IP6. The lower left shows the fit of the IP6 in the EM density
map.

The

contour

level
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is

5.0

sigma.

5.2.4 NAA38 plays a key role in the NatC complex
The structure of SpNatC was consistent with our biochemical data suggesting
that Naa38 plays important structural and functional roles within the NatC complex. A
more detailed view of the Naa35-Naa38 interface reveals that it is nucleated by the
formation of three anti-parallel β-sheets between Naa35 and Naa38, resulting in
extensive hydrogen bonding and van der Waals interactions, which also involve the a2
and a3 helices of Naa35. These interactions can roughly be divided into three regions
according to the relative position of the β-sheets (Figure 5.4).
The first sub-interface involves the Naa35 β1-α2 segment (Figure 5.4c).
Hydrogen bonds are formed between the backbone nitrogen of Naa35-Ala35 and the
backbone carbonyl of Naa38-Ala116, the backbone carbonyl of Naa35-Val38 and the
backbone nitrogen of Naa38-Val114, the sidechains of Naa35-Asp39 and of Naa38Ser113, the sidechain of Naa35-Thr41 and the backbone nitrogen of Naa38-Phe112,
and the backbone carbonyl of Naa35-Leu51 and the sidechain of Naa38-Arg79. This
region also features a large area of van der Waals interactions involving residues Ala35,
Gly36, Tyr37, Tyr44, Phe45, Ala47, and Thr48 from Naa35 and residues Gly48, Leu52,
Trp55, His 61, Ile71, Thr77, Asp78, Ile109, Arg115, and Ala116 from Naa38.
The second sub-interface is mediated by Naa35-β3 and α12 (Figure 5.4d).
Hydrogen bonds are formed between the backbone nitrogen of Naa35-Phe71 and the
backbone carbonyl of Naa38-Leu101, the backbone carbonyl of Naa35-Phe71 and the
backbone nitrogen of Naa38-Leu103, the sidechains of Naa35-Asp79 and Naa38-Arg68,
the sidechains of Naa35-Ser80 and Naa38-Arg97, and the backbone carbonyl of Naa35Gln296 and the sidechain of Naa38-Arg97. Residues involved in van der Waals
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interactions include Ala70, Glu72, Ile73, Met74, Tyr84, Ala 297, Gln 298, Val30, and
Ala301, from Naa35, and residues Phe95, Ala98, Leu99, Val102, Ile104, Pro105, and
His108 from Naa38.
The third sub-interface is mediated by Naa35-β2 but also involves extensive
interactions with the catalytic Naa30 subunit (Figure 5.4e). The hydrogen bonds
between Naa35 and Naa38 are formed between the sidechains of Naa35-Asp59 and
Naa38-Asn57, the backbone nitrogen of Naa35-Val57 and the backbone carbonyl of
Naa38-Thr77, and the backbone carbonyl of Naa35-Val57 and the backbone nitrogen of
Naa38-Thr77. Naa38 engages with the α2 helix of the Naa30 subunit to form an
extensive hydrogen bonding network via the Naa30-Tyr30 sidechain to the backbone
carbonyl of Naa38-Ala82, and the sidechains of Naa38-Cys76 and Asp78; the sidechain
of Naa30-Lys29 hydrogen bonds to the sidechains of Naa38-Asp78 and Glu80; and
between the sidechains of Naa30-Arg33 and Naa38-Asp78. As the a1-a2 loop of Naa30
plays a key role in protein N-terminal substrate recognition, these Naa38-Naa30
interactions likely play a key role in substrate recognition by NatC (see discussion).
Finally, the Naa30-a2 helix also interacts with Naa35 where Naa35-Glu54 forms
hydrogen bonds with Naa30-Arg33 and His37. Within this sub-interface, the hydrophobic
interactions are primarily mediated by residues Glu49, Leu52, Leu56, Leu75, Cys76,
Asp78, and Ile84 from Naa38 and residues Leu56, Cys58, Asp59 and Phe62 from
Naa35. Taken together, it appears that Naa38 plays key structural and, likely, functional
roles in NatC.
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5.2.5 The substrate binding α1-α2 loop and β6-β7 segments of NAA30 are buried within
NAA35
Naa30 uses its α1-α2 loop (Figure 5.4f) and β6-β7 segments to interact with
Naa35 (Figure 5.4g). Analogous segments in the NatA and NatB complexes are used
for N-terminal substrate recognition. In these complexes, however, the β6-β7 segment is
exposed to solvent (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Deng, Pan, et
al. 2020; Hong et al. 2017). By contrast, this interaction between Naa30 and Naa35 is
facilitated by hydrogen bonds between the Naa30 α1-α2 loop and Naa35 α3-β3
segment: the sidechain of Naa30-Ser28 and the backbone carbonyl of Naa35-Ala70;
between the sidechains of Naa30-Gln20 and Naa35-Glu75; and the backbone carbonyl
of Naa30-Gln20 and the sidechain of Naa35-Lys77.
Notably, the interactions between Naa30 β6-β7 and Naa35 are significantly more
extensive than those found in the NatA and NatB complexes (Figure 5.4g). Here,
hydrogen bonds are formed between the sidechain of Naa30-Glu122 and the sidechains
of Naa35-Gln507 and Tyr509, the sidechain of Naa30-Arg128 and the backbone
carbonyl of Naa35-Lys504, the backbone carbonyl of Naa30-Tyr129 and the sidechain
of Naa35-Arg446, the sidechain of Naa30-Arg131 and the backbone carbonyl of Naa35Gln503, the sidechain of Naa30-Arg134 and the backbone carbonyls of both Naa35Glu186 and Asp187, the backbone carbonyl of Naa30-Tyr136 and the sidechain of
Naa35-Arg306, and the sidechains of Naa30-Tyr148 and Naa35-Arg597. Van der Waals
interactions are observed between residues Cys127, Leu132, Tyr133, Leu137, Asn138,
Phe143, Ile146, and Tyr148 from Naa30, and residues Ile308, Asn441, Cys443, Leu505,
Phe581, Ser590, Tyr591, and Ala594 from Naa35. Together, it appears that the Naa35
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auxiliary subunit makes extensive contacts with the protein N-terminal substrate binding
loops of Naa30 to influence substrate recognition.

5.2.6 IP6 is bound to the interface between NAA30 and NAA35 in close proximity to the
peptide substrate binding site
EM density corresponding to a bound IP6 molecule is well-resolved, revealing a
IP6 binding pocket at the interface between the Naa30 and Naa35 subunits (Figure
5.4h). Notably, the IP6 binding region is distinct from its binding sites in the NatA and
NatE complexes (Deng, McTiernan, et al. 2020; Deng et al. 2019; Gottlieb and
Marmorstein 2018). In SpNatC, IP6 engages in polar interactions with Naa30 residues
His63, Arg64, Arg69, Tyr129, Lys130, and Arg144, and Naa35 residues Arg444, Arg447,
and Asn451. Interestingly, although the IP6 binding pocket of NatC features a similar
chemical environment to the one found in the NatA and NatE complexes, the location in
the architecture of these NAT complexes differs. In NatC, IP6 is located close (~8 Å) to
the peptide substrate entrance site, while the pocket found in NatA and NatE is close to
the Ac-CoA entrance site (Figure 5.5). Therefore, the NatC-bound IP6 molecule could be
in position to impact NatC activity. To evaluate this possibility, we assayed the effects of
IP6 on NatC activity and found that IP6 had a relatively modest inhibitory effect on NatC
activity, comparable to its similar modest inhibitory activity on SpNatA and hNatB
(Figure 5.6). While we cannot exclude the possibility that this modest inhibitor activity is
an artifact of the effect of IP6 on the radioactive activity, it appears that IP6 plays a
predominantly structural role in NatC.
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Figure 30.5 Comparison of NatC with Nat and NatB reveals divergent NatC
architecture
The auxiliary subunits are shown as transparent surface in grey or brown, while the
catalytic subunits are shown as cartoon in light pink (catalytic subunits are aligned in the
same orientation). The blue spheres, cyan spheres, and magenta sticks represent AcCoA, peptide substrate, and IP6, respectively. The highlighted green loops shown are
α1-α2 and β6-β7 substrate binding loops of the catalytic subunits. The PDB models for
generating this figure: HsNatA with IP6, PDB: 6C9M (the bisubstrate shown is aligned
from SpNatA, PDB:4KVM); HsNatB with the bisubstrate analogue, PDB: 6VP9; model of
SpNatC with the bisubstrate analogue and IP6, PDB: 7L1K. As NatE is a complex with
dual catalytic subunits and shares the same auxiliary subunit with NatA, for simplicity, it
is not compared in this figure.
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Figure 31.6 The activity impacts of IP6 on selective NATs
50 nM of either SpNatC, SpNatA, and hNatB was mixed with 2 µM or no IP6 for
measuring production formation. Data was normalized to NATs activity without IP6. Error
bars indicates Mean with SEM, n=3.
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5.2.7 NatC displays significant differences with NatA, NatE, and NatB
Overall, there are three notable differences between NatC and the other multisubunit NATs – NatA, NatE and NatB. First, the auxiliary subunits of NatA, NatE and
NatB contain only helical secondary structure, forming 10-13 conserved tetratricopeptide
repeat (TPR) motifs (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Hong et al.
2017; Deng, Pan, et al. 2020; Deng, McTiernan, et al. 2020; Deng et al. 2019). In
contrast, the NatC auxiliary subunits (Naa35 and Naa38) do not contain TPR repeats
and but do contain several beta strands that make key interactions in the complex
(Figure 5.4b). Secondly, the auxiliary subunits of NatA, NatE, and NatB form a closed
ring-like cradle to completely wrap around their corresponding catalytic subunit. In
contrast, NatC auxiliary subunits arrange themselves into a clamp-like structure to only
wrap roughly half-way around the Naa30 catalytic subunit (Figure 5.5). Thirdly, the
Naa30 β6-β7 peptide substrate recognition loop is buried within the auxiliary subunit,
while the corresponding loops in NatA, NatE, and NatB are largely exposed to solvent
(Figure 5.5). Thus, the relative orientation of the catalytic subunit to the auxiliary subunit
(s) is different in NatC relative to NatA and NatB. In turn, this has implications in altering
the NatC substrate binding mode: the NatC substrate binding tunnel is roughly
perpendicular to the Naa30-Naa35 interface, while the substrate binding tunnel of NatA,
NatE, and NatB is parallel to the catalytic-auxiliary subunit-interface (Figure 5.5). Taken
together, the NatC complex forms an architecture that is distinct from other multi-subunit
NATs.
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5.2.8 Substrate recognition by NAA30 shows similarity to NAA50
Overall, Naa30 displays a typical NAT fold containing four α-helices and seven βstrands with similar substrate binding modes: Ac-CoA enters the catalytic active site
through a groove formed by α3 and α4 of the catalytic subunit, while the peptide
substrate enters the active site on the opposite side of the catalytic subunit flanked by
the α1–α2 and β6-β7 peptide substrate binding loops (Deng and Marmorstein 2021)
(Figure 5.7a and 5.7b). In the Cryo-EM map, density for the CoA-Ac-MLGP conjugate
bisubstrate is well-resolved, allowing us to confidently model both the CoA portion and
all four residues of the peptide portion (Figure 5.7c).
Naa30 harbors a conserved Ac-CoA binding motif R82XXG85XA87 where Ac-CoA
binding is mediated by a series of hydrogen bonds, mainly to the pyrophosphate group.
Specifically, the sidechains of Arg82, Ser119, Arg123 and backbone atoms from Ile77,
Gly85, Ile86, and Ala87 contribute to Ac-CoA hydrogen bonding (Figure 5.7d).
In our NatC model, Naa30 binds the peptide substrate mainly through peptide
backbone hydrogen bonding and hydrophobic pockets for the sidechains of the first two
peptide residues. Direct hydrogen bonds are formed between the backbone amide
groups of the peptide residues 1 and 2 to Naa30 residues Tyr27, Glu109, Thr110,
Tyr121, and Tyr136 (Figure 5.7d). The binding pocket for the peptide Met1 is
surrounded by residues Leu23, Ser24, Glu25, Glu111, and Tyr136 (Figure 5.7e), while
the binding pocket for peptide Leu2 is half-open and surrounded by Tyr27, Val31, Tyr34,
Phe35, Lys59, Tyr71, and Met74 (Figure 5.7f). Beyond the first two residues, there are
no direct contacts between the peptide substrate and Naa30, with the exception of
distant contacts between the backbones of peptide Gly3 and peptide Pro4 with Naa30158

Tyr135 (4-4.5 Å) and Naa30-Glu25 (~4 Å), respectively. These two Naa30 residues likely
play a role in recognizing positions 3 and 4 of high-affinity NatC peptide substrates, as
supported by the recent report by Grunwald et al. (Grunwald et al. 2020)
Previous studies have described the overlapping substrate profile of NatC and
NAA50. Since our NatC model contains the canonical NatE (NAA50)-type peptide
substrate (Met2-Leu2-Gly3-Pro4) in the bisubstrate inhibitor, we were able to evaluate
this relationship by visual inspection of the inhibitor-bound SpNaa30 subunit from the
model. The SpNaa30 model aligns well with the HsNAA50 structure (PDB: 3TFY) bound
to the same MLGP peptide fragment, with a root-mean-square deviation (RMSD) of 1.23
Å (over 105 common Cα atoms) (Figure 5.7b). A more detailed view of the peptide
substrate binding site reveals that Met1 sits in similar binding pockets in both structures
(Figure 5.7e), consistent with their high specificity for Met1. Specificity for Leu at
position 2 is also similar. Notably, residues NatC-Tyr27 and Tyr71, which are
responsible for Leu2 backbone recognition align well with the corresponding residues in
NAA50 (Figure 5.7f). For Leu2 sidechain recognition, the residues, Naa30-Val31 and
Lys59 are replaced by bulkier residues, NAA50-Phe35 and Arg62 (Figure 5.7f),
respectively. However, Naa30-Phe35, Ala73 and Met74 are replaced by NAA50-Phe35,
Met75 and Thr76 (Figure 5.7f), perhaps explaining the greater tolerance of NAA50 for
other residues at position 2. In both models, the peptide substrates begin to diverge from
the architecture of their respective models at residue 3, where the Ca atoms of the
corresponding peptide Gly3 residues of both models are ~3 Å apart. This also seems to
be correlated with a shift in the p-hydroxyl group of a nearby conserved Tyr residue
(Naa30-Tyr135 and NAA50-Tyr138) by about 2.5 Å (Figure 5.7g). The corresponding
peptide Pro4 residues also point in different directions (Figure 5.7g). We propose that
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these differences in peptide substrate positioning beyond residue 2 is mediated by the
different active site environments of Naa30 and NAA50 in this region, thus allowing
these two enzymes to harbor varying activities toward substrates with the same residues
at positions 1 and 2 but differing residues at position 3 and beyond (See discussion).
Taken together, this comparison explains the overlapping yet distinct substrate profiles
of NatC and NatE.
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Figure 32.7 Substrate recognition by NAA30 is similar to NAA50
(a) The sequence alignment of NAA30 orthologs from Schizosaccharomyces pombe
(Sp),

Saccharomyces

cerevisiae

(Sc),

Arabidopsis

thaliana

(At),

Drosophila

melanogaster (Dm), and Homo sapiens (Hs). Numbering and secondary structure
elements for NAA30 are indicated above the sequence alignment. Residues of NAA30
that contact the peptide backbone (✵), CoA (❆), Met1 (✧), Leu2 (⦾), NAA38 (⦿), IP6
(✽), and catalytic residues (✚) are indicated. (b) Structural alignment of SpNAA30
(bright orange) with HsNAA50 (cyan), with secondary structure elements indicated. (c)
The fit of the bi-substrate inhibitor in the EM density map. The contour level is 5.0 sigma.
(d) Highlighted polar and hydrophobic interactions between CoA-Ac-MLGP and NAA30
are depicted in the 3D view. (e) Residues forming a hydrophobic pocket surrounding the
substrate peptide Met1 side chain are shown in sticks (Orange, SpNAA30; Cyan,
HsNAA50). (f) Residues forming a hydrophobic pocket surrounding the substrate
peptide Leu2 side chain are shown in sticks. (Orange, SpNAA30; Cyan, HsNAA50). (g)
Residues proposed as catalytic residues are shown in sticks. (Orange, SpNAA30, E109
and Y121; Cyan, HsNAA50, Y73 and H112).

5.2.9 Mutational analysis reveals that NAA30 Tyr-121 and Glu-109 play key catalytic
roles
In order to evaluate key Naa30 residues identified in our model and their
functional roles in substrate binding and catalysis, we used a radioactive in vitro
acetyltransferase activity assay in conjunction with the MLRF peptide as the peptide
substrate to kinetically characterize WT and mutant SpNatC proteins. Each mutant was
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purified to homogeneity and displayed identical gel filtration chromatography elution
profiles (data not shown), consistent with their native folding and complex formation.
Consistent with our structural observations, mutation of a majority of residues involved in
peptide substrate recognition resulted in an increase in Km (Table 5.2). As the “YY motif”
is shown to be conserved in most NATs (Stove et al. 2016) (except NatD/NAA40), single
mutation of either Naa30-Tyr135 or Tyr136 to an alanine resulted in a significant loss in
activity, with the Y136A mutant displaying almost no detectable activity. In previous
studies, NAA50 residues Tyr73 and His112 were proposed to contribute to catalysis
(Liszczak, Arnesen, and Marmorstein 2011). The corresponding residues in Naa30,
Tyr71 and Glu109, however, had an unexpected effect on catalysis. Instead, Naa30Y71A or Y71F primarily altered the Km, which ultimately resulted in a minor decrease
(12-67%) in catalytic efficiency in comparison with WT. On the other hand, mutation of
Naa30-Glu109 to either alanine or glutamine led to >90% loss of catalytic efficiency,
impacting both Km and kcat. NAA50-Tyr124 and hNatB-Tyr123 were recently proposed to
play analogous catalytic roles (Deng, Pan, et al. 2020), and the corresponding mutation
of Naa30-Tyr121 to alanine demonstrated that NatC activity was almost completely
abolished (Table 5.2). While Glu109 is positioned to function as a general base to
deprotonate the a-amino group of the peptide substrate, Tyr121 is positioned to function
as a general acid to re-protonate the CoA leaving group. This is consistent with the
proposed roles of the analogous Glu118 and Tyr130 residues in ScNatC (Grunwald et
al. 2020), as well as the conserved nature of these residues (Figure 5.7a). In addition,
Naa30-Asn114 is highly conserved among all NATs (data not shown) and it was recently
suggested to play a structural role in orienting the catalytic tyrosine residues (SpNaa30Tyr135 and Tyr136) by ensuring the proper position of the active site helix (a4) for
interaction with Ac-CoA (Deng, Pan, et al. 2020). Consistent with the importance of
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Asn114, we observed that Naa30-N114A exhibited an ~50% loss in activity. Taken
together, the conserved Naa30-Glu109 and Tyr121 residues likely play key catalytic
roles in NatC complex activity (Figure 5.7g).

Table 9.2 Catalytic parameter of wild-type and mutant NAA30 in SpNatC
Substrate

Protein
(SpNatC)

kcat*
(min-1)

Relative kcat
(normalized
to WT)

WT

23.9 ± 1.4

1.0

S24A
22.7 ± 1.6
0.95
E25A
49.3 ± 2.3
2.1
Y27A
7.33 ± 0.5
0.31
Y71A
44.7 ± 2.8
1.9
Y71F
30.2 ± 2.3
1.3
gag
M74A
13.7 ± 1.1
0.57
Peptide
E109A
10.5 ± 1.6
0.44
(MLRF-)
E109Q
3.2 ± 0.9
0.13
N114A
9.5 ± 0.6
0.40
Y121A
1.2 ± 0.1
0.050
Y121F
1.4 ± 0.2
0.060
Y135A
6.3 ± 0.8
0.26
Y136A
N.A
N.A
*values indicated represent mean ± S.D. of best-fit curves
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K m*
(μM)

Relative Km
(normalized
to WT)

7.6 ± 2.1

1.0

1.0

10.3 ± 3.2
19.7 ± 3.6
3.0 ± 1.0
16.1 ± 4.2
29.6 ± 8.5
18.7 ± 6.1
28.7 ± 16
201 ± 130
5.6 ± 1.7
16.0 ± 5.4
7.9 ± 4.3
9.5 ± 5.7
N.A

1.4
2.6
0.39
2.1
3.9
2.5
3.8
27
0.74
2.1
1.0
1.3
N.A

0.70
0.79
0.79
0.88
0.32
0.23
0.11
0.0050
0.53
0.023
0.057
0.21
N.A

kcat/Km
(normalized
to WT)

5.3 Discussion
Here, were report that the notably small SpNaa38 auxiliary subunit cooperates
with the large Naa35 auxiliary subunit to stabilize the active N-terminal acetyltransferase
NatC complex for its robust N-terminal acetylation activity. Through structure/function
studies, we observed that Naa38 interacts with Naa30-α2, a region that directly
contributes to recognition of peptide substrate backbone and sidechain residues. Based
on these observations and similar ScNatC complex biochemical and structural findings
described by Grunwald et al. (Grunwald et al. 2020), it appears that Naa38 is essential
for normal NatC acetylation activity. Therefore, we propose that Naa38 plays a
conserved role in yeast. Future studies are needed to further interrogate this in the plant
or human systems, as some reports suggest that Naa38 may not be as important in
higher eukaryotes (Pesaresi et al. 2003; Starheim et al. 2009), but there has also been a
report of a human developmental disorder linked to NAA38 deletion (Zhao et al. 2016).
In S. pombe, we have found that the ternary SpNatC complex displays
acetylation activity toward both canonical NatC and NatE-type peptide substates, but
with a preference for NatC-type substrates. While recognition of residues 1 and 2 of the
cognate substrate appears highly homologous between the Naa30 and NAA50 catalytic
subunits of NatC and NatE, respectively, the substrate binding pockets responsible for
recognizing substrate residues beyond the penultimate sidechain diverge significantly.
This likely explains the divergence in substrate profiles observed between these two
NATs.
IP6 was previously found to play a stabilizing role at the interface between the
NAA15 and NAA10 subunits of the NatA and NatE complexes (Deng, McTiernan, et al.
2020; Deng et al. 2019; Gottlieb and Marmorstein 2018), (Cheng et al. 2019). Here, we
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find that IP6 also appears to play a stabilizing role in both ScNatC and SpNatC, and that
the SpNatC structure reveals that IP6 binds at the Naa35-Naa30 interface located near
the peptide substrate entrance site, although it does not appear to play a major direct
role in modulating NatC activity.
Grunwald et al. recently reported X-ray crystal structures of ScNatC in several
liganded states along with associated biochemical studies (Grunwald et al. 2020).
Overall, their findings are in agreement with our findings on SpNatC reported here.
There are, however, some notable differences when comparing NatC from S. pombe
and S. cerevisiae, which have implications for the conserved and unique features of
NatC.
The ScNatC structures bound to cognate NatC-type peptide substrates shows
specificity for the first four residues, which is consistent with their reported peptide
substrate mutation and binding data. In contrast, our structure, featuring SpNatC bound
to a peptide sequence that is optimal for NatE (NAA50) acetylation, shows SpNaa30’s
specificity for only the first two residues. This mode of recognition is consistent with
recognition for these same residues by NAA50, while there is significant divergence in
the regions of the peptide binding grooves of Naa30 and NAA50 that are responsible for
interaction with substrates residues beyond residue 2. This comparison suggests that
discrimination between Naa30 and NAA50 substrates is largely dictated by the identities
of the third and fourth residues in an N-terminal substrate. As NatC-type and NatE-type
substrates can include many different hydrophobic/amphipathic N-termini (ML- MI-, MF,
MW-, MV-, MM-, MH-, and MK-) (Ree, Varland, and Arnesen 2018), it may be difficult for
a single enzyme to cover acetylation of such a broad repertoire of protein N-termini.
Given that Naa50 is inactive in yeast (Deng et al. 2019), we propose that the overlapping
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substrate profile for residues at positions 1 and 2 by NatC and NatE may have evolved
in higher eukaryotic cells to fully cover the acetylation on these types of N-terminal
substrates.
Grunwald et al. identified several electropositive regions (EPR) on ScNatC that
are implicated in ribosome association. Of these regions, labeled EPR1-EPR4
(Grunwald et al. 2020) (Figure 5.8), mutation of only EPR2 was found to influence
ribosome association. Comparison with the electrostatic surface potential of SpNatC
shows notable differences with ScNatC (Figure 5.8). Specifically, EPR2 is not present in
SpNatC, since the ScNatC “ScNaa35 tip” is missing in SpNatC. While EPR1 is
conserved, this electropositive patch harbors the IP6-binding pocket in SpNatC and,
therefore, is likely the IP6 binding site in ScNatC. In addition, the surface region of
SpNatC corresponding to EPR3 is broader compared to the corresponding surface of
ScNatC and is located close to where ScNatC-EPR2 would be. It is therefore possible
that SpNatC utilizes EPR3 to compensate for the absence of EPR2. Taken together, this
comparison suggests that the mode of ribosome association utilized by SpNatC and
ScNatC and, by extension, NatC complexes from other species, may differ. Future
studies would investigate the molecular details of these differing interactions.
NatC has been shown to be important for proper chloroplast (Pesaresi et al.
2003) and mitochondrial (Van Damme et al. 2016a) function, essential for embryonic
development (Wenzlau et al. 2006), cell viability and p53-dependent apoptosis (Starheim
et al. 2009), and as a potential therapeutic target in cancer (Mughal et al. 2015). In light
of these important connections to NatC function, the studies reported here have
important implications for health and disease.
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Figure 33.8 Divergent structural features exist between NatC in S. pombe and S.
cerevisiae
(a) Electrostatic surface potential of the ScNatC structure (PDB: 6YGB) with previous
EPRs indicated. (b) Electrostatic surface potential of SpNatC (PDB: 7L1K) aligned with
the orientations shown in (a).
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5.4 Materials and Methods
5.4.1 SpNatC expression and purification
SpNaa3531-708 (with truncation of the N-terminal 30 residues) and full-length
SpNaa30FL were cloned into a modified pET DUET vector containing an N-terminal His6SUMO tag. SpNaa3848-116 (with truncation of the N-terminal 47 residues) was cloned into
a pCDF vector with an N-terminal His6 tag. To obtain the heterotrimeric NatC complex
(WT ternary SpNatC), these two plasmids were used to co-transform Rosetta
(DE3)pLysS competent E. coli cells, which was then cultured to grow at 37 °C in the
presence of both ampicillin (100 µg/mL) and streptomycin (50 µg/mL). When the
absorbance OD600 reached ~ 0.7, protein expression was induced at 16°C with 0.5 mM
isopropyl 1-thio-β-galactopyranoside (IPTG) overnight. Cells were harvested by
centrifugation, resuspended, and lysed by sonication in lysis buffer containing 25 mM
Tris, pH 8.0, 300 mM NaCl, 10 mg/ml PMSF (phenylmethanesulfonylfluoride). The lysate
was clarified by centrifugation and passed over Nickel-NTA resin (Thermo Scientific),
which was subsequently washed with ~10 column volumes of wash buffer containing 25
mM Tris, pH 8.0, 300 mM NaCl, 20 mM imidazole, 10 mM 2-mercaptoethanol (βME).
The protein was eluted in batches with buffer containing 25 mM Tris, pH 8.0, 300 mM
NaCl, 200 mM imidazole, 10 mM βME. After elution, His6-tagged Ulp1 protease was
added to the eluate to cleave the His6-SUMO tag and dialyzed further into buffer
containing 25 mM sodium citrate monobasic, pH 5.5, 10 mM NaCl and 10 mM βME.
Protein was purified with a 5-mL HiTrap SP cation-exchange column (GE Healthcare)
and eluted with a salt gradient (10–1000 mM NaCl). Peak fractions were concentrated to
~0.5 mL with a 50 kDa concentrator (Amicon Ultra, Millipore), and loaded onto an S200
gel-filtration column (GE Healthcare) in a buffer containing 25 mM HEPES, pH 7.0, 200
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mM NaCl, 1 mM dithiothreitol (DTT). Peak fractions were pooled and concentrated to
~15 mg/ml as measured by UV280 using a Nanodrop and flash-frozen for storage at −80
°C until use. All protein mutants were generated using the QuikChange protocol from
Stratagene and obtained following the expression and purification protocols described
above.
5.4.2 Binary and ternary ScNatC expression and purification
ScNaa301-161 and ScNaa3519-733 were cloned into a pET DUET vector containing
an TEV cleavable N-terminal His6-tag. Binary complex (ScNaa301-161/ScNaa3519-733) was
obtained by transforming this plasmid in ScarabXpress T7lac (Scarab Genomics)
competent E. coli cells, which were grown in terrific broth media (DOT Scientific)
supplemented with ampicillin (100 µg mL-1) at 37°C to an OD600 of ~0.9 and induced by
addition of 0.5 mM IPTG at 17°C for 16 hr. All subsequent purification steps were carried
out at 4°C. Cells were isolated by centrifugation, lysed by sonication in lysis buffer
containing 25 mM Tris, pH 8.0, 300 M NaCl, 10 mM β-ME and 10 mg/mL PMSF. The
lysate was clarified by centrifugation and passed over nickel resin, which was
subsequently washed with >20 CV of lysis buffer supplemented with 25 mM imidazole.
The protein was eluted in lysis buffer supplemented with 200 mM imidazole by batch
elution. TEV protease (~1 mg/ml) was added to the eluted protein and dialyzed into
buffer containing 25 mM Tris, pH 8.0, 300 mM NaCl, 5 mM Imidazole, 10 mM β-ME. This
solution was passed through an additional nickel column to remove TEV protease as
well as any uncut binary ScNatC. The resin was then washed with approximately 3 CV
of dialysis buffer supplemented with 25 mM imidazole, which was then pooled with the
initial flowthrough. This solution was dialyzed into ion exchange buffer containing 25 mM
HEPES, pH 7.5, 50 mM NaCl and 10 mM β-ME and loaded onto a 5 ml HiTrap SP anion
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exchange column (GE HealthcarE). The binary complex ScNatC was then eluted using a
salt gradient (50–750 mM NaCl). Peak fractions were concentrated using a 50-kDa
MWCO concentrator (Amicon) and further purified Superdex 200 Increase 10/300 GL gel
filtration column (GE Healthcare) in a buffer containing 25 mM HEPES, pH 7.0, 200 mM
NaCl, 1 mM TCEP. Peak fractions were concentrated to a UV280 of ~4-5 mg mL-1 as
measured by nanodrop. The protein was then flash-frozen and stored at -80°C until use.

To obtain the ternary ScNatC complex, ScNaa381-70 was cloned into a pRSF
vector with a TEV-cleavable N-terminal STREP-tag. This plasmid was co-transformed
with the pET DUET plasmid containing ScNaa301-161 and ScNaa3519-733 and cultured as
described above except with the addition of kanamycin (50 µg mL-1) to select for pRSF
ScNaa381-70 plasmid. The purification of the ternary ScNatC complex was the same as
described for the binary ScNatC complex.

5.4.3 Acetyltransferase activity assays
All acetyltransferase assays were carried out at room temperature in a reaction
buffer containing 75 mM HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT as described
previously (Deng et al. 2019). The full sequence of peptide substrates are listed below:
“SASE”

peptide

peptide

(NatB-type):

(NatA-type):

NH2-SASEAGVRWGRPVGRRRRP-COOH;

“MDVF”

“MLRF”

peptide

NH2-MDVFMKGRWGRPVGRRRRP-COOH;

(NatC-type): NH2-MLRFVTKRWGRPVGRRRRP-COOH; “MLGP” peptide (NatE-type):
NH2-MLGPEGGRWGRPVGRRRRP-COOH; “SGRG”/H4 peptide (NatD-type): NH2-
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SGRGKGGKG LGKGGAKRHR-COOH). All peptides were purchased from GenScript.
To evaluate SpNatC activity against these peptides, 50 nM SpNatC was mixed with 50
μM Ac-CoA and 500 μM peptide, and allowed to react for 10 min. To determine steadystate catalytic parameters of SpNatC (WT or mutants) with respect to the peptide
substrate, 50 nM SpNatC (WT or mutants) was mixed with 50 μM Ac-CoA (14C-labeled,
4 mCi mmol−1; PerkinElmer Life Sciences) and varying peptide concentrations (ranging
from 1.95 μM to 500 μM, 9-data points) for 5-minute reactions. P81 paper was
purchased from SVI (St. Vincent’s Institute Medical Research). All radioactive count
values were converted to molar units with a standard curve created with known
concentrations of radioactive Ac-CoA added to scintillation fluid. GraphPad Prism
(version 5.01) was used for all data fitting to the Michaelis–Menten equation. The errors
in Table 2 represent the standard deviation of the best fit values of the curves.
For the comparison of ternary and binary ScNatC complex activity, 10 nM of
either binary ScNatC or ternary ScNatC was mixed with 100 μM of

14

C-labeled Ac-CoA

and “MLRF” peptide, for a 12-minute reaction in buffer containing 50 mM HEPES, pH
7.5, 150 mM NaCl and 1 mM DTT.
For the activity comparison of ternary SpNatC and other NATs in the presence or
absence of IP6, 50 nM of SpNatC, SpNatA or hNatB was mixed with 50 μM of

14

C-

labeled Ac-CoA, 50 μM of their peptide substrate, in reaction buffer containing 75 mM
HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT, supplemented with either 0 or 2 μM IP6
(Sigma-Aldrich), for a 5-minute reaction. The peptide substates for SpNatA and hNatB
are SASE peptide and MDVF peptide, respectively. SpNatA (Liszczak et al. 2013) and
hNatB (Deng, Pan, et al. 2020) are purified as previously described.
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5.4.4 ITC measurements
ITC measurements were carried out using a MicroCal iTC200 at 20 °C. Samples
were dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, and 1 mM
DTT. 15 μM of SpNatC in the cell and 300 μM of IP6 in the syringe were used. The raw
data were analyzed with the MicroCal ITC analysis software.

5.4.5 Differential scanning fluorimetry assays
Sypro Orange (50,000X stock, ThermoFisher Scientific) was diluted 1:200, and 4
µL was mixed with 16 µL solution with 0.1 mg/ml of various NatC samples in pH 7.0, 200
mM NaCl, and 1 mM DTT, with or without 10 µM IP6. Fluorescent readings were
recorded using a qPCR (ABI 7900 RealTime PCR) with a 1% ramp rate, while heated
from 20 °C to 95 °C. Melting curves were generated from these readings and melting
temperatures were determined by taking the first derivative of the curves. DSF scans of
all samples were performed in triplicate as technical replicates. Error bars in the figure
indicates the Standard Deviation (SD) of each sample.

5.4.6 Cryo-EM data collection
For initial sample screening, 0.05 mg/ml fresh SpNatC sample was prepared with
3-molar excess of both bisubstrate and IP6. SpNatC particles on cryo grids exhibited a
severe preferred orientation, which generated an incorrect initial 3D model (data not
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shown). Further screening by addition of detergent NP-40 in sample did not improve this
situation. To solve this issue, 1 μL of 80 mM CHAPSO was mixed with 20 μL of 12
mg/mL SpNatC. 3 μL of this mixed sample was applied to Quantifoil R1.2/1.3 holey
carbon support grids, blotted and plunged into liquid ethane, using an FEI Vitrobot Mark
IV. An FEI TF20 was used for screening the grids and data collection was performed
with a Titan Krios equipped with a K3 Summit direct detector (Gatan), at a magnification
of 105,000 ×, with defocus values from −0.1 to −3.0 µm. Each stack was exposed and
counted in super-resolution mode with a total dose of 42 e-/Å2, resulting in 35 frames per
stack. Image stacks were automatically collected with EPU. A full description of the
Cryo-EM data collection parameters can be found in Table 5.1.

5.4.7 Cryo-EM data processing
Original image stacks were summed and corrected for drift and beam-induced
motion at the micrograph level using MotionCor2 (Zheng et al. 2017), and binned
twofold, resulting in a pixel size of 0.84 A˚ /pixel. After motion correction in Relion 3.0
(Kimanius et al. 2016), corrected micrographs were imported into CryoSPARC (Punjani
et al. 2017) to perform defocus estimation, the resolution range of each micrograph with
Gctf (Zhang 2016) and all the subsequent data analysis. 2D classifications were
performed on the particles auto-picked by “blob picker” with particle diameter of 100 200 Å. The representative 2D classes were used as templates to further auto-pick
1,860,276 particles from 5514 micrographs. After bad particles were removed by two
runs of 2D classification, 849,844 particles were used to generate four Ab-Initio models
and two rounds of heterogeneous refinement were performed using the four models.
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508, 298 particles were used for auto refinement and per particle CTF refinement. The
final map was refined to an overall resolution of 3.20 Å, with local resolution estimated in
Cryo-SPARC (Punjani et al. 2017).
5.4.8 Cryo-EM model building and refinement
The SpNatC atomic model was manually built de novo using the program COOT
(Emsley and Cowtan 2004) according to the Cryo-EM map, with the guidance of
predicted secondary structure and bulky residues such as Phe, Tyr, Trp and Arg. The
complete model was then refined by real-space refinement in PHENIX (Adams et al.
2010). All representations of Cryo-EM density and structural models were performed
with

Chimera

(Pettersen

et

al.

2004)

and

PyMol

(Schrodinger

2015)

(https://pymol.org/2/). The sequence alignments with secondary structure display were
created by ESPript 3.0 (Robert and Gouet 2014a). The surface area calculation was
performed using PDBePISA (Krissinel and Henrick 2007) (Proteins, Interfaces,
Structures and Assemblies) (http://www.ebi.ac.uk/pdbe/pisa/ ).
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CHAPTER 6: Conclusions and Future Directions
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While Nt-acetylation is a protein modification present in all kingdoms of life, it’s
much more abundant and complicated in eukaryotes than in bacterial and archaea, in
term of target substrate profile. Meanwhile, the biological relevance of Nt-acetylation is
also comparably more significant in eukaryotes, impacting diverse cellular processes
and diseases. In correspondence to these, eukaryotic NATs have evolved some distinct
features. Among these features, the major one is that some eukaryotic NATs, like NatA,
B, C, and E collaborate with at least one auxiliary subunit, a small molecule (IP6, for
NatA, NatC, and NatE), and in the case of NatA and NatE, the HYPK regulatory protein
to form multi-subunit enzyme complexes and perform the acetylation co-translationally in
a controlled manner. Overall, these enzymes are collectively responsible for Ntacetylation of over 80% human proteins and abnormal activities of them have been
reported to be corelated with developmental diseases such as Ogden syndrome,
neurodegenerative diseases, and cancers (Dorfel and Lyon 2015; Myklebust, Stove, and
Arnesen 2015; Kalvik and Arnesen 2013). Motivated by the biological significance and
disease connections of these protein complexes, this thesis set out to provide
comprehensive studies towards understanding the molecular and regulatory mechanism
of these multi-subunit NATs, as described in previous chapters.
While important insights are provided here, some questions remain unanswered.
How do NatA and NatE toggle between co-translational activity and post-translational
activities? NAA10 has been reported to act alone towards acidic substrates (distinct from
NatA-type), while human NAA50 per se is also active towards NatE-type substrates.
Moreover, controversial reports indicate that both NAA10 and NAA50 can perform lysine
acetylation and auto-acetylation (Magin, March, and Marmorstein 2016; Seo et al. 2010;
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Evjenth et al. 2009). Thus, the biological relevance of these potential versatile activities
of NAA10 and NAA50 requires further investigation.
Can NATs carry out cross regulation amongst themselves? Nt-acetylation is
known to be important for protein complex formation and protein function in some cases.
NATs themselves are also subjected to Nt-acetylation depending on their N-terminal
sequence identity. A recent report highlighted that NAA20 maturation mediated by NatA
activity is essential for NatB complex formation (Lasa et al. 2020).
What is the molecular mechanism of co-translational acetylation on the ribosome
of NatA/E, and other NATs that function co-translationally such as NatC/B/D? How do
NATs with co-translational activities navigate the same or different ribosomes? How do
ribosomes distinguish and selects the correct NAT for co-translational nascent chain Ntacetylation? How do NATs cooperate or compete with other N-terminal modification
enzymes like NME? These are challenging but important questions that remain to be
answered. For the known yeast NatE-ribosome architecture, ScNAA50 is inactive and
remote from the ribosome exit tunnel. However, in humans, hNAA50 is active, and how
hNAA50 shifts its distance relative to the exit tunnel when the nascent chain contains a
NatE-type substrate is also an interesting question that remains to be answered.
Recently, Electropositive regions (EPRs) on the surface of NatB and NatC were
proposed to participate in ribosome association (Magin et al. 2017; Grunwald et al.
2020), structural studies are required to confirm these results
As HYPK reduces ~ 90% of hNatA activity and influences NatE activity as well in
vitro (Gottlieb and Marmorstein 2018; Deng, McTiernan, et al. 2020), why are such
strong inhibition effects on hNatA not observed in vivo? What is the biological function of
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the presence of HYPK in humans, as HYPK is absent in most yeast? Do other NATs
agonists or antagonists exist? Learning from HYPK, can we develop novel and specific
inhibitors for NATs? In humans, NATs are frequently correlated with disease and
cancers, especially hNatA. The development of bi-substrate analogues has been
important for understanding NAT catalytic mechanism but are unsuitable as drugs. It will
be of great interest to develop drug-like NAT-specific inhibitors.
Lastly, to date, the structure and mechanism of the chloroplast localized NATs
are unknown. What are the unique features of these NATs? These, among many other
remaining questions, regarding NAT mechanism will keep the field vibrant for decades to
come.
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